{"questions": [{"id": "5a70dfd599e2c3af26000006", "body": "What is Dysphoric Milk Ejection Reflex?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20443435", "http://www.ncbi.nlm.nih.gov/pubmed/29115857", "http://www.ncbi.nlm.nih.gov/pubmed/21645333"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "A case of dysphoric milk ejection reflex (D-MER).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20443435"}, {"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "Dysphoric milk ejection reflex (D-MER) results in waves of negative emotions that last from shortly before initial milk ejection until baby starts to feed vigorously Symptoms may decrease by 3 months or they may continue throughout the breastfeeding period.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20443435"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "Dysphoric Milk Ejection Reflex: A Case Series.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "BACKGROUND: Dysphoric milk ejection reflex (D-MER) is characterized by an abrupt dysphoria, or undesirable feeling that occurs with the MER and continues for no more than a few minutes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857"}, {"offsetInBeginSection": 186, "offsetInEndSection": 234, "text": "After milk ejection, the dysphoria vanishes.CASE", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857"}, {"offsetInBeginSection": 434, "offsetInEndSection": 482, "text": "The dysphoria vanished after each milk ejection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "Dysphoric milk ejection reflex: A case report.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21645333"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": " Dysphoric Milk Ejection Reflex (D-MER) is an abrupt emotional \"drop\" that occurs in some women just before milk release and continues for not more than a few minutes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21645333"}]}, {"id": "5a76160a83b0d9ea66000020", "body": "Which sequence-based algorithm for branch point prediction has been proposed?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28633445"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "BPP: a sequence-based algorithm for branch point prediction.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445"}, {"offsetInBeginSection": 0, "offsetInEndSection": 287, "text": "Motivation: Although high-throughput sequencing methods have been proposed to identify splicing branch points in the human genome, these methods can only detect a small fraction of the branch points subject to the sequencing depth, experimental cost and the expression level of the mRNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445"}, {"offsetInBeginSection": 288, "offsetInEndSection": 558, "text": "An accurate computational model for branch point prediction is therefore an ongoing objective in human genome research.Results: We here propose a novel branch point prediction algorithm that utilizes information on the branch point sequence and the polypyrimidine tract.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445"}]}, {"id": "5a9922981d1251d03b000007", "body": "How do circRNAs relate to tumorigenesis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28991235", "http://www.ncbi.nlm.nih.gov/pubmed/28933584", "http://www.ncbi.nlm.nih.gov/pubmed/29034621", "http://www.ncbi.nlm.nih.gov/pubmed/29069731", "http://www.ncbi.nlm.nih.gov/pubmed/29156822", "http://www.ncbi.nlm.nih.gov/pubmed/28279183", "http://www.ncbi.nlm.nih.gov/pubmed/28928231", "http://www.ncbi.nlm.nih.gov/pubmed/27363013", "http://www.ncbi.nlm.nih.gov/pubmed/27040497", "http://www.ncbi.nlm.nih.gov/pubmed/27158380"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Circular RNA (circRNA) is a novel member of the noncoding cancer genome with distinct properties and diverse cellular functions, which is being explored at a steadily increasing pace.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28991235"}, {"offsetInBeginSection": 489, "offsetInEndSection": 630, "text": "Many circRNAs are highly conserved and have tissue-specific expression patterns, which often do not correlate well with host gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28991235"}, {"offsetInBeginSection": 631, "offsetInEndSection": 866, "text": "Here we review the current knowledge on circRNAs in relation to their implications in tumorigenesis as well as their potential as diagnostic and prognostic biomarkers and as possible therapeutic targets in future personalized medicine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28991235"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Circular RNAs (circRNAs) are a type of noncoding RNAs generated from back-splicing, which have been verified to mediate multiple tumorigenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584"}, {"offsetInBeginSection": 1152, "offsetInEndSection": 1394, "text": "In summary, our study preliminarily investigates the circRNA expression in breast cancer tissue and explores the role of competing endogenous RNA (ceRNA) mechanism in the progression, providing a novel insight for breast cancer tumorigenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Recently, with the development of RNA research techniques, a wide variety of circular RNAs (circRNAs) have been discovered and some of them are confirmed to have crucial biological functions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29034621"}, {"offsetInBeginSection": 192, "offsetInEndSection": 223, "text": "CircRNAs arise from exons (i.e.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29034621"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Profiling and bioinformatic analysis of circular RNA expression regulated by c-Myc.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069731"}, {"offsetInBeginSection": 152, "offsetInEndSection": 265, "text": "Circular RNAs (circRNAs) are widely expressed non-coding RNAs participating in the regulation of gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069731"}, {"offsetInBeginSection": 515, "offsetInEndSection": 638, "text": "Subsequently, Myc-binding sites were found to generally exist in the promoter regions of differentially expressed circRNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069731"}]}, {"id": "5a8ee9d1fcd1d6a10c000027", "body": "Is there a disease or condition called Exploding Head Syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2769286", "http://www.ncbi.nlm.nih.gov/pubmed/25773787", "http://www.ncbi.nlm.nih.gov/pubmed/1896728", "http://www.ncbi.nlm.nih.gov/pubmed/24703829", "http://www.ncbi.nlm.nih.gov/pubmed/28622122", "http://www.ncbi.nlm.nih.gov/pubmed/20726288", "http://www.ncbi.nlm.nih.gov/pubmed/26252589", "http://www.ncbi.nlm.nih.gov/pubmed/11309216", "http://www.ncbi.nlm.nih.gov/pubmed/24907167"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "Clinical features of the exploding head syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2769286"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Fifty patients suffering from the \"exploding head syndrome\" are described.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2769286"}, {"offsetInBeginSection": 211, "offsetInEndSection": 364, "text": "The associated symptoms are varied, but the benign nature of the condition is emphasised and neither extensive investigation nor treatment are indicated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2769286"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "Exploding head syndrome is common in college students.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Exploding head syndrome is characterized by the perception of loud noises during sleep-wake or wake-sleep transitions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787"}, {"offsetInBeginSection": 249, "offsetInEndSection": 354, "text": "At present there are little systematic data on exploding head syndrome, and prevalence rates are unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787"}, {"offsetInBeginSection": 513, "offsetInEndSection": 806, "text": "In order to test these hypotheses, 211 undergraduate students were assessed for both exploding head syndrome and isolated sleep paralysis using semi-structured diagnostic interviews: 18.00% of the sample experienced lifetime exploding head syndrome, this reduced to 16.60% for recurrent cases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787"}, {"offsetInBeginSection": 915, "offsetInEndSection": 1140, "text": "Exploding head syndrome episodes were accompanied by clinically significant levels of fear, and a minority (2.80%) experienced it to such a degree that it was associated with clinically significant distress and/or impairment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787"}, {"offsetInBeginSection": 1141, "offsetInEndSection": 1272, "text": "Contrary to some earlier theorizing, exploding head syndrome was found to be a relatively common experience in younger individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "The exploding head syndrome: polysomnographic recordings and therapeutic suggestions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1896728"}]}, {"id": "5a9d8a651d1251d03b00001f", "body": "What is the BioArchive system?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28716596", "http://www.ncbi.nlm.nih.gov/pubmed/12513800"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Quality comparison of umbilical cord blood cryopreserved with conventional versus automated systems.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Umbilical cord blood (CB) banks usually freeze and store CB for clinical transplantation using conventional controlled-rate freezer or the automated BioArchive system.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596"}, {"offsetInBeginSection": 355, "offsetInEndSection": 480, "text": "The experiment used 80\u00a0CB units: 40 were conventionally cryopreserved and the remainder were cryopreserved with a BioArchive.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596"}, {"offsetInBeginSection": 946, "offsetInEndSection": 1118, "text": "MNC and CD34+ cell viability were as follows: MNC, 78.2%\u00a0\u00b1\u00a06.8% (conventional), 81.7%\u00a0\u00b1\u00a07.2% (automated); CD34+ cell, 90.6%\u00a0\u00b1\u00a06.9% (conventional), 94.7%\u00a0\u00b1\u00a03.5% (automated).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596"}, {"offsetInBeginSection": 168, "offsetInEndSection": 354, "text": "The aim of this study is to compare the quality of CB cryopreserved with conventional and automated methods and to make clear the cause of the quality difference between the two methods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596"}, {"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "The aim of this study was to investigate the cryobiological characteristics of placental cord blood (PCB) cryopereserved by using BioArchive auto-preserved liquid nitrogen system (BioArchive system).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12513800"}]}, {"id": "5a723a652dc08e987e00000a", "body": "Describe mechanism of action of Romosozumab.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27569204", "http://www.ncbi.nlm.nih.gov/pubmed/28064540", "http://www.ncbi.nlm.nih.gov/pubmed/28458516", "http://www.ncbi.nlm.nih.gov/pubmed/24665957", "http://www.ncbi.nlm.nih.gov/pubmed/28428078"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569204"}, {"offsetInBeginSection": 0, "offsetInEndSection": 43, "text": "Romosozumab is a humanized immunoglobulin G", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569204"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "Romosozumab for the treatment of osteoporosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "INTRODUCTION: Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the canonical Wnt signaling bone formation pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540"}, {"offsetInBeginSection": 134, "offsetInEndSection": 361, "text": "Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540"}, {"offsetInBeginSection": 362, "offsetInEndSection": 457, "text": "Clinical studies with romosozumab have shown dramatic improvements in BMD at the spine and hip.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540"}, {"offsetInBeginSection": 458, "offsetInEndSection": 661, "text": "Romosozumab is associated with improvement in bone strength through mechanisms that include increases in bone formation and, different from classical osteoanabolic agents, suppression of bone resorption.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1104, "text": "Expert opinion: Monthly subcutaneous dosing of romosozumab reduces the risk of vertebral and clinical fractures in women with postmenopausal osteoporosis, with a favorable balance of benefits and risks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540"}, {"offsetInBeginSection": 1105, "offsetInEndSection": 1277, "text": "Romosozumab is a promising emerging anabolic agent with a novel mechanism of action that may expand the options for treating osteoporotic patients at high risk of fracture.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Profile of romosozumab and its potential in the management of osteoporosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28458516"}]}, {"id": "5a76179d83b0d9ea66000021", "body": "Which algorithm has been proposed for efficient storage of WGS variant calls?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27085415", "http://www.ncbi.nlm.nih.gov/pubmed/28334390", "http://www.ncbi.nlm.nih.gov/pubmed/27964746"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Reducing animal sequencing redundancy by preferentially selecting animals with low-frequency haplotypes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27085415"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Many studies leverage targeted whole-genome sequencing (WGS) experiments to identify rare and causal variants within populations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27085415"}, {"offsetInBeginSection": 380, "offsetInEndSection": 591, "text": "We propose a new algorithm, called inverse weight selection (IWS), that preferentially selects individuals based on the cumulative presence of rare frequency haplotypes to maximize the efficiency of WGS surveys.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27085415"}, {"offsetInBeginSection": 735, "offsetInEndSection": 958, "text": "We demonstrate that IWS is at least 6.8% more efficient than previously published methods in selecting the least number of individuals required to sequence all haplotype segments \u22654% frequency in the US Holstein population.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27085415"}, {"offsetInBeginSection": 959, "offsetInEndSection": 1155, "text": "We also suggest that future surveys focus on sequencing homozygous haplotype segments as a first pass to achieve a 50% reduction in cost with an added benefit of phasing variant calls efficiently.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27085415"}, {"offsetInBeginSection": 1156, "offsetInEndSection": 1404, "text": "Together, this new selection algorithm and experimental design suggestion significantly reduce the overall cost of variant discovery through WGS experiments, making surveys for causal variants influencing disease and production even more efficient.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27085415"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "SeqArray-a storage-efficient high-performance data format for WGS variant calls.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334390"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Motivation: Whole-genome sequencing (WGS) data are being generated at an unprecedented rate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334390"}, {"offsetInBeginSection": 93, "offsetInEndSection": 192, "text": "Analysis of WGS data requires a flexible data format to store the different types of DNA variation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334390"}, {"offsetInBeginSection": 193, "offsetInEndSection": 309, "text": "Variant call format (VCF) is a general text-based format developed to store variant genotypes and their annotations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334390"}]}, {"id": "5a9924ea1d1251d03b000008", "body": "What is the association of circular RNA to breast cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28933584", "http://www.ncbi.nlm.nih.gov/pubmed/28744405", "http://www.ncbi.nlm.nih.gov/pubmed/27829232", "http://www.ncbi.nlm.nih.gov/pubmed/28739726", "http://www.ncbi.nlm.nih.gov/pubmed/28349836", "http://www.ncbi.nlm.nih.gov/pubmed/29109417", "http://www.ncbi.nlm.nih.gov/pubmed/28803498", "http://www.ncbi.nlm.nih.gov/pubmed/27965971", "http://www.ncbi.nlm.nih.gov/pubmed/29045858", "http://www.ncbi.nlm.nih.gov/pubmed/28484086"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Circular RNA hsa_circ_0001982 Promotes Breast Cancer Cell Carcinogenesis Through Decreasing miR-143.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Circular RNAs (circRNAs) are a type of noncoding RNAs generated from back-splicing, which have been verified to mediate multiple tumorigenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584"}, {"offsetInBeginSection": 248, "offsetInEndSection": 338, "text": "However, the potential physiological effect of circRNAs in breast cancer is still unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584"}, {"offsetInBeginSection": 339, "offsetInEndSection": 518, "text": "The purpose of this study is to investigate the expression profile of circRNA in breast cancer tissue and explore the in-depth regulatory mechanism in breast cancer tumorigenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584"}, {"offsetInBeginSection": 519, "offsetInEndSection": 643, "text": "In the present study, we screened the circRNA expression profiles in breast cancer tissue using circRNA microarray analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584"}, {"offsetInBeginSection": 712, "offsetInEndSection": 830, "text": "Among these dysregulated circRNAs, hsa_circ_0001982 was markedly overexpressed in breast cancer tissue and cell lines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584"}, {"offsetInBeginSection": 970, "offsetInEndSection": 1151, "text": "Loss-of-function and rescue experiments revealed that hsa_circ_0001982 knockdown suppressed breast cancer cell proliferation and invasion and induced apoptosis by targeting miR-143.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584"}, {"offsetInBeginSection": 1152, "offsetInEndSection": 1394, "text": "In summary, our study preliminarily investigates the circRNA expression in breast cancer tissue and explores the role of competing endogenous RNA (ceRNA) mechanism in the progression, providing a novel insight for breast cancer tumorigenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744405"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Circular RNA (circRNA) is a key regulator in the development and progression of human cancers, however its role in breast cancer tumorigenesis is not well understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744405"}]}, {"id": "5a95765bfcd1d6a10c000028", "body": "What part of what body organ controls the circadian clock?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23704227", "http://www.ncbi.nlm.nih.gov/pubmed/21969583", "http://www.ncbi.nlm.nih.gov/pubmed/21763748", "http://www.ncbi.nlm.nih.gov/pubmed/24013905", "http://www.ncbi.nlm.nih.gov/pubmed/26144255", "http://www.ncbi.nlm.nih.gov/pubmed/20448639", "http://www.ncbi.nlm.nih.gov/pubmed/11743124", "http://www.ncbi.nlm.nih.gov/pubmed/28779094", "http://www.ncbi.nlm.nih.gov/pubmed/28707700", "http://www.ncbi.nlm.nih.gov/pubmed/27385482"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 31, "text": "The circadian clock and asthma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704227"}, {"offsetInBeginSection": 211, "offsetInEndSection": 455, "text": "An extensive body of research has demonstrated that nocturnal symptoms of cough and dyspnea are accompanied by circadian variations in airway inflammation and physiologic variables, including airflow limitation and airways hyper-responsiveness.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704227"}, {"offsetInBeginSection": 589, "offsetInEndSection": 736, "text": "Clock genes control circadian rhythms both centrally, in the suprachiasmatic nucleus of the brain and peripherally, within every organ of the body.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704227"}, {"offsetInBeginSection": 737, "offsetInEndSection": 802, "text": "Here, we will discuss how clock genes regulate circadian rhythms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704227"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Tissue-intrinsic dysfunction of circadian clock confers transplant arteriosclerosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21969583"}, {"offsetInBeginSection": 347, "offsetInEndSection": 651, "text": "To determine the impact of circadian clock function in organ transplantation and dissect the influence of intrinsic tissue clocks versus extrinsic clocks, we implemented a blood vessel grafting approach to surgically assemble a chimeric mouse that was part wild-type (WT) and part circadian clock mutant.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21969583"}, {"offsetInBeginSection": 834, "offsetInEndSection": 1069, "text": "Similarly, when WT grafts were anastamosed to mice with disrupted circadian clocks, the structural features of the WT grafts immersed in the milieu of circadian malfunction were normal and absent of lesions, comparable to WT:WT grafts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21969583"}, {"offsetInBeginSection": 1479, "offsetInEndSection": 1735, "text": "These data demonstrate the significance of intrinsic tissue clocks as an autonomous influence in experimental models of arteriosclerotic disease, which may have implications with regard to the influence of circadian clock function in organ transplantation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21969583"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Role of the renal circadian timing system in maintaining water and electrolytes homeostasis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21763748"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Many basic physiological functions exhibit circadian rhythmicity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21763748"}]}, {"id": "5aa4f47cd6d6b54f7900000a", "body": "When is 16S rRNA Gene Sequencing used?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/14535548", "http://www.ncbi.nlm.nih.gov/pubmed/26770469", "http://www.ncbi.nlm.nih.gov/pubmed/27842515", "http://www.ncbi.nlm.nih.gov/pubmed/28940494", "http://www.ncbi.nlm.nih.gov/pubmed/25646627", "http://www.ncbi.nlm.nih.gov/pubmed/21240067", "http://www.ncbi.nlm.nih.gov/pubmed/21121044", "http://www.ncbi.nlm.nih.gov/pubmed/27077030", "http://www.ncbi.nlm.nih.gov/pubmed/18353221", "http://www.ncbi.nlm.nih.gov/pubmed/17037387"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "This study evaluated 16S rRNA gene sequence analysis methods as tools for identification of 22 phenotypically difficult to identify veterinary clinical bacterial isolates in a veterinary diagnostic laboratory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14535548"}, {"offsetInBeginSection": 210, "offsetInEndSection": 305, "text": "The study compared 16S rRNA gene sequencing and conventional phenotypic identification methods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14535548"}, {"offsetInBeginSection": 306, "offsetInEndSection": 443, "text": "Using 16S rRNA full-gene sequencing, 95% (21/22) of the isolates were identified to the genus level and 86% (19/22) to the species level.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14535548"}, {"offsetInBeginSection": 653, "offsetInEndSection": 834, "text": "However, only 55% (12/22) or 4.5% (1/22) of the phenotypic identifications were correct at the genus or species level when they were compared with the 16S rRNA full-gene sequencing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14535548"}, {"offsetInBeginSection": 835, "offsetInEndSection": 907, "text": "This study also compared 16S rRNA full-gene and partial-gene sequencing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14535548"}, {"offsetInBeginSection": 908, "offsetInEndSection": 1062, "text": "The results demonstrated that the best 16S rRNA gene-sequencing approach is full-gene sequencing because it gives the most precise species identification.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14535548"}, {"offsetInBeginSection": 1063, "offsetInEndSection": 1309, "text": "Sequencing of the variable regions 1, 2, and 3 of the 16S rRNA gene could be used for tentative identification because the ability of this sequencing to identify bacteria to the genus level is similar to that of the 16S rRNA full-gene sequencing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14535548"}, {"offsetInBeginSection": 1310, "offsetInEndSection": 1437, "text": "This method identified only 14% (3/22) isolates differently to the species level compared with the 16S rRNA full gene sequence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14535548"}, {"offsetInBeginSection": 1438, "offsetInEndSection": 1552, "text": "Sequencing of the variable regions 7, 8, and 9 is not recommended because it gives more ambiguous identifications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14535548"}, {"offsetInBeginSection": 1553, "offsetInEndSection": 1762, "text": "The cost of a 16S RNA full-gene-sequencing analysis was Can 160 dollars and Can 60 dollars for a partial 16S rRNA gene sequence, i.e., sequencing of variable regions 1, 2, and 3 or variable regions 7, 8 and 9.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14535548"}]}, {"id": "5a723cd12dc08e987e00000b", "body": "Can CD55 deficiency cause thrombosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22696589", "http://www.ncbi.nlm.nih.gov/pubmed/28657829"], "snippets": [{"offsetInBeginSection": 193, "offsetInEndSection": 364, "text": "We assessed the role of PNH defect in 81 patients with intra-abdominal thrombosis, 44 patients of Budd Chiari syndrome and 37 patients of extra hepatic venous obstruction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696589"}, {"offsetInBeginSection": 664, "offsetInEndSection": 755, "text": "This was due to CD55 deficiency on red blood cells and CD16 deficiency on the granulocytes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696589"}, {"offsetInBeginSection": 756, "offsetInEndSection": 818, "text": "Deficiency of multiple GPI-APs was less frequent (3.7% cases).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696589"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657829"}]}, {"id": "5a7633a89e632bc066000002", "body": "What is the purpose of the Tabix tool?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21208982", "http://www.ncbi.nlm.nih.gov/pubmed/29137598"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Tabix: fast retrieval of sequence features from generic TAB-delimited files.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "UNLABELLED: Tabix is the first generic tool that indexes position sorted files in TAB-delimited formats such as GFF, BED, PSL, SAM and SQL export, and quickly retrieves features overlapping specified regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982"}, {"offsetInBeginSection": 209, "offsetInEndSection": 335, "text": "Tabix features include few seek function calls per query, data compression with gzip compatibility and direct FTP/HTTP access.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982"}, {"offsetInBeginSection": 336, "offsetInEndSection": 434, "text": "Tabix is implemented as a free command-line tool as well as a library in C, Java, Perl and Python.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982"}, {"offsetInBeginSection": 435, "offsetInEndSection": 636, "text": "It is particularly useful for manually examining local genomic features on the command line and enables genome viewers to support huge data files and remote custom tracks over networks.AVAILABILITY AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "GFF3sort: a novel tool to sort GFF3 files for tabix indexing.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598"}, {"offsetInBeginSection": 148, "offsetInEndSection": 311, "text": "The latest version of JBrowse supports rendering sorted GFF3 files indexed by tabix, a novel strategy that is more convenient than the original conversion process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598"}, {"offsetInBeginSection": 460, "offsetInEndSection": 539, "text": "RESULTS: We developed GFF3sort, a script to sort GFF3 files for tabix indexing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598"}, {"offsetInBeginSection": 938, "offsetInEndSection": 1014, "text": "CONCLUSIONS: GFF3sort is a novel tool to sort GFF3 files for tabix indexing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598"}]}, {"id": "5a9929ed1d1251d03b000009", "body": "What is maternal spindle transfer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27973714", "http://www.ncbi.nlm.nih.gov/pubmed/28429249", "http://www.ncbi.nlm.nih.gov/pubmed/28852557", "http://www.ncbi.nlm.nih.gov/pubmed/28683668", "http://www.ncbi.nlm.nih.gov/pubmed/29121011"], "snippets": [{"offsetInBeginSection": 662, "offsetInEndSection": 779, "text": "I investigate, specifically, the moral permissibility of employing pronuclear transfer and maternal spindle transfer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27973714"}, {"offsetInBeginSection": 780, "offsetInEndSection": 990, "text": "I conclude that, according to a Habermasian perspective on prenatal genetic manipulation, maternal spindle transfer (without using a preselected sperm and egg) and pronuclear transfer are morally impermissible.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27973714"}, {"offsetInBeginSection": 991, "offsetInEndSection": 1149, "text": "Maternal spindle transfer is, in principle, morally permissible, but only when we have beforehand preselected a sperm and an egg for our reproductive purpose.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27973714"}, {"offsetInBeginSection": 1422, "offsetInEndSection": 1683, "text": "In fact, the answer to this question does not only normatively prescribe what bioconservatives should do in terms of their personal morality, but it also points towards what kind of legislation regulating mitochondrial replacement techniques they should aim at.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27973714"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Are there moral differences between maternal spindle transfer and pronuclear transfer?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28429249"}, {"offsetInBeginSection": 0, "offsetInEndSection": 325, "text": "This paper examines whether there are moral differences between the mitochondrial replacement techniques that have been recently developed in order to help women afflicted by mitochondrial DNA diseases to have genetically related children\u00a0absent such conditions: maternal spindle transfer (MST) and pronuclear transfer (PNT).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28429249"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Mitochondrial replacement techniques and Mexico's rule of law: on the legality of the first maternal spindle transfer case.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28852557"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "News about the first baby born after a mitochondrial replacement technique (MRT; specifically maternal spindle transfer) broke on September 27, 2016 and, in a matter of hours, went global.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28852557"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Kinship Identities in the Context of UK Maternal Spindle Transfer and Pronuclear Transfer Legislation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683668"}, {"offsetInBeginSection": 0, "offsetInEndSection": 340, "text": "In the discussions leading up to the enactment of the UK Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015, it was repeatedly emphasised, by many commentators, that maternal spindle transfer (MST) and pronuclear transfer (PNT) did not give rise to children who could be considered as having three or more parents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683668"}]}, {"id": "5a96c74cfcd1d6a10c000029", "body": "What illness is transmitted by the Lone Star Tick, Amblyomma americanum?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28319627", "http://www.ncbi.nlm.nih.gov/pubmed/19054615", "http://www.ncbi.nlm.nih.gov/pubmed/19874183", "http://www.ncbi.nlm.nih.gov/pubmed/18452807", "http://www.ncbi.nlm.nih.gov/pubmed/20380308", "http://www.ncbi.nlm.nih.gov/pubmed/19378409", "http://www.ncbi.nlm.nih.gov/pubmed/18447622", "http://www.ncbi.nlm.nih.gov/pubmed/27729288", "http://www.ncbi.nlm.nih.gov/pubmed/23637969", "http://www.ncbi.nlm.nih.gov/pubmed/20496596"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 18, "text": "What's eating you?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627"}, {"offsetInBeginSection": 19, "offsetInEndSection": 57, "text": "lone star tick (Amblyomma americanum).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Role of the lone star tick, Amblyomma americanum (L.), in human and animal diseases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19054615"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "We reviewed scientific literature pertaining to known and putative disease agents associated with the lone star tick, Amblyomma americanum.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19054615"}, {"offsetInBeginSection": 140, "offsetInEndSection": 321, "text": "Reports in the literature concerning the role of the lone star tick in the transmission of pathogens of human and animal diseases have sometimes been unclear and even contradictory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19054615"}, {"offsetInBeginSection": 633, "offsetInEndSection": 787, "text": "Also, there is a definite association between A. americanum and tularemia, as well as between the lone star tick and Theileria cervi to white-tailed deer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19054615"}, {"offsetInBeginSection": 911, "offsetInEndSection": 1074, "text": "The role of A. americanum in cases of southern tick-associated rash illness (STARI) is currently a subject of intensive investigations with important implications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19054615"}, {"offsetInBeginSection": 1075, "offsetInEndSection": 1226, "text": "The lone star tick has been historically reported to be a vector of Rocky Mountain spotted fever rickettsiae, but current opinions are to the contrary.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19054615"}, {"offsetInBeginSection": 1351, "offsetInEndSection": 1472, "text": "Q fever virus has been found in unfed A. americanum, but the vector potential, if any, is poorly understood at this time.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19054615"}, {"offsetInBeginSection": 1473, "offsetInEndSection": 1602, "text": "Typhus fever and toxoplasmosis have been studied in the lone star tick, and several non-pathogenic organisms have been recovered.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19054615"}]}, {"id": "5aa50086d6d6b54f7900000c", "body": "Which is the function of ubiquilins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24674348", "http://www.ncbi.nlm.nih.gov/pubmed/19398896", "http://www.ncbi.nlm.nih.gov/pubmed/22628307", "http://www.ncbi.nlm.nih.gov/pubmed/18307982", "http://www.ncbi.nlm.nih.gov/pubmed/26152284", "http://www.ncbi.nlm.nih.gov/pubmed/27345149", "http://www.ncbi.nlm.nih.gov/pubmed/17603015"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "BACKGROUND: Ubiquilins are proteins that function as ubiquitin receptors in eukaryotes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24674348"}, {"offsetInBeginSection": 768, "offsetInEndSection": 829, "text": "Seven different ubiquilins have been detected in vertebrates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24674348"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Ubiquilins accelerate autophagosome maturation and promote cell  survival during nutrient starvation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19398896"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Ubiquilins (UBQLN), a family of adaptor proteins with partial homology with ubiquitin, are proposed to facilitate proteasomal degradation of ubiquitinated substrates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19398896"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Ubiquilins in the crosstalk among proteolytic pathways.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22628307"}, {"offsetInBeginSection": 110, "offsetInEndSection": 233, "text": "There is evidence that these processes are linked and that crosstalk among these major protein degradation pathways occurs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22628307"}, {"offsetInBeginSection": 234, "offsetInEndSection": 335, "text": "Ubiquilins, a family of ubiquitin-binding proteins, are involved in all protein degradation pathways.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22628307"}, {"offsetInBeginSection": 336, "offsetInEndSection": 535, "text": "This minireview provides an overview of ubiquilin function in protein degradation and contrasts it with sequestosome-1 (p62), a protein that also has been implicated in multiple proteolytic pathways.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22628307"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Herp enhances ER-associated protein degradation by recruiting ubiquilins.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18307982"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "ER-associated protein degradation (ERAD) is a protein quality control system of ER, which eliminates misfolded proteins by proteasome-dependent degradation and ensures export of only properly folded proteins from ER.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18307982"}]}, {"id": "5a7240aa2dc08e987e00000d", "body": "List two human monoclonal antibodies against Clostridium difficile toxins.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20089970", "http://www.ncbi.nlm.nih.gov/pubmed/23629713", "http://www.ncbi.nlm.nih.gov/pubmed/28274145", "http://www.ncbi.nlm.nih.gov/pubmed/1900059", "http://www.ncbi.nlm.nih.gov/pubmed/16966409", "http://www.ncbi.nlm.nih.gov/pubmed/9237345", "http://www.ncbi.nlm.nih.gov/pubmed/27336843", "http://www.ncbi.nlm.nih.gov/pubmed/25486992", "http://www.ncbi.nlm.nih.gov/pubmed/1378062"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Treatment with monoclonal antibodies against Clostridium difficile toxins.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089970"}, {"offsetInBeginSection": 146, "offsetInEndSection": 326, "text": "METHODS: We performed a randomized, double-blind, placebo-controlled study of two neutralizing, fully human monoclonal antibodies against C. difficile toxins A (CDA1) and B (CDB1).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089970"}, {"offsetInBeginSection": 327, "offsetInEndSection": 550, "text": "The antibodies were administered together as a single infusion, each at a dose of 10 mg per kilogram of body weight, in patients with symptomatic C. difficile infection who were receiving either metronidazole or vancomycin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089970"}, {"offsetInBeginSection": 551, "offsetInEndSection": 701, "text": "The primary outcome was laboratory-documented recurrence of infection during the 84 days after the administration of monoclonal antibodies or placebo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089970"}, {"offsetInBeginSection": 701, "offsetInEndSection": 963, "text": "RESULTS: Among the 200 patients who were enrolled (101 in the antibody group and 99 in the placebo group), the rate of recurrence of C. difficile infection was lower among patients treated with monoclonal antibodies (7% vs. 25%; 95% confidence interval, 7 to 29;", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089970"}, {"offsetInBeginSection": 964, "offsetInEndSection": 1128, "text": "PCONCLUSIONS: The addition of monoclonal antibodies against C. difficile toxins to antibiotic agents significantly reduced the recurrence of C. difficile infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089970"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629713"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Clostridium difficile infection (CDI) is a common and debilitating nosocomial infection with high morbidity and mortality.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629713"}, {"offsetInBeginSection": 123, "offsetInEndSection": 211, "text": "C. difficile mediates diarrhea and colitis by releasing two toxins, toxin A and toxin B.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629713"}, {"offsetInBeginSection": 212, "offsetInEndSection": 452, "text": "Since both toxins stimulate proinflammatory signaling pathways in human colonocytes and both are involved in the pathophysiology of CDI, neutralization of toxin A and B activities may represent an important therapeutic approach against CDI.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629713"}]}, {"id": "5a76344e9e632bc066000003", "body": "Which algorithms are used for compression of SAM files?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29046896", "http://www.ncbi.nlm.nih.gov/pubmed/22164252", "http://www.ncbi.nlm.nih.gov/pubmed/26026138", "http://www.ncbi.nlm.nih.gov/pubmed/27540265", "http://www.ncbi.nlm.nih.gov/pubmed/23533605"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "GeneComp, a new reference-based compressor for SAM files.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29046896"}, {"offsetInBeginSection": 138, "offsetInEndSection": 264, "text": "The most popular format for genomic data is the SAM format, which contains information such as alignment, quality values, etc.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29046896"}, {"offsetInBeginSection": 265, "offsetInEndSection": 347, "text": "These files are large (on the order of terabytes), which necessitates compression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29046896"}, {"offsetInBeginSection": 348, "offsetInEndSection": 515, "text": "In this work we propose a new reference-based compressor for SAM files, which can accommodate different levels of compression, based on the specific needs of the user.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29046896"}, {"offsetInBeginSection": 516, "offsetInEndSection": 732, "text": "In particular, the proposed compressor GeneComp allows the user to perform lossy compression of the quality scores, which have been proven to occupy more than half of the compressed file (when losslessly compressed).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29046896"}, {"offsetInBeginSection": 733, "offsetInEndSection": 888, "text": "We show that the proposed compressor GeneComp overall achieves better compression ratios than previously proposed algorithms when working on lossless mode.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29046896"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Improving transmission efficiency of large sequence alignment/map (SAM) files.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22164252"}, {"offsetInBeginSection": 187, "offsetInEndSection": 319, "text": "In recent years, some research has been done to find efficient compression algorithms to reduce the size of various sequencing data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22164252"}, {"offsetInBeginSection": 320, "offsetInEndSection": 427, "text": "One way to improve the transmission time of large files is to apply a maximum lossless compression on them.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22164252"}, {"offsetInBeginSection": 428, "offsetInEndSection": 638, "text": "In this paper, we present SAMZIP, a specialized encoding scheme, for sequence alignment data in SAM (Sequence Alignment/Map) format, which improves the compression ratio of existing compression tools available.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22164252"}]}, {"id": "5a992b371d1251d03b00000a", "body": "What does MetaHIT stand for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24949196", "http://www.ncbi.nlm.nih.gov/pubmed/25291122", "http://www.ncbi.nlm.nih.gov/pubmed/24416266", "http://www.ncbi.nlm.nih.gov/pubmed/28357466"], "snippets": [{"offsetInBeginSection": 754, "offsetInEndSection": 932, "text": "While eukaryotic DNA was most efficiently extracted by the MetaHIT protocol, DNA from bacteria within the Bacteroidetes phylum was most efficiently extracted by the HMP protocol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24949196"}, {"offsetInBeginSection": 932, "offsetInEndSection": 1180, "text": "CONCLUSIONS: Whereas it is comforting that the inter-individual variation clearly exceeded the variation resulting from choice of extraction method, our data highlight the challenge of comparing data across studies applying different methodologies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24949196"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "A taxonomic signature of obesity in the microbiome?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24416266"}, {"offsetInBeginSection": 261, "offsetInEndSection": 418, "text": "However, human and animal-model studies have yielded conflicting results about the precise nature of associations between microbiome composition and obesity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24416266"}, {"offsetInBeginSection": 419, "offsetInEndSection": 658, "text": "In this paper, we use publicly available data from the Human Microbiome Project (HMP) and MetaHIT, both surveys of healthy adults that include obese individuals, plus two smaller studies that specifically examined lean versus obese adults.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24416266"}, {"offsetInBeginSection": 243, "offsetInEndSection": 387, "text": "With the introduction of culture-independent analysis methods, comprehensive cataloging of the human microbiome was possible for the first time.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28357466"}, {"offsetInBeginSection": 465, "offsetInEndSection": 583, "text": "The goals of the Human Microbiome Project and MetaHIT include comparative studies of healthy and diseased individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28357466"}, {"offsetInBeginSection": 710, "offsetInEndSection": 793, "text": "However, a mathematical correlation does not equal biological or medical relevance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28357466"}]}, {"id": "5a981dd0fcd1d6a10c00002e", "body": "Are sleep apnea and snoring associated with cardiac arrhythmias?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7774322", "http://www.ncbi.nlm.nih.gov/pubmed/2669355", "http://www.ncbi.nlm.nih.gov/pubmed/3106890", "http://www.ncbi.nlm.nih.gov/pubmed/1630643"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "Cardiac arrhythmias, snoring, and sleep apnea.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7774322"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "We investigated the frequency of cardiac arrhythmias in patients suspected of having sleep apnea, and related them to the severity of apnea, snoring, and nocturnal hypoxemia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7774322"}, {"offsetInBeginSection": 175, "offsetInEndSection": 485, "text": "We prospectively studied 458 patients who had nocturnal polysomnography which included objective measurement of snoring (quantified by the number of snores per hour of sleep [snoring index (SI)] and maximum nocturnal sound intensity [(dBmax)], as well as examination of the electrocardiogram (modified lead 2).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7774322"}, {"offsetInBeginSection": 486, "offsetInEndSection": 771, "text": "We found 58 percent prevalence of arrhythmias in patients with sleep apnea (apnea/hypopnea index = AHI > 10), vs 42 percent in nonapneic controls (chi 2 = 16.7, p  90 percent (chi 2 = 7.4, p = 0.006), and 70 percent of patients with AHI > or = 40 had arrhythmias vs 42 percent with AHI", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7774322"}, {"offsetInBeginSection": 0, "offsetInEndSection": 35, "text": "[Snoring and sleep apnea syndrome].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669355"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Sleep apnea and obstructive snoring are sleep related breathing disorders (SRBD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669355"}, {"offsetInBeginSection": 82, "offsetInEndSection": 192, "text": "Nevertheless, there is only a quantitative difference between snoring and the obstructive form of sleep apnea.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669355"}, {"offsetInBeginSection": 193, "offsetInEndSection": 277, "text": "Snoring occurs in at least 20% of the population; 50% of the 50 year old male snore.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669355"}, {"offsetInBeginSection": 344, "offsetInEndSection": 546, "text": "It becomes serious if it leads as the independent SRBD \"obstructive snoring\" to a continuous oxygen desaturation and a sleep disturbance or, if in cases of sleep apnea a postapnoic snoring is concerned.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669355"}, {"offsetInBeginSection": 625, "offsetInEndSection": 712, "text": "Still, no exact statement can be given concerning the frequency of obstructive snoring.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669355"}]}, {"id": "5aa80873d6d6b54f79000013", "body": "List ribosomal biogenesis proteins.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18773413", "http://www.ncbi.nlm.nih.gov/pubmed/19878869", "http://www.ncbi.nlm.nih.gov/pubmed/28685141", "http://www.ncbi.nlm.nih.gov/pubmed/20554519", "http://www.ncbi.nlm.nih.gov/pubmed/25088252", "http://www.ncbi.nlm.nih.gov/pubmed/20061553", "http://www.ncbi.nlm.nih.gov/pubmed/23169665", "http://www.ncbi.nlm.nih.gov/pubmed/29143558", "http://www.ncbi.nlm.nih.gov/pubmed/20188109", "http://www.ncbi.nlm.nih.gov/pubmed/28986221"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Crosstalk between c-Myc and ribosome in ribosomal biogenesis and cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18773413"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Protein production is driven by protein translation and relies on ribosomal biogenesis, globally essential for cell growth, proliferation, and animal development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18773413"}, {"offsetInBeginSection": 373, "offsetInEndSection": 567, "text": "One newly identified key regulator for ribosomal biogenesis and translation is the oncoprotein c-Myc, whose aberrantly excessive level and activity are highly associated with human cancers, too.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18773413"}, {"offsetInBeginSection": 568, "offsetInEndSection": 662, "text": "Recently, we have shown that ribosomal protein L11 functions as a feedback regulator of c-Myc.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18773413"}, {"offsetInBeginSection": 663, "offsetInEndSection": 838, "text": "Hence, in this review, we will provide some prospects on the interplay between c-Myc and ribosomal proteins during ribosomal biogenesis and discuss its implications in cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18773413"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Signaling to p53: ribosomal proteins find their way.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19878869"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Inherently disparate cell growth and division, which are intimately coupled through a delicate network of intracellular and extracellular signaling, require ribosomal biogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19878869"}, {"offsetInBeginSection": 179, "offsetInEndSection": 271, "text": "A number of events imparting instability to ribosomal biogenesis can cause nucleolar stress.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19878869"}, {"offsetInBeginSection": 272, "offsetInEndSection": 445, "text": "In response to this stress, several ribosomal proteins bind to MDM2 and block MDM2-mediated p53 ubiquitination and degradation, resulting in p53-dependent cell cycle arrest.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19878869"}, {"offsetInBeginSection": 446, "offsetInEndSection": 573, "text": "By doing so, the ribosomal proteins play a crucial role in connecting deregulated cell growth with inhibition of cell division.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19878869"}]}, {"id": "5a7339372dc08e987e000013", "body": "List drugs that are included in the Vosevi polypill.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24561141", "http://www.ncbi.nlm.nih.gov/pubmed/27818251", "http://www.ncbi.nlm.nih.gov/pubmed/20549577", "http://www.ncbi.nlm.nih.gov/pubmed/27538505", "http://www.ncbi.nlm.nih.gov/pubmed/16783994", "http://www.ncbi.nlm.nih.gov/pubmed/21205325", "http://www.ncbi.nlm.nih.gov/pubmed/28341983", "http://www.ncbi.nlm.nih.gov/pubmed/26390808", "http://www.ncbi.nlm.nih.gov/pubmed/26747390", "http://www.ncbi.nlm.nih.gov/pubmed/29127755"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Polypills: essential medicines for cardiovascular disease secondary prevention?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561141"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Polypill is a medication designed for preventing heart attacks through a combination of drugs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251"}, {"offsetInBeginSection": 95, "offsetInEndSection": 203, "text": "Current formulations contain blood pressure-lowering drugs and others, such statins or acetylsalicylic acid.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251"}, {"offsetInBeginSection": 204, "offsetInEndSection": 306, "text": "These drugs exhibit different physical chemical features, and consequently different release kinetics.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251"}, {"offsetInBeginSection": 625, "offsetInEndSection": 805, "text": "The procedure is based on mesoporous silica nanoparticles (MSN) with MCM-41 structure (MSN-41) used as carrier, aimed to control release of the four drugs included in the polypill.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251"}, {"offsetInBeginSection": 1103, "offsetInEndSection": 1206, "text": "Amlodipine, losartan and simvastatin were released from the polypill-MSN-41 system in a controlled way.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251"}, {"offsetInBeginSection": 1448, "offsetInEndSection": 1567, "text": "In addition, an increase in the stability of amlodipine and hydrochlorothiazide occurred in the polypill-MSN-41 system.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Mesoporous silica nanoparticles as a new carrier methodology in the controlled release of the active components in a polypill.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251"}, {"offsetInBeginSection": 0, "offsetInEndSection": 29, "text": "Polypill: lights and shadows.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20549577"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "The idea of packaging and formulating several drugs commonly used in cardiovascular disease prevention into a single polypill is appealing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20549577"}]}, {"id": "5a7639419e632bc066000005", "body": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29036616"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "DeepLoc: prediction of protein subcellular localization using deep learning.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Motivation: The prediction of eukaryotic protein subcellular localization is a well-studied topic in bioinformatics due to its relevance in proteomics research.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616"}, {"offsetInBeginSection": 161, "offsetInEndSection": 327, "text": "Many machine learning methods have been successfully applied in this task, but in most of them, predictions rely on annotation of homologues from knowledge databases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616"}, {"offsetInBeginSection": 328, "offsetInEndSection": 691, "text": "For novel proteins where no annotated homologues exist, and for predicting the effects of sequence variants, it is desirable to have methods for predicting protein properties from sequence information only.Results: Here, we present a prediction algorithm using deep neural networks to predict protein subcellular localization relying only on sequence information.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616"}, {"offsetInBeginSection": 692, "offsetInEndSection": 899, "text": "At its core, the prediction model uses a recurrent neural network that processes the entire protein sequence and an attention mechanism identifying protein regions important for the subcellular localization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616"}]}, {"id": "5a99332a1d1251d03b00000e", "body": "How is Hsd17b1 associated with endometriosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15640252", "http://www.ncbi.nlm.nih.gov/pubmed/28405865", "http://www.ncbi.nlm.nih.gov/pubmed/20586553", "http://www.ncbi.nlm.nih.gov/pubmed/25403437", "http://www.ncbi.nlm.nih.gov/pubmed/22613790", "http://www.ncbi.nlm.nih.gov/pubmed/26261478"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Association between endometriosis and genetic polymorphisms of the estradiol-synthesizing enzyme genes HSD17B1 and CYP19.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "BACKGROUND: Endometriosis, an estrogen-dependent disease, is believed to be influenced by multiple genetic and environmental factors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252"}, {"offsetInBeginSection": 134, "offsetInEndSection": 431, "text": "Here, we evaluated whether the risk and severity of endometriosis are associated with polymorphisms in estradiol-synthesizing enzyme genes: the Ser312Gly polymorphism in 17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) and the Arg264Cys polymorphism in cytochrome P450, subfamily XIX (CYP19).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252"}, {"offsetInBeginSection": 431, "offsetInEndSection": 604, "text": "METHODS: All participants underwent diagnostic laparoscopy, and the stage of endometriosis was determined according to the Revised American Fertility Society classification.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252"}, {"offsetInBeginSection": 605, "offsetInEndSection": 727, "text": "Of the 138 women enrolled, 59 had no endometriosis, 21 had stage I, 10 had stage II, 23 had stage III and 25 had stage IV.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252"}, {"offsetInBeginSection": 801, "offsetInEndSection": 1040, "text": "RESULTS: Individuals having at least one A-allele (A/G or A/A genotype) of HSD17B1 showed a significantly increased risk of endometriosis (A/G genotype: adjusted OR, 3.06; 95%CI 1.21-7.74; A/A genotype: adjusted OR, 3.02; 95%CI 1.08-8.43).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252"}, {"offsetInBeginSection": 1041, "offsetInEndSection": 1146, "text": "There was a significant trend associating A/G + A/A genotypes with severity of endometriosis (P for trend", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252"}, {"offsetInBeginSection": 1147, "offsetInEndSection": 1284, "text": "CONCLUSIONS: Evidence for association between the Ser312Gly polymorphism in HSD17B1 and endometriosis was found in a Japanese population.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252"}, {"offsetInBeginSection": 1285, "offsetInEndSection": 1357, "text": "The A-allele of HSD17B1 appears to confer higher risk for endometriosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Involvement of 17\u03b2-hydroxysteroid dehydrogenase type gene 1 937 A>G polymorphism in infertility in Polish Caucasian women with endometriosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28405865"}]}, {"id": "5a9eb008d6d6b54f79000001", "body": "List the continent of origin for the brown marmorated stinkbug(Halyomorpha halys)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22828257", "http://www.ncbi.nlm.nih.gov/pubmed/26955631", "http://www.ncbi.nlm.nih.gov/pubmed/25474148", "http://www.ncbi.nlm.nih.gov/pubmed/24871833", "http://www.ncbi.nlm.nih.gov/pubmed/24586332", "http://www.ncbi.nlm.nih.gov/pubmed/27744285", "http://www.ncbi.nlm.nih.gov/pubmed/23865219", "http://www.ncbi.nlm.nih.gov/pubmed/26463187", "http://www.ncbi.nlm.nih.gov/pubmed/24285660", "http://www.ncbi.nlm.nih.gov/pubmed/28984006"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Irritant contact dermatitis to the brown marmorated stink bug, Halyomorpha halys.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22828257"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "The brown marmorated stink bug, Halyomorpha halys, is native to Asia (China, Taiwan, Japan, and the Korean peninsula).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22828257"}, {"offsetInBeginSection": 233, "offsetInEndSection": 333, "text": "As of October 2010, at least 26 states have reported the presence of the brown marmorated stink bug.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22828257"}, {"offsetInBeginSection": 584, "offsetInEndSection": 686, "text": "Fruit crop workers have complained of a slight allergic reaction to the chemicals released by the bug.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22828257"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Real-Time PCR Assay for the Identification of the Brown Marmorated Stink Bug (Halyomorpha halys).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26955631"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "The brown marmorated stink bug, Halyomorpha halys (Hemiptera: Pentatomidae), is a gregarious crop pest that has rapidly spread across the world in the last two decades.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26955631"}, {"offsetInBeginSection": 391, "offsetInEndSection": 569, "text": "Inadequate identification keys and similarity to common species has assisted its spread across Europe, while accurate identification from immature stages or eggs is not possible.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26955631"}, {"offsetInBeginSection": 570, "offsetInEndSection": 708, "text": "We developed a real-time TaqMan PCR assay for the accurate and sensitive detection of the brown marmorated stink bug from all life stages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26955631"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Electronically monitored labial dabbing and stylet 'probing' behaviors of brown marmorated stink bug, Halyomorpha halys, in simulated environments.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25474148"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "Brown marmorated stink bug, Halyomorpha halys (St\u00e5l), (Hemiptera: Pentatomidae) is an invasive polyphagous agricultural and urban nuisance pest of Asian origin that is becoming widespread in North America and Europe.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25474148"}]}, {"id": "5aa82180d6d6b54f79000015", "body": "Are osteoclasts specialized in bone degradation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19372577", "http://www.ncbi.nlm.nih.gov/pubmed/24992711", "http://www.ncbi.nlm.nih.gov/pubmed/9819571", "http://www.ncbi.nlm.nih.gov/pubmed/8395372", "http://www.ncbi.nlm.nih.gov/pubmed/14702187", "http://www.ncbi.nlm.nih.gov/pubmed/11193210", "http://www.ncbi.nlm.nih.gov/pubmed/27514812", "http://www.ncbi.nlm.nih.gov/pubmed/22941736", "http://www.ncbi.nlm.nih.gov/pubmed/10968780", "http://www.ncbi.nlm.nih.gov/pubmed/27620531"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19372577"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Tumor cells in the bone microenvironment are able to initiate a vicious cycle of bone degradation by mobilizing osteoclasts, multinucleated cells specialized in bone degradation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19372577"}, {"offsetInBeginSection": 464, "offsetInEndSection": 644, "text": "The effect on osteoclasts formed in vivo was assessed in mouse fetal calvarial explants and in isolated rabbit osteoclasts, where it dose-dependently inhibited osteoclast activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19372577"}, {"offsetInBeginSection": 645, "offsetInEndSection": 801, "text": "Its effect on formation and activity of human osteoclasts in vitro was determined in cocultures of human osteoblasts and peripheral blood mononuclear cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19372577"}, {"offsetInBeginSection": 1214, "offsetInEndSection": 1388, "text": "Furthermore, it reversibly prevented osteoclast precursor migration from the osteoblast layer to the bone surface and subsequent formation of actin rings and resorption pits.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19372577"}, {"offsetInBeginSection": 1389, "offsetInEndSection": 1563, "text": "These data suggest that Src is pivotal for the formation and activity of human osteoclasts, probably through its effect on the distribution of the actin microfilament system.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19372577"}, {"offsetInBeginSection": 1564, "offsetInEndSection": 1799, "text": "The reversible effect of AZD0530 on osteoclast formation and activity makes it a promising candidate to temper osteoclastic bone degradation in bone diseases with enhanced osteoclast activity such as osteolytic metastatic bone disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19372577"}, {"offsetInBeginSection": 240, "offsetInEndSection": 373, "text": "Therefore, drugs like AZD0530, designed to inhibit Src activity, could selectively interfere with both tumor and osteoclast activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19372577"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "The mineral dissolution function of osteoclasts is dispensable for hypertrophic cartilage degradation during long bone development and growth.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992711"}, {"offsetInBeginSection": 173, "offsetInEndSection": 354, "text": "In the primary spongiosa, osteoclasts degrade the mineralized cartilage produced by hypertrophic chondrocytes to generate cartilage trabeculae that osteoblasts embed in bone matrix.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992711"}]}, {"id": "5a733a672dc08e987e000014", "body": "Does temsirolimus improve survival of glioblastoma patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28259301", "http://www.ncbi.nlm.nih.gov/pubmed/27143690", "http://www.ncbi.nlm.nih.gov/pubmed/23564811", "http://www.ncbi.nlm.nih.gov/pubmed/24470557", "http://www.ncbi.nlm.nih.gov/pubmed/15998902", "http://www.ncbi.nlm.nih.gov/pubmed/23099651", "http://www.ncbi.nlm.nih.gov/pubmed/17538086", "http://www.ncbi.nlm.nih.gov/pubmed/28351321", "http://www.ncbi.nlm.nih.gov/pubmed/26786929"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301"}, {"offsetInBeginSection": 157, "offsetInEndSection": 291, "text": "We performed a systematic review and a meta-analysis to clarify and evaluate their effectiveness in glioblastoma patients.PATIENTS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301"}, {"offsetInBeginSection": 292, "offsetInEndSection": 542, "text": "METHODS: we searched relevant published and unpublished randomized clinical trials analyzing antiangiogenic drugs versus chemotherapy in glioblastoma patients from January 2006 to January 2016 in MEDLINE, WEB of SCIENCE, ASCO, ESMO and SNO databases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301"}, {"offsetInBeginSection": 542, "offsetInEndSection": 734, "text": "RESULTS: fourteen randomized clinical trials were identified (7 with bevacizumab, 2 cilengitide, 1 enzastaurin, 1 dasatinib, 1 vandetanib, 1 temsirolimus, 1 cediranib) including 4330 patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301"}, {"offsetInBeginSection": 1248, "offsetInEndSection": 1446, "text": "CONCLUSIONS: antiangiogenic drugs did not improve overall survival in glioblastoma patients, either as first or second-line treatment, and either as single agent or in combination with chemotherapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301"}, {"offsetInBeginSection": 1447, "offsetInEndSection": 1614, "text": "Among antiangiogenic drugs, only bevacizumab improved progression-free survival regardless of treatment line, both as single agent or in combination with chemotherapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27143690"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "PURPOSE: EORTC 26082 assessed the activity of temsirolimus in patients with newly diagnosed glioblastoma harboring an unmethylated O6 methylguanine-DNA-methyltransferase (MGMT) promoter.EXPERIMENTAL", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27143690"}, {"offsetInBeginSection": 199, "offsetInEndSection": 289, "text": "DESIGN: Patients (n = 257) fulfilling eligibility criteria underwent central MGMT testing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27143690"}, {"offsetInBeginSection": 469, "offsetInEndSection": 527, "text": "Primary endpoint was overall survival at 12 months (OS12).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27143690"}]}, {"id": "5a763b679e632bc066000006", "body": "Describe RIblast", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28459942"], "snippets": []}, {"id": "5a991ee21d1251d03b000005", "body": "Are there sex differences in the transcriptome of the mouse hippocampus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28302071"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Sex differences in the molecular signature of the developing mouse hippocampus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071"}, {"offsetInBeginSection": 499, "offsetInEndSection": 626, "text": "RESULTS: The transcriptomic analysis identifies 2699 genes that are differentially expressed between animals of different ages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071"}, {"offsetInBeginSection": 1144, "offsetInEndSection": 1251, "text": "We also find a modest correlation between levels of mRNA and protein in the mouse hippocampus (Rho\u2009=\u20090.53).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071"}, {"offsetInBeginSection": 1394, "offsetInEndSection": 1643, "text": "Additionally, this analysis reveals sex differences in the transcriptome of the developing mouse hippocampus, and further clarifies the need to include both female and male mice in longitudinal studies involving molecular changes in the hippocampus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071"}]}, {"id": "5aa0495bd6d6b54f79000002", "body": "What is the role of the blood-brain barrier?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24501156", "http://www.ncbi.nlm.nih.gov/pubmed/16120931", "http://www.ncbi.nlm.nih.gov/pubmed/28781208", "http://www.ncbi.nlm.nih.gov/pubmed/19077110", "http://www.ncbi.nlm.nih.gov/pubmed/21963971", "http://www.ncbi.nlm.nih.gov/pubmed/28369884", "http://www.ncbi.nlm.nih.gov/pubmed/15920760", "http://www.ncbi.nlm.nih.gov/pubmed/23508590", "http://www.ncbi.nlm.nih.gov/pubmed/8955532", "http://www.ncbi.nlm.nih.gov/pubmed/12742070"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Role of caveolin-1 in the biology of the blood-brain barrier.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24501156"}, {"offsetInBeginSection": 69, "offsetInEndSection": 242, "text": "It plays an important role in physiological and pathological conditions of the blood-brain barrier and serves as a mediator in drug delivery through the blood-brain barrier.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24501156"}, {"offsetInBeginSection": 243, "offsetInEndSection": 451, "text": "Caveolin-1 is related to the diminished expression of tight junction-associated proteins and metabolic pinocytosis vesicles when the blood-brain barrier is destroyed by outside invaders or malignant stimulus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24501156"}, {"offsetInBeginSection": 452, "offsetInEndSection": 625, "text": "The permeability of the blood-brain barrier, regulated by types of drugs or physical irradiation, is connected with drug transportation with the participation of caveolin-1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24501156"}, {"offsetInBeginSection": 763, "offsetInEndSection": 924, "text": "Silencing of caveolin-1 and disruption of caveolae can attenuate or remove pathological damage and even engender the opposite effects in the blood-brain barrier.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24501156"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1118, "text": "This review considers the role of caveolin-1 in the blood-brain barrier that may have profound implications for central nervous system disease and drug delivery through the blood-brain barrier.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24501156"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "The role of blood-brain barrier permeability in brain tumor imaging and therapeutics.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16120931"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "OBJECTIVE: Our purpose is to describe methods of assessing leakiness of the blood-brain barrier and explain mechanisms for exploiting the blood-brain barrier for therapeutic purposes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16120931"}, {"offsetInBeginSection": 183, "offsetInEndSection": 400, "text": "CONCLUSION: Knowledge of the workings of the blood-brain barrier is important for an understanding of the ways in which blood-brain barrier permeability may be used as a surrogate marker for drug therapeutic response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16120931"}, {"offsetInBeginSection": 401, "offsetInEndSection": 512, "text": "Manipulation of the blood-brain barrier may provide a means for selectively targeting tumors for drug delivery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16120931"}]}, {"id": "5aa824a8fcf4565872000002", "body": "What is the drug Tecfidera used against?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28258191", "http://www.ncbi.nlm.nih.gov/pubmed/27849348", "http://www.ncbi.nlm.nih.gov/pubmed/23946617"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "Dimethyl fumarate (DMF; trade name Tecfidera) is an oral formulation of the fumaric acid ester that is Food and Drug Administration approved for treatment of relapsing-remitting multiple sclerosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258191"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Reconsidering the economic value of multiple sclerosis therapies.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27849348"}, {"offsetInBeginSection": 316, "offsetInEndSection": 555, "text": "We used economic theory to derive the value of therapy to patients with MS and to individuals who face the risk of contracting MS in the future, under the alternative assumptions that therapies were fully insured or paid for out of pocket.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27849348"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "Dimethyl fumarate capsules (Tecfidera) for multiple sclerosis, ado-trastuzumab emtansine injection (Kadcyla) for HER-2-positive breast cancer, and ospemifene tablets (Osphena) for painful intercourse in postmenopausal women.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23946617"}]}, {"id": "5a733d2a2dc08e987e000015", "body": "Is Tocilizumab effective for Giant-Cell Arteritis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28745999", "http://www.ncbi.nlm.nih.gov/pubmed/23650978", "http://www.ncbi.nlm.nih.gov/pubmed/24357324", "http://www.ncbi.nlm.nih.gov/pubmed/28499892", "http://www.ncbi.nlm.nih.gov/pubmed/27182063", "http://www.ncbi.nlm.nih.gov/pubmed/24854376", "http://www.ncbi.nlm.nih.gov/pubmed/29146018", "http://www.ncbi.nlm.nih.gov/pubmed/22965672", "http://www.ncbi.nlm.nih.gov/pubmed/21243547", "http://www.ncbi.nlm.nih.gov/pubmed/22284606"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 45, "text": "Trial of Tocilizumab in Giant-Cell Arteritis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745999"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "BACKGROUND: Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of glucocorticoids is associated with side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745999"}, {"offsetInBeginSection": 159, "offsetInEndSection": 333, "text": "The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relapse during glucocorticoid tapering was studied in patients with giant-cell arteritis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745999"}, {"offsetInBeginSection": 637, "offsetInEndSection": 841, "text": "The primary outcome was the rate of sustained glucocorticoid-free remission at week 52 in each tocilizumab group as compared with the rate in the placebo group that underwent the 26-week prednisone taper.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745999"}, {"offsetInBeginSection": 1051, "offsetInEndSection": 1396, "text": "RESULTS: Sustained remission at week 52 occurred in 56% of the patients treated with tocilizumab weekly and in 53% of those treated with tocilizumab every other week, as compared with 14% of those in the placebo group that underwent the 26-week prednisone taper and 18% of those in the placebo group that underwent the 52-week prednisone taper (", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745999"}, {"offsetInBeginSection": 1396, "offsetInEndSection": 1669, "text": "PCONCLUSIONS: Tocilizumab, received weekly or every other week, combined with a 26-week prednisone taper was superior to either 26-week or 52-week prednisone tapering plus placebo with regard to sustained glucocorticoid-free remission in patients with giant-cell arteritis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745999"}, {"offsetInBeginSection": 1670, "offsetInEndSection": 1767, "text": "Longer follow-up is necessary to determine the durability of remission and safety of tocilizumab.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745999"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1051, "text": "Dosing of prednisone and safety were also assessed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745999"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23650978"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Tocilizumab is a highly effective therapeutic agent for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23650978"}]}, {"id": "5a76420c9e632bc066000007", "body": "What is MULTOVL?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23071271"], "snippets": []}, {"id": "5a992d981d1251d03b00000b", "body": "Can nanoparticles be used for afterglow imaging?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28657119", "http://www.ncbi.nlm.nih.gov/pubmed/29035373", "http://www.ncbi.nlm.nih.gov/pubmed/20798470", "http://www.ncbi.nlm.nih.gov/pubmed/28608898", "http://www.ncbi.nlm.nih.gov/pubmed/27594671"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Ultralong Phosphorescence of Water-Soluble Organic Nanoparticles for In Vivo Afterglow Imaging.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657119"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Afterglow or persistent luminescence eliminates the need for light excitation and thus circumvents the issue of autofluorescence, holding promise for molecular imaging.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657119"}, {"offsetInBeginSection": 266, "offsetInEndSection": 459, "text": "This study reports the design principle, synthesis, and proof-of-concept application of organic semiconducting nanoparticles (OSNs) with ultralong phosphorescence for in vivo afterglow imaging.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657119"}, {"offsetInBeginSection": 641, "offsetInEndSection": 801, "text": "This prolongs the particle luminesce to the timescale that can be detected by the commercial whole-animal imaging system after removal of external light source.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657119"}, {"offsetInBeginSection": 802, "offsetInEndSection": 975, "text": "Such ultralong phosphorescent of OSNs is inert to oxygen and can be repeatedly activated, permitting imaging of lymph nodes in living mice with a high signal-to-noise ratio.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657119"}, {"offsetInBeginSection": 976, "offsetInEndSection": 1246, "text": "This study not only introduces the first category of water-soluble ultralong phosphorescence organic nanoparticles but also reveals a universal design principle to prolong the lifetime of phosphorescent molecules to the level that can be effective for molecular imaging.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657119"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Molecular afterglow imaging with bright, biodegradable polymer nanoparticles.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29035373"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "Afterglow optical agents, which emit light long after cessation of excitation, hold promise for ultrasensitive in vivo imaging because they eliminate tissue autofluorescence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29035373"}, {"offsetInBeginSection": 175, "offsetInEndSection": 332, "text": "However, afterglow imaging has been limited by its reliance on inorganic nanoparticles with relatively low brightness and short-near-infrared (NIR) emission.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29035373"}, {"offsetInBeginSection": 333, "offsetInEndSection": 392, "text": "Here we present semiconducting polymer nanoparticles (SPNs)", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29035373"}]}, {"id": "5aa13fd3d6d6b54f79000003", "body": "List 4 drugs used to treat opioid addiction or overdose", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26495843", "http://www.ncbi.nlm.nih.gov/pubmed/28358791", "http://www.ncbi.nlm.nih.gov/pubmed/25583888", "http://www.ncbi.nlm.nih.gov/pubmed/26054008", "http://www.ncbi.nlm.nih.gov/pubmed/16953647", "http://www.ncbi.nlm.nih.gov/pubmed/12738346", "http://www.ncbi.nlm.nih.gov/pubmed/28627395", "http://www.ncbi.nlm.nih.gov/pubmed/23059064", "http://www.ncbi.nlm.nih.gov/pubmed/28219963", "http://www.ncbi.nlm.nih.gov/pubmed/21668757"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Understanding Heroin Overdose: A Study of the Acute Respiratory Depressant Effects of Injected Pharmaceutical Heroin.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495843"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Opioids are respiratory depressants and heroin/opioid overdose is a major contributor to the excess mortality of heroin addicts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495843"}, {"offsetInBeginSection": 249, "offsetInEndSection": 383, "text": "This study used advanced respiratory monitoring to follow the time course and severity of acute opioid-induced respiratory depression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495843"}, {"offsetInBeginSection": 384, "offsetInEndSection": 710, "text": "10 patients (9/10 with chronic airflow obstruction) undergoing supervised injectable opioid treatment for heroin addiction received their usual prescribed dose of injectable opioid (diamorphine or methadone) (IOT), and their usual prescribed dose of oral opioid (methadone or sustained release oral morphine) after 30 minutes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495843"}, {"offsetInBeginSection": 1381, "offsetInEndSection": 1450, "text": "Baseline NRD and opioid-induced drop in SpO2% were inversely related.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495843"}, {"offsetInBeginSection": 1451, "offsetInEndSection": 1582, "text": "We conclude that significant acute respiratory depression is commonly induced by opioid drugs prescribed to treat opioid addiction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495843"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Methadone Prescribing and Overdose and the Association with Medicaid Preferred Drug List Policies - United States, 2007-2014.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28358791"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "Drug overdose is a leading cause of injury death in the United States; 47,055 fatal drug overdoses were reported in 2014, a 6.5% increase from the previous year (1), driven by opioid use disorder (2,3).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28358791"}, {"offsetInBeginSection": 203, "offsetInEndSection": 342, "text": "Methadone is an opioid prescribed for pain management and is also provided through opioid treatment programs to treat opioid use disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28358791"}, {"offsetInBeginSection": 1364, "offsetInEndSection": 1469, "text": "The analyses found that, from 2007 to 2014, large declines in methadone-related overdose deaths occurred.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28358791"}]}, {"id": "5aa825b1fcf4565872000003", "body": "Are stress granules membraneous?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17209421", "http://www.ncbi.nlm.nih.gov/pubmed/26199455", "http://www.ncbi.nlm.nih.gov/pubmed/29129640", "http://www.ncbi.nlm.nih.gov/pubmed/19193871", "http://www.ncbi.nlm.nih.gov/pubmed/6581717", "http://www.ncbi.nlm.nih.gov/pubmed/27489304", "http://www.ncbi.nlm.nih.gov/pubmed/18710928", "http://www.ncbi.nlm.nih.gov/pubmed/24090136", "http://www.ncbi.nlm.nih.gov/pubmed/26777405", "http://www.ncbi.nlm.nih.gov/pubmed/24033457"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "[Stress granules: RNP-containing cytoplasmic bodies springing up under stress.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209421"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "In this review recent data describing stress granules are summarized.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209421"}, {"offsetInBeginSection": 70, "offsetInEndSection": 268, "text": "Stress granules are specific RNA-containing structures in the cytoplasm of living cells which arise under stress conditions (e. g. heat shock, UV irradiation, energy depletion and oxidative stress).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209421"}, {"offsetInBeginSection": 269, "offsetInEndSection": 454, "text": "It became evident that stress granules accumulate non-canonical 48S initiation complexes and contain mRNA with associated proteins, small ribosomal subunits and some initiation factors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209421"}, {"offsetInBeginSection": 455, "offsetInEndSection": 533, "text": "Stress granules are depleted with ternary complex and large ribosomal subunit.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209421"}, {"offsetInBeginSection": 883, "offsetInEndSection": 991, "text": "Cytoskeletal structures facilitate the accumulation of stress granule components in local cytoplasmic sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209421"}, {"offsetInBeginSection": 992, "offsetInEndSection": 1141, "text": "Investigation of process of stress granule formation is important for understanding of cell reaction to stress and translation regulation mechanisms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209421"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Differential effects of Ydj1 and Sis1 on Hsp70-mediated clearance of stress granules in Saccharomyces cerevisiae.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26199455"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Stress granules and P-bodies are conserved assemblies of nontranslating mRNAs in eukaryotic cells that can be related to RNA-protein aggregates found in some neurodegenerative diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26199455"}, {"offsetInBeginSection": 186, "offsetInEndSection": 323, "text": "Herein, we examine how the Hsp70/Hsp40 protein chaperones affected the assembly and disassembly of stress granules and P-bodies in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26199455"}]}, {"id": "5a733efc2dc08e987e000016", "body": "Describe Achenbach\u2019s syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16760737", "http://www.ncbi.nlm.nih.gov/pubmed/20512338", "http://www.ncbi.nlm.nih.gov/pubmed/25709171", "http://www.ncbi.nlm.nih.gov/pubmed/835533", "http://www.ncbi.nlm.nih.gov/pubmed/4017281", "http://www.ncbi.nlm.nih.gov/pubmed/9777339", "http://www.ncbi.nlm.nih.gov/pubmed/6703533", "http://www.ncbi.nlm.nih.gov/pubmed/17326116", "http://www.ncbi.nlm.nih.gov/pubmed/23565480", "http://www.ncbi.nlm.nih.gov/pubmed/3144988"], "snippets": [{"offsetInBeginSection": 190, "offsetInEndSection": 308, "text": "We describe two brothers from a non-consanguineous family who have classical features of Goldberg-Shprintzen syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16760737"}, {"offsetInBeginSection": 309, "offsetInEndSection": 505, "text": "The novel findings in this instance are of foot anomalies including camptodactyly and clinodactyly of the 2nd to 4th toes, which have not been previously described in Goldberg-Shprintzen syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16760737"}, {"offsetInBeginSection": 292, "offsetInEndSection": 401, "text": "This case report describe a patient with giant cell arteritis with initial presentation of Ortner's syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20512338"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "A rare newly described overgrowth syndrome with vascular malformations-Cloves syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709171"}, {"offsetInBeginSection": 113, "offsetInEndSection": 213, "text": "We describe a rare, newly described syndrome with features of overgrowth and vascular malformations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709171"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Multiple dysmorphic features and pancytopenia: a new syndrome?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281"}, {"offsetInBeginSection": 211, "offsetInEndSection": 267, "text": "Syndrome) the Aase Syndrome and Diamond-Blackfan Anemia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281"}, {"offsetInBeginSection": 456, "offsetInEndSection": 573, "text": "In this paper, we report a constellation of dysmorphic features and pancytopenia which may constitute a new syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Catel-Manzke syndrome in a female infant: We describe a girl with typical features of the Catel-Manzke syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9777339"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "A new case of Robinow dwarfism syndrome, in a 26 month old child is described.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6703533"}]}, {"id": "5a774e40faa1ab7d2e000007", "body": "Is there a link between nuclear position and DNA repair pathway choice?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25366693", "http://www.ncbi.nlm.nih.gov/pubmed/27266837", "http://www.ncbi.nlm.nih.gov/pubmed/25463437"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Nuclear position dictates DNA repair pathway choice.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Faithful DNA repair is essential to avoid chromosomal rearrangements and promote genome integrity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693"}, {"offsetInBeginSection": 99, "offsetInEndSection": 346, "text": "Nuclear organization has emerged as a key parameter in the formation of chromosomal translocations, yet little is known as to whether DNA repair can efficiently occur throughout the nucleus and whether it is affected by the location of the lesion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693"}, {"offsetInBeginSection": 347, "offsetInEndSection": 451, "text": "Here, we induce DNA double-strand breaks (DSBs) at different nuclear compartments and follow their fate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693"}, {"offsetInBeginSection": 452, "offsetInEndSection": 655, "text": "We demonstrate that DSBs induced at the nuclear membrane (but not at nuclear pores or nuclear interior) fail to rapidly activate the DNA damage response (DDR) and repair by homologous recombination (HR).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693"}, {"offsetInBeginSection": 656, "offsetInEndSection": 911, "text": "Real-time and superresolution imaging reveal that DNA DSBs within lamina-associated domains do not migrate to more permissive environments for HR, like the nuclear pores or the nuclear interior, but instead are repaired in situ by alternative end-joining.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693"}, {"offsetInBeginSection": 912, "offsetInEndSection": 1137, "text": "Our results are consistent with a model in which nuclear position dictates the choice of DNA repair pathway, thus revealing a new level of regulation in DSB repair controlled by spatial organization of DNA within the nucleus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693"}, {"offsetInBeginSection": 0, "offsetInEndSection": 43, "text": "Nuclear compartmentalization of DNA repair.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27266837"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "The continuous threats on genome integrity by endogenous and exogenous sources have rendered cells competent to overcome these challenges by activating DNA repair pathways.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27266837"}, {"offsetInBeginSection": 173, "offsetInEndSection": 366, "text": "A complex network of proteins and their modifications participate in orchestrated signaling cascades, which are induced in response to DNA damage and may determine the choice of repair pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27266837"}]}, {"id": "5a992eac1d1251d03b00000c", "body": "Can non ubiquitinated Tomm20 promote mitophagy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27503909"], "snippets": []}, {"id": "5aa304f1d6d6b54f79000004", "body": "Is the consumption of chocolate associated with an increase in cardiovascular disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27493901", "http://www.ncbi.nlm.nih.gov/pubmed/22653982", "http://www.ncbi.nlm.nih.gov/pubmed/21665390", "http://www.ncbi.nlm.nih.gov/pubmed/21666964", "http://www.ncbi.nlm.nih.gov/pubmed/26076934", "http://www.ncbi.nlm.nih.gov/pubmed/20858571", "http://www.ncbi.nlm.nih.gov/pubmed/23225768", "http://www.ncbi.nlm.nih.gov/pubmed/21875885", "http://www.ncbi.nlm.nih.gov/pubmed/16390538", "http://www.ncbi.nlm.nih.gov/pubmed/18827977"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Relation of Habitual Chocolate Consumption to Arterial Stiffness in a Community-Based Sample: Preliminary Findings.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493901"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "BACKGROUND: The consumption of chocolate and cocoa has established cardiovascular benefits.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493901"}, {"offsetInBeginSection": 92, "offsetInEndSection": 207, "text": "Less is known about the effects of chocolate on arterial stiffness, a marker of subclinical cardiovascular disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493901"}, {"offsetInBeginSection": 208, "offsetInEndSection": 403, "text": "The aim of this study was to investigate whether chocolate intakes are independently associated with pulse wave velocity (PWV), after adjustment for cardiovascular, lifestyle and dietary factors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493901"}, {"offsetInBeginSection": 703, "offsetInEndSection": 927, "text": "RESULTS: Chocolate intake was significantly associated with PWV in a non-linear fashion with the highest levels of PWV in those who never or rarely ate chocolate and lowest levels in those who consumed chocolate once a week.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493901"}, {"offsetInBeginSection": 928, "offsetInEndSection": 1090, "text": "This pattern of results remained and was not attenuated after multivariate adjustment for diabetes, cardiovascular risk factors and dietary variables (p = 0.002).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493901"}, {"offsetInBeginSection": 1168, "offsetInEndSection": 1326, "text": "Further studies are needed to explore the underlying mechanisms that may mediate the observed effects of habitual chocolate consumption on arterial stiffness.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493901"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22653982"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "OBJECTIVE: To model the long term effectiveness and cost effectiveness of daily dark chocolate consumption in a population with metabolic syndrome at high risk of cardiovascular disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22653982"}, {"offsetInBeginSection": 488, "offsetInEndSection": 691, "text": "MEASURES: Treatment effects associated with dark chocolate consumption derived from published meta-analyses were used to determine the absolute number of cardiovascular events with and without treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22653982"}]}, {"id": "5aacd38efcf4565872000006", "body": "Is DNA polymerase \u03b8 involved in DNA repair?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27264557", "http://www.ncbi.nlm.nih.gov/pubmed/25775267", "http://www.ncbi.nlm.nih.gov/pubmed/28542210", "http://www.ncbi.nlm.nih.gov/pubmed/24989122", "http://www.ncbi.nlm.nih.gov/pubmed/28695890", "http://www.ncbi.nlm.nih.gov/pubmed/26514729", "http://www.ncbi.nlm.nih.gov/pubmed/26484154", "http://www.ncbi.nlm.nih.gov/pubmed/28668117"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "DNA polymerase \u03b8 (POLQ), double-strand break repair, and cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "DNA polymerase theta (pol \u03b8) is encoded in the genomes of many eukaryotes, though not in fungi.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 96, "offsetInEndSection": 149, "text": "Pol \u03b8 is encoded by the POLQ gene in mammalian cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 150, "offsetInEndSection": 283, "text": "The C-terminal third of the protein is a family A DNA polymerase with additional insertion elements relative to prokaryotic homologs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 284, "offsetInEndSection": 366, "text": "The N-terminal third is a helicase-like domain with DNA-dependent ATPase activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 367, "offsetInEndSection": 457, "text": "Pol \u03b8 is important in the repair of genomic double-strand breaks (DSBs) from many sources.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 458, "offsetInEndSection": 697, "text": "These include breaks formed by ionizing radiation and topoisomerase inhibitors, breaks arising at stalled DNA replication forks, breaks introduced during diversification steps of the mammalian immune system, and DSB induced by CRISPR-Cas9.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 698, "offsetInEndSection": 783, "text": "Pol \u03b8 participates in a route of DSB repair termed \"alternative end-joining\" (altEJ).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 784, "offsetInEndSection": 874, "text": "AltEJ is independent of the DNA binding Ku protein complex and requires DNA end resection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}, {"offsetInBeginSection": 875, "offsetInEndSection": 969, "text": "Pol \u03b8 is able to mediate joining of two resected 3' ends harboring DNA sequence microhomology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557"}]}, {"id": "5a7341fe2dc08e987e000018", "body": "What is the link between lithium use during pregnancy and Ebstein anomaly?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18982835", "http://www.ncbi.nlm.nih.gov/pubmed/8031346", "http://www.ncbi.nlm.nih.gov/pubmed/2743779", "http://www.ncbi.nlm.nih.gov/pubmed/28591541", "http://www.ncbi.nlm.nih.gov/pubmed/6518066", "http://www.ncbi.nlm.nih.gov/pubmed/1346886", "http://www.ncbi.nlm.nih.gov/pubmed/16611133", "http://www.ncbi.nlm.nih.gov/pubmed/12114921", "http://www.ncbi.nlm.nih.gov/pubmed/24781368", "http://www.ncbi.nlm.nih.gov/pubmed/15702702"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 28, "text": "Is lithium a real teratogen?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18982835"}, {"offsetInBeginSection": 29, "offsetInEndSection": 100, "text": "What can we conclude from the prospective versus retrospective studies?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18982835"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "BACKGROUND: Lithium is a drug used mainly for the treatment of Bipolar Disorder (BD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18982835"}, {"offsetInBeginSection": 461, "offsetInEndSection": 633, "text": "In the retrospective studies there were, in the Lithium Baby Registry, 225 registered cases with 25 anomalies, 18 of them being cardiac, of which six had Ebstein's anomaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18982835"}, {"offsetInBeginSection": 731, "offsetInEndSection": 903, "text": "On the other hand, none of the prospective studies (296 liveborn infants) demonstrated any increase in the rate of congenital anomalies, although two had Ebstein's anomaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18982835"}, {"offsetInBeginSection": 904, "offsetInEndSection": 1102, "text": "All case control studies regarding Ebstein's anomaly were negative, and among 222 infants with Ebstein's anomaly and 44 with tricuspid atresia none of the mothers had taken lithium during pregnancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18982835"}, {"offsetInBeginSection": 1102, "offsetInEndSection": 1333, "text": "CONCLUSIONS: Considering the serious limitations of the retrospective and case control studies that are also retrospective, lithium does not seem to be a significant teratogen, and hence should be given, if indicated, in pregnancy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18982835"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "OBJECTIVE: To reevaluate the risk associated with in utero exposure to lithium.DATA SOURCES AND STUDY", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8031346"}, {"offsetInBeginSection": 102, "offsetInEndSection": 260, "text": "SELECTION: Data were obtained from all published studies, in multiple languages, referenced in MEDLINE, Toxline, and the Lithium Information Center databases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8031346"}, {"offsetInBeginSection": 300, "offsetInEndSection": 441, "text": "The search terms were lithium, pregnancy, teratogen, abnormalities (drug induced), Ebstein's anomaly, and adverse effects.DATA EXTRACTION AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8031346"}]}, {"id": "5a774fdcfaa1ab7d2e000008", "body": "Which protein is regulated by Tudor interacting repair regulator (TIRR)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28241136"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "TIRR regulates 53BP1 by masking its histone methyl-lysine binding function.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136"}, {"offsetInBeginSection": 248, "offsetInEndSection": 423, "text": "Central to all 53BP1 activities is its recruitment to double-strand breaks via the interaction of the tandem Tudor domain with dimethylated lysine 20 of histone H4 (H4K20me2).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136"}, {"offsetInBeginSection": 424, "offsetInEndSection": 593, "text": "Here we identify an uncharacterized protein, Tudor interacting repair regulator (TIRR), that directly binds the tandem Tudor domain and masks its H4K20me2 binding motif.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136"}, {"offsetInBeginSection": 594, "offsetInEndSection": 770, "text": "Upon DNA damage, the protein kinase ataxia-telangiectasia mutated (ATM) phosphorylates 53BP1 and recruits RAP1-interacting factor 1 (RIF1) to dissociate the 53BP1-TIRR complex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136"}, {"offsetInBeginSection": 771, "offsetInEndSection": 879, "text": "However, overexpression of TIRR impedes 53BP1 function by blocking its localization to double-strand breaks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136"}, {"offsetInBeginSection": 880, "offsetInEndSection": 1023, "text": "Depletion of TIRR destabilizes 53BP1 in the nuclear-soluble fraction and alters the double-strand break-induced protein complex centring 53BP1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136"}, {"offsetInBeginSection": 1024, "offsetInEndSection": 1200, "text": "These findings identify TIRR as a new factor that influences double-strand break repair using a unique mechanism of masking the histone methyl-lysine binding function of 53BP1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "P53-binding protein 1 (53BP1) is a multi-functional double-strand break repair protein that is essential for class switch recombination in B lymphocytes and for sensitizing BRCA1-deficient tumours to poly-ADP-ribose polymerase-1 (PARP) inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136"}]}, {"id": "5a9931cd1d1251d03b00000d", "body": "Does SARM1 deletion cause neurodegeneration?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28978465", "http://www.ncbi.nlm.nih.gov/pubmed/27797810", "http://www.ncbi.nlm.nih.gov/pubmed/26686637", "http://www.ncbi.nlm.nih.gov/pubmed/28485482", "http://www.ncbi.nlm.nih.gov/pubmed/24993772"], "snippets": [{"offsetInBeginSection": 265, "offsetInEndSection": 450, "text": "Recently, we and others discovered that genetic deletion of SARM1 (sterile alpha and TIR motif containing protein 1) dramatically protects axons from degeneration after axotomy in mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27797810"}, {"offsetInBeginSection": 971, "offsetInEndSection": 1329, "text": "In wild-type mice, 4 weeks of twice-weekly intraperitoneal injections of 1.5 mg/kg vincristine cause pronounced mechanical and heat hyperalgesia, a significant decrease in tail compound nerve action potential amplitude, loss of intraepidermal nerve fibres and significant degeneration of myelinated axons in both the distal sural nerve and nerves of the toe.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27797810"}, {"offsetInBeginSection": 509, "offsetInEndSection": 668, "text": "While inhibition of NMN synthesis and SARM1 deletion block Ca(2+) rise and preserve axonal integrity, they fail to prevent early mitochondrial dynamic changes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26686637"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28485482"}]}, {"id": "5aa55b65d6d6b54f7900000e", "body": "Please list 6 symptoms of Scarlet fever.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11086489", "http://www.ncbi.nlm.nih.gov/pubmed/1919136", "http://www.ncbi.nlm.nih.gov/pubmed/29081840", "http://www.ncbi.nlm.nih.gov/pubmed/26585817", "http://www.ncbi.nlm.nih.gov/pubmed/19868695", "http://www.ncbi.nlm.nih.gov/pubmed/2772682", "http://www.ncbi.nlm.nih.gov/pubmed/3619689", "http://www.ncbi.nlm.nih.gov/pubmed/3284506", "http://www.ncbi.nlm.nih.gov/pubmed/28468073", "http://www.ncbi.nlm.nih.gov/pubmed/19871154"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "[An outbreak of scarlet fever, impetigo and pharyngitis caused by the same Streptococcus pyogenes type T4M4 in a primary school].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11086489"}, {"offsetInBeginSection": 12, "offsetInEndSection": 201, "text": "EPIDEMIC: Following the notification of an unusual number of scarlet fever cases within the same primary school, the epidemiological and clinical features of the outbreak were investigated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11086489"}, {"offsetInBeginSection": 639, "offsetInEndSection": 711, "text": "Eight had scarlet fever, 5 suffered from impetigo and 8 had pharyngitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11086489"}, {"offsetInBeginSection": 712, "offsetInEndSection": 814, "text": "A further 6 children, outside of this class, had complaints of scarlet fever, impetigo or pharyngitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11086489"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "[A dying clinical diagnosis of scarlet fever--the last sixteen years survey].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1919136"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "11,119 patients with scarlet fever admitted in the last sixteen years, from 1973 to 1988, to Sapporo City General Hospital, were studied statistically on symptoms and laboratory findings.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1919136"}, {"offsetInBeginSection": 810, "offsetInEndSection": 961, "text": "In recent statistical analysis (1982-1988), we found, however, a tendency that patients having stronger symptoms were being introduced to our hospital.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1919136"}, {"offsetInBeginSection": 965, "offsetInEndSection": 1068, "text": "The higher rates of cases showing elevated ASD titer were seen in the elder patients and in the winter.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1919136"}, {"offsetInBeginSection": 1542, "offsetInEndSection": 1619, "text": "Reinfection or relapse cases of scarlet fever were found in 6.7% (642/9,585).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1919136"}, {"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "Scarlet fever: a guide for general practitioners.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29081840"}]}, {"id": "5aacd83ffcf4565872000008", "body": "What is PARP inhibitor (PARPi) resistance?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23103855", "http://www.ncbi.nlm.nih.gov/pubmed/28255272", "http://www.ncbi.nlm.nih.gov/pubmed/28973445", "http://www.ncbi.nlm.nih.gov/pubmed/28588062", "http://www.ncbi.nlm.nih.gov/pubmed/28069876", "http://www.ncbi.nlm.nih.gov/pubmed/28242626", "http://www.ncbi.nlm.nih.gov/pubmed/27454289", "http://www.ncbi.nlm.nih.gov/pubmed/23165508", "http://www.ncbi.nlm.nih.gov/pubmed/26984416", "http://www.ncbi.nlm.nih.gov/pubmed/28450426"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855"}, {"offsetInBeginSection": 148, "offsetInEndSection": 349, "text": "We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inhibitor (PARPi) olaparib through activation of the P-glycoprotein drug efflux transporter.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855"}, {"offsetInBeginSection": 350, "offsetInEndSection": 564, "text": "Here, we show that tumor-specific genetic inactivation of P-glycoprotein increases the long-term response of BRCA1-deficient mouse mammary tumors to olaparib, but these tumors eventually developed PARPi resistance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855"}, {"offsetInBeginSection": 696, "offsetInEndSection": 843, "text": "Importantly, PARPi resistance was minimized by long-term treatment with the novel PARP inhibitor AZD2461, which is a poor P-glycoprotein substrate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855"}, {"offsetInBeginSection": 844, "offsetInEndSection": 1116, "text": "Together, our data suggest that restoration of homologous recombination is an important mechanism for PARPi resistance in BRCA1-deficient mammary tumors and that the risk of relapse of BRCA1-deficient tumors can be effectively minimized by using optimized PARP inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855"}, {"offsetInBeginSection": 1116, "offsetInEndSection": 1261, "text": "SIGNIFICANCE: In this study, we show that loss of 53BP1 causes resistance to PARP inhibition in mouse mammary tumors that are deficient in BRCA1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855"}, {"offsetInBeginSection": 1262, "offsetInEndSection": 1402, "text": "We hypothesize that low expression or absence of 53BP1 also reduces the response of patients with BRCA1-deficient tumors to PARP inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855"}, {"offsetInBeginSection": 0, "offsetInEndSection": 42, "text": "Reverse the Resistance to PARP Inhibitors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255272"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "One of the DNA repair machineries is activated by Poly (ADP-ribose) Polymerase (PARP) enzyme.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255272"}, {"offsetInBeginSection": 253, "offsetInEndSection": 360, "text": "Therefore, the concept to block PARP enzymes by PARP inhibitor (PARPi) was appreciated in cancer treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255272"}]}, {"id": "5a7347a02dc08e987e00001b", "body": "Gallbladder carriage is a well recognised means of spread of which bacteria?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24349565", "http://www.ncbi.nlm.nih.gov/pubmed/28018582", "http://www.ncbi.nlm.nih.gov/pubmed/23171127", "http://www.ncbi.nlm.nih.gov/pubmed/27131005", "http://www.ncbi.nlm.nih.gov/pubmed/28096978", "http://www.ncbi.nlm.nih.gov/pubmed/25206941"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Histopathological analysis of Salmonella chronic carriage in the mouse hepatopancreatobiliary system.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349565"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Salmonella Typhi asymptomatic chronic carriage represents a challenge for the diagnosis and prevention of typhoid fever in endemic areas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349565"}, {"offsetInBeginSection": 138, "offsetInEndSection": 215, "text": "Such carriers are thought to be reservoirs for further spread of the disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349565"}, {"offsetInBeginSection": 216, "offsetInEndSection": 380, "text": "Gallbladder carriage has been demonstrated to be mediated by biofilm formation on gallstones and by intracellular persistence in the gallbladder epithelium of mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349565"}, {"offsetInBeginSection": 381, "offsetInEndSection": 523, "text": "In addition, both gallstones and chronic carriage have been associated with chronic inflammation and the development of gallbladder carcinoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349565"}, {"offsetInBeginSection": 524, "offsetInEndSection": 777, "text": "However, the pathogenic relationship between typhoid carriage and the development of pre-malignant and/or malignant lesions in the hepatopancreatobiliary system as well as the host-pathogen interactions occurring during chronic carriage remains unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349565"}, {"offsetInBeginSection": 1149, "offsetInEndSection": 1327, "text": "However, pre-malignant lesions, atypical hyperplasia and metaplasia of the gallbladder and exocrine pancreas, respectively, were only associated with chronic Salmonella carriage.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349565"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "Carriage of ESBL/AmpC-producing or ciprofloxacin non-susceptible", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28018582"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "BACKGROUND: Asymptomatic carriage has been recognised as an important risk factor for infection caused by antibiotic resistant bacteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28018582"}, {"offsetInBeginSection": 296, "offsetInEndSection": 396, "text": "We investigated the faecal carriage rates of ESBL-, AmpC-producing and ciprofloxacin non-susceptible", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28018582"}]}, {"id": "5a775182faa1ab7d2e000009", "body": "What is the role of tankyrases in response to Double Strand Breaks (DSBs)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26845027"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Tankyrases Promote Homologous Recombination and Check Point Activation in Response to DSBs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845027"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "DNA lesions are sensed by a network of proteins that trigger the DNA damage response (DDR), a signaling cascade that acts to delay cell cycle progression and initiate DNA repair.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845027"}, {"offsetInBeginSection": 519, "offsetInEndSection": 626, "text": "Here we identify two novel binding partners of MDC1, the poly (ADP-ribose) Polymerases (PARPs) TNKS1 and 2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845027"}, {"offsetInBeginSection": 627, "offsetInEndSection": 829, "text": "We find that TNKSs are recruited to DNA lesions by MDC1 and regulate DNA end resection and BRCA1A complex stabilization at lesions leading to efficient DSB repair by HR and proper checkpoint activation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845027"}]}, {"id": "5a9ac4161d1251d03b000010", "body": "Does MC1R palmitoylation reduce pigmentation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28869973"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Palmitoylation-dependent activation of MC1R prevents melanomagenesis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973"}, {"offsetInBeginSection": 727, "offsetInEndSection": 922, "text": "Here we demonstrate a potential MC1R-targeted intervention strategy in mice to rescue loss-of-function MC1R in MC1R RHC variants for therapeutic benefit by activating MC1R protein palmitoylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973"}, {"offsetInBeginSection": 923, "offsetInEndSection": 1203, "text": "MC1R palmitoylation, primarily mediated by the protein-acyl transferase ZDHHC13, is essential for activating MC1R signalling, which triggers increased pigmentation, ultraviolet-B-induced G1-like cell cycle arrest and control of senescence and melanomagenesis in vitro and in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973"}]}, {"id": "5a96c886fcd1d6a10c00002a", "body": "A bite from the Lone Star Tick Amblyomma americanum, can cause the victim to become allergic to red meat, yes or no?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28319627", "http://www.ncbi.nlm.nih.gov/pubmed/24690977", "http://www.ncbi.nlm.nih.gov/pubmed/25108787", "http://www.ncbi.nlm.nih.gov/pubmed/9722725", "http://www.ncbi.nlm.nih.gov/pubmed/21940418", "http://www.ncbi.nlm.nih.gov/pubmed/17848069"], "snippets": [{"offsetInBeginSection": 19, "offsetInEndSection": 57, "text": "lone star tick (Amblyomma americanum).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627"}, {"offsetInBeginSection": 0, "offsetInEndSection": 45, "text": "A case of tick-bite-induced red meat allergy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24690977"}, {"offsetInBeginSection": 358, "offsetInEndSection": 511, "text": "A link has been discovered between the bite of the Lone Star Tick (Amblyomma americanum) and the development of sensitivity to galactose-\u03b1-1,3-galactose.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24690977"}, {"offsetInBeginSection": 512, "offsetInEndSection": 713, "text": "With a high prevalence of Lone Star Tick populations inhabiting major U.S. Army Installations, and the type of duty required by our Service members, it could potentially affect susceptible individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24690977"}, {"offsetInBeginSection": 113, "offsetInEndSection": 357, "text": "A recent discovery of an IgE antibody specific to galactose-\u03b1-1,3-galactose, which is a carbohydrate abundantly expressed on cells and tissues of beef, pork, and lamb, adds one more tool to aid the clinician in making the appropriate diagnosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24690977"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Expression of bovine genes associated with local and systemic immune response to infestation with the Lone Star tick, Amblyomma americanum.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108787"}, {"offsetInBeginSection": 0, "offsetInEndSection": 322, "text": "The Lone Star tick, Amblyomma americanum Linnaeus 1758 (Acari; Ixodidae), causes considerable production losses to the southern U.S. cattle industry due to reduced weight, infertility, secondary infections at bite wound sites, damaged hides, and potentially death, as these ticks tend to infest livestock in large numbers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108787"}, {"offsetInBeginSection": 673, "offsetInEndSection": 800, "text": "In this study, 7 calves were phenotyped as susceptible, moderately resistant, or highly resistant to adult A. americanum ticks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108787"}, {"offsetInBeginSection": 801, "offsetInEndSection": 927, "text": "Tick bite-site biopsies and blood leukocytes were collected at multiple time points throughout 3 successive tick infestations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108787"}, {"offsetInBeginSection": 928, "offsetInEndSection": 1051, "text": "Gene expression at tick bite-site biopsies was assessed by microarray analysis over 3 time points for each phenotype group.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108787"}]}, {"id": "5aad547efcf456587200000b", "body": "What is the \"protein inference problem\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26935399", "http://www.ncbi.nlm.nih.gov/pubmed/23385215", "http://www.ncbi.nlm.nih.gov/pubmed/22954624", "http://www.ncbi.nlm.nih.gov/pubmed/17990506", "http://www.ncbi.nlm.nih.gov/pubmed/19645593", "http://www.ncbi.nlm.nih.gov/pubmed/22626983", "http://www.ncbi.nlm.nih.gov/pubmed/22331862", "http://www.ncbi.nlm.nih.gov/pubmed/24407311"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Protein inference: A protein quantification perspective.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "In mass spectrometry-based shotgun proteomics, protein quantification and protein identification are two major computational problems.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399"}, {"offsetInBeginSection": 135, "offsetInEndSection": 232, "text": "To quantify the protein abundance, a list of proteins must be firstly inferred from the raw data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399"}, {"offsetInBeginSection": 233, "offsetInEndSection": 349, "text": "Then the relative or absolute protein abundance is estimated with quantification methods, such as spectral counting.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399"}, {"offsetInBeginSection": 433, "offsetInEndSection": 628, "text": "In fact, the protein inference problem can be regarded as a special protein quantification problem in the sense that truly present proteins are those proteins whose abundance values are not zero.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399"}, {"offsetInBeginSection": 793, "offsetInEndSection": 918, "text": "In this paper, we investigate the feasibility of using protein quantification methods to solve the protein inference problem.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1025, "text": "Protein inference methods aim to determine whether each candidate protein is present in the sample or not.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399"}, {"offsetInBeginSection": 1026, "offsetInEndSection": 1111, "text": "Protein quantification methods estimate the abundance value of each inferred protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399"}, {"offsetInBeginSection": 1112, "offsetInEndSection": 1179, "text": "Naturally, the abundance value of an absent protein should be zero.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399"}, {"offsetInBeginSection": 1180, "offsetInEndSection": 1366, "text": "Thus, we argue that the protein inference problem can be viewed as a special protein quantification problem in which one protein is considered to be present if its abundance is not zero.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399"}]}, {"id": "5a736f0c3b9d13c708000007", "body": "What is included in the Mentzer index?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24818016", "http://www.ncbi.nlm.nih.gov/pubmed/18192142", "http://www.ncbi.nlm.nih.gov/pubmed/19579993", "http://www.ncbi.nlm.nih.gov/pubmed/25806419", "http://www.ncbi.nlm.nih.gov/pubmed/6185967", "http://www.ncbi.nlm.nih.gov/pubmed/24388269", "http://www.ncbi.nlm.nih.gov/pubmed/24139948", "http://www.ncbi.nlm.nih.gov/pubmed/28706390"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Hematological indices for differential diagnosis of Beta thalassemia trait and iron deficiency anemia.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016"}, {"offsetInBeginSection": 12, "offsetInEndSection": 130, "text": "The two most frequent types of microcytic anemia are beta thalassemia trait ( \u03b2 -TT) and iron deficiency anemia (IDA).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016"}, {"offsetInBeginSection": 285, "offsetInEndSection": 361, "text": "A total of 290 carefully selected children aged 1.1-16 years were evaluated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016"}, {"offsetInBeginSection": 631, "offsetInEndSection": 948, "text": "The patient groups were evaluated according to red blood cell (RBC) count; red blood distribution width index; the Mentzer, Shine and Lal, England and Fraser, Srivastava and Bevington, Green and King, Ricerca, Sirdah, and Ehsani indices; mean density of hemoglobin/liter of blood; and mean cell density of hemoglobin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016"}, {"offsetInBeginSection": 958, "offsetInEndSection": 1185, "text": "The Mentzer index was the most reliable index, as it had the highest sensitivity (98.7%), specificity (82.3%), and Youden's index (81%) for detecting \u03b2 -TT; this was followed by the Ehsani index (94.8%, 73.5%, and 68.3%, resp.)", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016"}, {"offsetInBeginSection": 1239, "offsetInEndSection": 1327, "text": "The Mentzer index provided the highest reliabilities for differentiating \u03b2 -TT from IDA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016"}, {"offsetInBeginSection": 523, "offsetInEndSection": 630, "text": "All children with IDA received oral iron for 16 weeks, and HbA2 screening was performed after iron therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "BACKGROUND: beta-thalassemia screening is primarily limited to pregnant women.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18192142"}, {"offsetInBeginSection": 79, "offsetInEndSection": 232, "text": "The ratio of the mean corpuscular volume (MCV) and red blood cell count (RBC) can be automatically calculated with any of the newer hematology analyzers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18192142"}, {"offsetInBeginSection": 361, "offsetInEndSection": 524, "text": "The Mentzer ratio was determined through a receiver operating characteristic (ROC) curve on the first subset, and screened for thalassemia using the second subset.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18192142"}]}, {"id": "5a804f71faa1ab7d2e00001d", "body": "Which algorithm is used for detection of long repeat expansions?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28887402"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Detection of long repeat expansions from PCR-free whole-genome sequence data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887402"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "Identifying large expansions of short tandem repeats (STRs), such as those that cause amyotrophic lateral sclerosis (ALS) and fragile X syndrome, is challenging for short-read whole-genome sequencing (WGS) data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887402"}, {"offsetInBeginSection": 308, "offsetInEndSection": 508, "text": "We developed a software tool called ExpansionHunter that, using PCR-free WGS short-read data, can genotype repeats at the locus of interest, even if the expanded repeat is larger than the read length.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887402"}, {"offsetInBeginSection": 509, "offsetInEndSection": 613, "text": "We applied our algorithm to WGS data from 3001 ALS patients who have been tested for the presence of the", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887402"}]}, {"id": "5a9ac4e81d1251d03b000011", "body": "Which brain tumors does neuroligin-3 promote?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25913192", "http://www.ncbi.nlm.nih.gov/pubmed/16300891", "http://www.ncbi.nlm.nih.gov/pubmed/28959975", "http://www.ncbi.nlm.nih.gov/pubmed/26032268", "http://www.ncbi.nlm.nih.gov/pubmed/18555979", "http://www.ncbi.nlm.nih.gov/pubmed/25957677", "http://www.ncbi.nlm.nih.gov/pubmed/24854097", "http://www.ncbi.nlm.nih.gov/pubmed/23248271"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913192"}, {"offsetInBeginSection": 572, "offsetInEndSection": 751, "text": "The synaptic protein neuroligin-3 (NLGN3) was identified as the leading candidate mitogen, and soluble NLGN3 was sufficient and necessary to promote robust HGG cell proliferation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913192"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Expression patterns of neurexin-1 and neuroligins in brain and retina of the chick embryo: Neuroligin-3 is absent in retina.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16300891"}, {"offsetInBeginSection": 564, "offsetInEndSection": 683, "text": "While neurexin-1 increased continuously in both brain and retina, the expression of both neuroligins was more variable.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16300891"}, {"offsetInBeginSection": 921, "offsetInEndSection": 989, "text": "In different brain regions, NL-1 showed a different time regulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16300891"}, {"offsetInBeginSection": 1046, "offsetInEndSection": 1266, "text": "This study indicates that synaptogenetic processes in brain and retina use different molecular machineries, whereby the neuroligins might represent the more distinctly regulated part of the neurexin-neuroligin complexes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16300891"}, {"offsetInBeginSection": 1267, "offsetInEndSection": 1347, "text": "Noticeably, NL-3 does not seem to be involved in the making of retinal synapses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16300891"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "A frightening thought: Neuronal activity enhances tumor growth.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26032268"}, {"offsetInBeginSection": 82, "offsetInEndSection": 303, "text": "Recent studies reported that sequence polymorphisms in neuroligin-3 (NLGN3) and neuroligin-4 (NLGN4) genes have been linked to autism spectrum disorders indicating neuroligin genes as candidate targets in brain disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18555979"}, {"offsetInBeginSection": 548, "offsetInEndSection": 897, "text": "To examine whether the introduction of a Cys in the C-terminal region of other alpha/beta-hydrolase fold proteins could promote the same cellular phenotype, we made homologous mutations in acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) and found a similar processing deficiency and intracellular retention (De Jaco et al., J Biol Chem.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18555979"}]}, {"id": "5a96f40cfcd1d6a10c00002b", "body": "What is calciphylaxis", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10764004", "http://www.ncbi.nlm.nih.gov/pubmed/27321367", "http://www.ncbi.nlm.nih.gov/pubmed/20019019", "http://www.ncbi.nlm.nih.gov/pubmed/24096524", "http://www.ncbi.nlm.nih.gov/pubmed/23430392", "http://www.ncbi.nlm.nih.gov/pubmed/23663061", "http://www.ncbi.nlm.nih.gov/pubmed/16108246", "http://www.ncbi.nlm.nih.gov/pubmed/26779700", "http://www.ncbi.nlm.nih.gov/pubmed/29053546", "http://www.ncbi.nlm.nih.gov/pubmed/21324820"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Calciphylaxis: is there a role for parathyroidectomy?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10764004"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "OBJECTIVE: Calciphylaxis, a rare disorder typically affecting renal failure patients, results in vascular calcification with subsequent skin necrosis, gangrene, and often death from sepsis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10764004"}, {"offsetInBeginSection": 1375, "offsetInEndSection": 1437, "text": "Postoperative hypocalcemia required treatment in two patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10764004"}, {"offsetInBeginSection": 1547, "offsetInEndSection": 1661, "text": "CONCLUSIONS: Calciphylaxis is a serious disease and patients often succumb to sepsis and infectious complications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10764004"}, {"offsetInBeginSection": 1994, "offsetInEndSection": 2097, "text": "Key Words: Calciphylaxis, parathyroid hormone, parathyroidectomy, skin necrosis, chronic renal failure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10764004"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Warfarin-induced calciphylaxis in patients with normal renal function.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27321367"}, {"offsetInBeginSection": 358, "offsetInEndSection": 461, "text": "No other predisposing factors besides obesity and warfarin were found in these patients.WHAT IS NEW AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27321367"}, {"offsetInBeginSection": 159, "offsetInEndSection": 344, "text": "Although calciphylaxis is most frequently associated with end-stage renal disease (ESRD) and secondary hyperparathyroidism, it has been reported infrequently among patients on warfarin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20019019"}, {"offsetInBeginSection": 693, "offsetInEndSection": 854, "text": "REPORT: We present a 63-year-old Polynesian woman with biopsy-proven calciphylaxis in the absence of ESRD or elevated serum calcium levels while taking warfarin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20019019"}, {"offsetInBeginSection": 1087, "offsetInEndSection": 1194, "text": "No guidelines exist for treatment of atypical calciphylaxis in the setting of concomitant warfarin therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20019019"}]}, {"id": "5a9d79ca1d1251d03b00001d", "body": "Is the gene CDKN2A nevogenic?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10620111", "http://www.ncbi.nlm.nih.gov/pubmed/15304099", "http://www.ncbi.nlm.nih.gov/pubmed/28830827", "http://www.ncbi.nlm.nih.gov/pubmed/12406345"], "snippets": [{"offsetInBeginSection": 1074, "offsetInEndSection": 1198, "text": "Gene carriers were also significantly more likely to have noticeable freckling and possibly also Fitzpatrick skin types 1-3.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10620111"}, {"offsetInBeginSection": 1199, "offsetInEndSection": 1384, "text": "The overlap between gene carriers and nongene carriers was, however, marked: the atypical mole syndrome did not clearly differentiate mutant gene carriers from those with a normal gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10620111"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Phenotypic characteristics of members of a melanoma prone kindred with a V126D CDKN2A gene mutation were monitored over approximately 15 y. Thirty-eight previously studied subjects were recruited.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15304099"}]}, {"id": "5a7373f63b9d13c708000008", "body": "Which disease is treated with Fexinidazole?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23133682", "http://www.ncbi.nlm.nih.gov/pubmed/22301556", "http://www.ncbi.nlm.nih.gov/pubmed/22539226", "http://www.ncbi.nlm.nih.gov/pubmed/24841257", "http://www.ncbi.nlm.nih.gov/pubmed/21200426", "http://www.ncbi.nlm.nih.gov/pubmed/29113731", "http://www.ncbi.nlm.nih.gov/pubmed/28552771"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "Fexinidazole: a potential new drug candidate for Chagas disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "BACKGROUND: New safe and effective treatments for Chagas disease (CD) are urgently needed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682"}, {"offsetInBeginSection": 91, "offsetInEndSection": 290, "text": "Current chemotherapy options for CD have significant limitations, including failure to uniformly achieve parasitological cure or prevent the chronic phase of CD, and safety and tolerability concerns.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682"}, {"offsetInBeginSection": 291, "offsetInEndSection": 661, "text": "Fexinidazole, a 2-subsituted 5-nitroimidazole drug candidate rediscovered following extensive compound mining by the Drugs for Neglected Diseases initiative and currently in Phase I clinical study for the treatment of human African trypanosomiasis, was evaluated in experimental models of acute and chronic CD caused by different strains of Trypanosoma cruzi.METHODS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682"}, {"offsetInBeginSection": 662, "offsetInEndSection": 763, "text": "FINDINGS: We investigated the in vivo activity of fexinidazole against T. cruzi, using mice as hosts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682"}, {"offsetInBeginSection": 1023, "offsetInEndSection": 1171, "text": "Our results demonstrated that fexinidazole was effective in suppressing parasitemia and preventing death in infected animals for all strains tested.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682"}, {"offsetInBeginSection": 1602, "offsetInEndSection": 1828, "text": "Fexinidazole treatment was also shown to reduce myocarditis in all animals infected with VL-10 or Colombian resistant T. cruzi strains, although parasite eradication was not achieved in all treated animals at the tested doses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682"}, {"offsetInBeginSection": 1828, "offsetInEndSection": 2002, "text": "CONCLUSIONS: Fexinidazole is an effective oral treatment of acute and chronic experimental CD caused by benznidazole-susceptible, partially resistant, and resistant T. cruzi.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682"}, {"offsetInBeginSection": 2003, "offsetInEndSection": 2109, "text": "These findings illustrate the potential of fexinidazole as a drug candidate for the treatment of human CD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556"}]}, {"id": "5a8056a2faa1ab7d2e00001f", "body": "Which web resource for LIR motif-containing proteins in eukaryotes has been developed?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27484196", "http://www.ncbi.nlm.nih.gov/pubmed/28806134"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "iLIR database: A web resource for LIR motif-containing proteins in eukaryotes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196"}, {"offsetInBeginSection": 625, "offsetInEndSection": 900, "text": "In the past few years it has been revealed that Atg8-interacting proteins include not only receptors but also components of the core autophagic machinery, proteins associated with vesicles and their transport, and specific proteins that are selectively degraded by autophagy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196"}, {"offsetInBeginSection": 901, "offsetInEndSection": 1110, "text": "Atg8-interacting proteins contain a short linear LC3-interacting region/LC3 recognition sequence/Atg8-interacting motif (LIR/LRS/AIM) motif which is responsible for their interaction with Atg8-family proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196"}, {"offsetInBeginSection": 1111, "offsetInEndSection": 1178, "text": "These proteins are referred to as LIR-containing proteins (LIRCPs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196"}, {"offsetInBeginSection": 1329, "offsetInEndSection": 1670, "text": "Given the need for the identification of LIRCPs in various organisms, we developed the iLIR database ( https://ilir.warwick.ac.uk ) as a freely available web resource, listing all the putative canonical LIRCPs identified in silico in the proteomes of 8 model organisms using the iLIR server, combined with a Gene Ontology (GO) term analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "iLIR@viral: A web resource for LIR motif-containing proteins in viruses.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "Macroautophagy/autophagy has been shown to mediate the selective lysosomal degradation of pathogenic bacteria and viruses (xenophagy), and to contribute to the activation of innate and adaptative immune responses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134"}, {"offsetInBeginSection": 522, "offsetInEndSection": 605, "text": "Such interactions are usually mediated through LC3-interacting region (LIR) motifs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134"}, {"offsetInBeginSection": 606, "offsetInEndSection": 743, "text": "So far, only one viral protein has been experimentally shown to have a functional LIR motif, leaving open a vast field for investigation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134"}, {"offsetInBeginSection": 744, "offsetInEndSection": 929, "text": "Here, we have developed the iLIR@viral database ( http://ilir.uk/virus/ ) as a freely accessible web resource listing all the putative canonical LIR motifs identified in viral proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134"}]}, {"id": "5a9ac6821d1251d03b000012", "body": "How does neuronal activity affect neuroligin-3?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25913192", "http://www.ncbi.nlm.nih.gov/pubmed/26032268", "http://www.ncbi.nlm.nih.gov/pubmed/27725662", "http://www.ncbi.nlm.nih.gov/pubmed/28959975", "http://www.ncbi.nlm.nih.gov/pubmed/15150161", "http://www.ncbi.nlm.nih.gov/pubmed/16300891", "http://www.ncbi.nlm.nih.gov/pubmed/28067903", "http://www.ncbi.nlm.nih.gov/pubmed/19406211", "http://www.ncbi.nlm.nih.gov/pubmed/15152050", "http://www.ncbi.nlm.nih.gov/pubmed/24619977"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913192"}, {"offsetInBeginSection": 163, "offsetInEndSection": 373, "text": "By using optogenetic control of cortical neuronal activity in a patient-derived pediatric glioblastoma xenograft model, we demonstrate that active neurons similarly promote HGG proliferation and growth in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913192"}, {"offsetInBeginSection": 572, "offsetInEndSection": 751, "text": "The synaptic protein neuroligin-3 (NLGN3) was identified as the leading candidate mitogen, and soluble NLGN3 was sufficient and necessary to promote robust HGG cell proliferation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913192"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Stem cells present in the adult brain are regulated by neuronal activity; malignant gliomas, which most likely originate from this population of cells, could also be regulated in this manner.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26032268"}, {"offsetInBeginSection": 227, "offsetInEndSection": 329, "text": "published in Cell has identified Neuroligin-3 (NLGN3) as a mitogen promoting high-grade glioma growth.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26032268"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Developmental plasticity shapes synaptic phenotypes of autism-associated neuroligin-3 mutations in the calyx of Held.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725662"}, {"offsetInBeginSection": 89, "offsetInEndSection": 217, "text": "Mutations in neuroligin-3 predispose to autism, but how such mutations affect synaptic function remains incompletely understood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725662"}, {"offsetInBeginSection": 218, "offsetInEndSection": 502, "text": "Here we systematically examined the effect of three autism-associated mutations, the neuroligin-3 knockout, the R451C knockin, and the R704C knockin, on synaptic transmission in the calyx of Held, a central synapse ideally suited for high-resolution analyses of synaptic transmission.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725662"}, {"offsetInBeginSection": 503, "offsetInEndSection": 699, "text": "Surprisingly, germline knockout of neuroligin-3 did not alter synaptic transmission, whereas the neuroligin-3 R451C and R704C knockins decreased and increased, respectively, synaptic transmission.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725662"}, {"offsetInBeginSection": 700, "offsetInEndSection": 825, "text": "These puzzling results prompted us to ask whether neuroligin-3 mutant phenotypes may be reshaped by developmental plasticity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725662"}]}, {"id": "5a9700adfcd1d6a10c00002c", "body": "Sclerostin regulates what process?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23737439", "http://www.ncbi.nlm.nih.gov/pubmed/28571484", "http://www.ncbi.nlm.nih.gov/pubmed/28081119", "http://www.ncbi.nlm.nih.gov/pubmed/25030653", "http://www.ncbi.nlm.nih.gov/pubmed/21890009", "http://www.ncbi.nlm.nih.gov/pubmed/12702725", "http://www.ncbi.nlm.nih.gov/pubmed/24151757", "http://www.ncbi.nlm.nih.gov/pubmed/20043874", "http://www.ncbi.nlm.nih.gov/pubmed/22082361", "http://www.ncbi.nlm.nih.gov/pubmed/21312267"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439"}, {"offsetInBeginSection": 95, "offsetInEndSection": 359, "text": "It has recently been shown that osteocyte production of receptor activator of NF-\u03baB ligand (RANKL) is important in osteoclastic bone resorption, and we reported that exogenous treatment of osteocytes with sclerostin can increase RANKL-mediated osteoclast activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439"}, {"offsetInBeginSection": 360, "offsetInEndSection": 485, "text": "There is good evidence that osteocytes can themselves liberate mineral from bone in a process known as osteocytic osteolysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439"}, {"offsetInBeginSection": 970, "offsetInEndSection": 1052, "text": "Sclerostin stimulated CA2 mRNA and protein expression in hOCy and in MLO-Y4 cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439"}, {"offsetInBeginSection": 1053, "offsetInEndSection": 1235, "text": "Sclerostin induced a decrease in intracellular pH (pHi) in both cell types as well as a decrease in extracellular pH (pHo) and the release of calcium ions from mineralized substrate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Sclerostin Deficiency Promotes Reparative Dentinogenesis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28571484"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "In humans, the SOST gene encodes sclerostin, an inhibitor of bone growth and remodeling, which also negatively regulates the bone repair process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28571484"}, {"offsetInBeginSection": 146, "offsetInEndSection": 257, "text": "Sclerostin has also been implicated in tooth formation, but its potential role in pulp healing remains unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28571484"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Sclerostin Promotes Bone Remodeling in the Process of Tooth Movement.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28081119"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Tooth movement is a biological process of bone remodeling induced by mechanical force.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28081119"}]}, {"id": "5a9d7caa1d1251d03b00001e", "body": "What is Alzheimers disease resilience?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28078981", "http://www.ncbi.nlm.nih.gov/pubmed/28299413", "http://www.ncbi.nlm.nih.gov/pubmed/27815399", "http://www.ncbi.nlm.nih.gov/pubmed/29124107", "http://www.ncbi.nlm.nih.gov/pubmed/23127468", "http://www.ncbi.nlm.nih.gov/pubmed/18728949", "http://www.ncbi.nlm.nih.gov/pubmed/28025282"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Resilience to Alzheimer's disease: the role of physical activity.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981"}, {"offsetInBeginSection": 0, "offsetInEndSection": 306, "text": "BACKGROUND: Although Alzheimer's disease (AD) is a neurodegenerative pathology characterized by accumulation of \u03b2-amyloid plaques and neurofibrillary tangles at cerebral level, recent studies highlighted that AD might be the result of many altered physiological processes occurring at whole-organism level.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981"}, {"offsetInBeginSection": 1112, "offsetInEndSection": 1289, "text": "The following terminology was applied: Alzheimer resilience, brain resilience, metabolic resilience, cardiovascular resilience, mitochondrial resilience and exercise resilience.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981"}, {"offsetInBeginSection": 1335, "offsetInEndSection": 1520, "text": "Five papers defined Alzheimer's resilience, 15 papers brain resilience, five cardiovascular resilience, one metabolic resilience, 11 mitochondrial resilience, and 7 exercise resilience.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981"}, {"offsetInBeginSection": 1602, "offsetInEndSection": 1912, "text": "CONCLUSION: knowing that disturbances in brain, neuroendocrine, vascular and mitochondria metabolism are important events in neurodegeneration and dementia development, the ability of exercise to trigger adaptive mechanisms might represent an important non-pharmacological strategy to improve resilience to AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "The apolipoprotein E (apoE) gene has been implicated in various conditions, most notably Alzheimer's disease and coronary artery disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28299413"}, {"offsetInBeginSection": 1452, "offsetInEndSection": 1615, "text": "However, unlike other conditions (e.g., Alzheimer's disease and coronary artery disease), resilience to trauma is not a disease but an adaptive response to trauma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28299413"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Asymptomatic Alzheimer disease: Defining resilience.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815399"}, {"offsetInBeginSection": 284, "offsetInEndSection": 442, "text": "METHODS: Participants with normal cognition (n = 297) and mild cognitive impairment (n = 432) were drawn from the Alzheimer's Disease Neuroimaging Initiative.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815399"}, {"offsetInBeginSection": 443, "offsetInEndSection": 604, "text": "Resilience metrics were defined at baseline by examining the residuals when regressing brain aging outcomes (hippocampal volume and cognition) on CSF biomarkers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815399"}]}, {"id": "5a7376e33b9d13c708000009", "body": "Describe Vanishing lung syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26259424", "http://www.ncbi.nlm.nih.gov/pubmed/25322795", "http://www.ncbi.nlm.nih.gov/pubmed/22564798", "http://www.ncbi.nlm.nih.gov/pubmed/28219569", "http://www.ncbi.nlm.nih.gov/pubmed/22937434", "http://www.ncbi.nlm.nih.gov/pubmed/28975065", "http://www.ncbi.nlm.nih.gov/pubmed/24511405", "http://www.ncbi.nlm.nih.gov/pubmed/7272201", "http://www.ncbi.nlm.nih.gov/pubmed/25618882", "http://www.ncbi.nlm.nih.gov/pubmed/24977015"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 39, "text": "A Rare Case of Vanishing Lung Syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259424"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Vanishing lung syndrome (VLS) is a rare radiological syndrome in which the lungs appear to be disappearing on X-ray.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259424"}, {"offsetInBeginSection": 695, "offsetInEndSection": 792, "text": "Eventually, his CT chest revealed the diagnosis of giant bullous disease/vanishing lung syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259424"}, {"offsetInBeginSection": 793, "offsetInEndSection": 862, "text": "He had been surviving with his little lung tissue for about 10 years.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259424"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Vanishing lung syndrome in one family: five cases with a 20-year follow-up.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25322795"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Vanishing lung syndrome, also known as idiopathic giant bullous emphysema, is a rare disease characterized by giant emphysematous bullae.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25322795"}, {"offsetInBeginSection": 138, "offsetInEndSection": 300, "text": "The disease is diagnosed by radiological findings of giant bullae in one, or both, of the upper lobes of the lung, occupying at least one-third of the hemithorax.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25322795"}, {"offsetInBeginSection": 301, "offsetInEndSection": 456, "text": "There have been several reports of vanishing lung syndrome, however it remains to be determined whether genetic inheritance is associated with the disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25322795"}, {"offsetInBeginSection": 457, "offsetInEndSection": 596, "text": "In the present study, five patients within one family, with vanishing lung syndrome, were reported during a follow-up period of ~ 20 years.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25322795"}, {"offsetInBeginSection": 1316, "offsetInEndSection": 1448, "text": "The present study suggests that vanishing lung syndrome may be associated with autosomal dominant and recessive genetic inheritance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25322795"}]}, {"id": "5a80dbaafaa1ab7d2e000026", "body": "Are there ways of joint Bayesian inference of risk variants?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27407109"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Joint Bayesian inference of risk variants and tissue-specific epigenomic enrichments across multiple complex human diseases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Genome wide association studies (GWAS) provide a powerful approach for uncovering disease-associated variants in human, but fine-mapping the causal variants remains a challenge.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109"}, {"offsetInBeginSection": 178, "offsetInEndSection": 301, "text": "This is partly remedied by prioritization of disease-associated variants that overlap GWAS-enriched epigenomic annotations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109"}, {"offsetInBeginSection": 302, "offsetInEndSection": 535, "text": "Here, we introduce a new Bayesian model RiVIERA (Risk Variant Inference using Epigenomic Reference Annotations) for inference of driver variants from summary statistics across multiple traits using hundreds of epigenomic annotations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109"}, {"offsetInBeginSection": 536, "offsetInEndSection": 697, "text": "In simulation, RiVIERA promising power in detecting causal variants and causal annotations, the multi-trait joint inference further improved the detection power.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109"}, {"offsetInBeginSection": 1244, "offsetInEndSection": 1444, "text": "Moreover, the variants from the 95% credible sets exhibited high conservation and enrichments for GTEx whole-blood eQTLs located within transcription-factor-binding-sites and DNA-hypersensitive-sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109"}]}, {"id": "5a9ac7ba1d1251d03b000013", "body": "What does intepirdine target?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28253832"], "snippets": [{"offsetInBeginSection": 189, "offsetInEndSection": 406, "text": "Characterized by neuronal cell death accompanied by the accumulation of neurofibrillary tangles and neuritic plaques, AD results in devastating clinical symptomatology with a lasting psychosocial and financial impact.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832"}]}, {"id": "5a981bcffcd1d6a10c00002d", "body": "List 3 symptoms of Wernicke encephalopathy.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15141340", "http://www.ncbi.nlm.nih.gov/pubmed/25539041", "http://www.ncbi.nlm.nih.gov/pubmed/16219837", "http://www.ncbi.nlm.nih.gov/pubmed/24293308", "http://www.ncbi.nlm.nih.gov/pubmed/27399058", "http://www.ncbi.nlm.nih.gov/pubmed/25856744", "http://www.ncbi.nlm.nih.gov/pubmed/17039990", "http://www.ncbi.nlm.nih.gov/pubmed/9279523", "http://www.ncbi.nlm.nih.gov/pubmed/23696407", "http://www.ncbi.nlm.nih.gov/pubmed/26653343"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Successful treatment of Wernicke encephalopathy in terminally ill cancer patients: report of 3 cases and review of the literature.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141340"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Although Wernicke encephalopathy has been reported in the oncological literature, only one terminally ill cancer patient with Wernicke encephalopathy has been reported.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141340"}, {"offsetInBeginSection": 169, "offsetInEndSection": 284, "text": "Wernicke encephalopathy, a potentially reversible condition, may be unrecognized in terminally ill cancer patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141340"}, {"offsetInBeginSection": 285, "offsetInEndSection": 393, "text": "In this communication, we report three terminally ill cancer patients who developed Wernicke encephalopathy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141340"}, {"offsetInBeginSection": 484, "offsetInEndSection": 570, "text": "Two of the three patients did not show the classical triad of Wernicke encephalopathy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141340"}, {"offsetInBeginSection": 745, "offsetInEndSection": 934, "text": "In terminally ill cancer patients, clinicians must remain aware of the possibility of Wernicke encephalopathy when patients with a poor nutritional status present with unexplained delirium.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141340"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Need for early diagnosis of mental and mobility changes in Wernicke encephalopathy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Korsakoff syndrome is a chronic form of amnesia resulting from thiamine deficiency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041"}, {"offsetInBeginSection": 84, "offsetInEndSection": 167, "text": "The syndrome can develop from unrecognized or undertreated Wernicke encephalopathy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041"}, {"offsetInBeginSection": 168, "offsetInEndSection": 361, "text": "The intra-individual course of Wernicke-Korsakoff syndrome has not been studied extensively, nor has the temporal progression of gait disturbances and other symptoms of Wernicke encephalopathy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041"}]}, {"id": "5a9d8d691d1251d03b000020", "body": "What is the association of the protein RAB10 and Alzheimers disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26082458", "http://www.ncbi.nlm.nih.gov/pubmed/19008234", "http://www.ncbi.nlm.nih.gov/pubmed/29127256"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Identification of Biomarkers Associated With Alzheimer's Disease by Bioinformatics Analysis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26082458"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "BACKGROUND: This study aimed to explore the biomarkers of Alzheimer's disease (AD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26082458"}, {"offsetInBeginSection": 83, "offsetInEndSection": 263, "text": "METHODS: The microarray data of GSE16759 were from the expression profile samples of 4 parietal lobe tissues from patients with AD and 4 ones from age-matched control participants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26082458"}, {"offsetInBeginSection": 264, "offsetInEndSection": 422, "text": "The differentially expressed micro RNAs (miRNAs) and genes (DEGs) underwent hierarchical clustering and function analysis followed by target genes prediction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26082458"}, {"offsetInBeginSection": 675, "offsetInEndSection": 1038, "text": "The target genes SEC22 vesicle trafficking protein homolog B (SEC22B) and SEC63 homolog (SEC63) regulated by miRNA-206, RAB10, member RAS oncogene family (RAB10) regulated by miRNA-655, and fms-related tyrosine kinase 1 (FLT1) regulated by miRNA-30e-3p and miRNA-369-3p were involved in the biological processes of protein transport and regulation of cell motion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26082458"}, {"offsetInBeginSection": 1038, "offsetInEndSection": 1125, "text": "CONCLUSION: The target genes SEC22B, RAB10, and FLT1 may be potential biomarkers of AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26082458"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Alternative splicing in class V myosins determines association with Rab10.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19008234"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Rab proteins influence vesicle trafficking pathways through the assembly of regulatory protein complexes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19008234"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127256"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Mutations that activate the LRRK2 protein kinase, predispose to Parkinson's disease, suggesting that LRRK2 inhibitors might have therapeutic benefit.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127256"}]}, {"id": "5a7379a83b9d13c70800000a", "body": "Is Rucaparib effective for ovarian cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29166829", "http://www.ncbi.nlm.nih.gov/pubmed/28790837", "http://www.ncbi.nlm.nih.gov/pubmed/28247266", "http://www.ncbi.nlm.nih.gov/pubmed/27002934", "http://www.ncbi.nlm.nih.gov/pubmed/29050241", "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "http://www.ncbi.nlm.nih.gov/pubmed/28751443", "http://www.ncbi.nlm.nih.gov/pubmed/28057616"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "OBJECTIVE: To review the pharmacology, safety, efficacy, and the role of rucaparib in the treatment of relapsed, advanced ovarian cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829"}, {"offsetInBeginSection": 137, "offsetInEndSection": 273, "text": "SUMMARY: A total of 2 phase I/II trials and 1 phase II trial have evaluated the safety and efficacy of oral rucaparib in ovarian cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829"}, {"offsetInBeginSection": 274, "offsetInEndSection": 447, "text": "In patients with deleterious BRCA1/2 mutation, an overall response rate of 80% was achieved in the phase II trial Assessment of Rucaparib in Ovarian CancEr Trial 2 (ARIEL2).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829"}, {"offsetInBeginSection": 632, "offsetInEndSection": 774, "text": "Rucaparib was found to be relatively well tolerated in clinical trials, with the most common adverse events being anemia, fatigue, and nausea.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829"}, {"offsetInBeginSection": 774, "offsetInEndSection": 911, "text": "CONCLUSION: Rucaparib appears to be a safe and effective new option in the treatment of relapsed, advanced BRCA1/2 mutant ovarian cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829"}, {"offsetInBeginSection": 912, "offsetInEndSection": 1052, "text": "The role of rucaparib in this setting will likely expand and be further elucidated as results from several ongoing studies become available.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790837"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790837"}, {"offsetInBeginSection": 103, "offsetInEndSection": 164, "text": "Phase I and II studies demonstrated clinical efficacy in both", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790837"}]}, {"id": "5a8b27e6fcd1d6a10c00001e", "body": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24990604", "http://www.ncbi.nlm.nih.gov/pubmed/28449648", "http://www.ncbi.nlm.nih.gov/pubmed/25238658", "http://www.ncbi.nlm.nih.gov/pubmed/24927192"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "RAPIDR: an analysis package for non-invasive prenatal testing of aneuploidy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "UNLABELLED: Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free fetal DNA is becoming part of routine clinical practice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604"}, {"offsetInBeginSection": 142, "offsetInEndSection": 307, "text": "RAPIDR (Reliable Accurate Prenatal non-Invasive Diagnosis R package) is an easy-to-use open-source R package that implements several published NIPT analysis methods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604"}, {"offsetInBeginSection": 494, "offsetInEndSection": 592, "text": "RAPIDR has been extensively tested with a large sample set as part of the RAPID project in the UK.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Development and evaluation of training resources to prepare health professionals for counselling pregnant women about non-invasive prenatal testing for Down syndrome: a mixed methods study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449648"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "BACKGROUND: The availability of non-invasive prenatal testing (NIPT) for aneuploidies is expanding rapidly throughout the world.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449648"}, {"offsetInBeginSection": 129, "offsetInEndSection": 244, "text": "Training health professionals to offer NIPT in a way that supports informed choice is essential for implementation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449648"}, {"offsetInBeginSection": 245, "offsetInEndSection": 398, "text": "The aim of this study was to develop and evaluate a training package for health professionals to support the introduction of NIPT into clinical practice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449648"}, {"offsetInBeginSection": 956, "offsetInEndSection": 1037, "text": "Interviews explored opinions about the training and experiences of offering NIPT.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449648"}, {"offsetInBeginSection": 1037, "offsetInEndSection": 1279, "text": "RESULTS: The training provided to the health professionals was found to positively impact on their confidence in discussing NIPT with women in their clinic, and both their perceived and actual knowledge and understanding of NIPT was improved.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449648"}]}, {"id": "5a9acba61d1251d03b000014", "body": "Has intepirdine been evaluated in clinical trials? (November 2017)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28253832", "http://www.ncbi.nlm.nih.gov/pubmed/29131320", "http://www.ncbi.nlm.nih.gov/pubmed/29151578", "http://www.ncbi.nlm.nih.gov/pubmed/25027481", "http://www.ncbi.nlm.nih.gov/pubmed/29155424", "http://www.ncbi.nlm.nih.gov/pubmed/25454208", "http://www.ncbi.nlm.nih.gov/pubmed/28591872", "http://www.ncbi.nlm.nih.gov/pubmed/29026293", "http://www.ncbi.nlm.nih.gov/pubmed/28985716", "http://www.ncbi.nlm.nih.gov/pubmed/29047408"], "snippets": [{"offsetInBeginSection": 551, "offsetInEndSection": 724, "text": "The 5-HT-6 receptor antagonists Idalopirdine and Intepirdine have shown the most progress in current clinical trials and warrant consideration as emerging treatments for AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832"}, {"offsetInBeginSection": 725, "offsetInEndSection": 947, "text": "Areas covered: This review discusses 5-HT6 antagonists currently in clinical trials as potential treatments for AD symptomatology and how 5-HT6 physiology may play a positive role in alleviating AD symptom pathophysiology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832"}, {"offsetInBeginSection": 1077, "offsetInEndSection": 1165, "text": "Clinicaltrials.gov and Alzforum were also used to obtain information on clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832"}, {"offsetInBeginSection": 1166, "offsetInEndSection": 1399, "text": "Expert opinion: If current Phase-3 trials are positive, 5-HT6 antagonists such as Idalopirdine and Intepirdine may be considered as supplementary treatments to ChEI's and NMDA receptor antagonists for the symptomatic treatment of AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "In November 2017, the Council of the European Society of Clinical Investigation (ESCI) evaluated all basic research articles published in the European Journal of Clinical Investigation (EJCI) from November 2016 to October 2017.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29131320"}, {"offsetInBeginSection": 114, "offsetInEndSection": 323, "text": "Since it takes an extremely long time to accurately determine the protective efficacy of TB vaccines, there is a great need to identify the surrogate signatures of protection to facilitate vaccine development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29151578"}, {"offsetInBeginSection": 324, "offsetInEndSection": 538, "text": "Unfortunately, antigen-specific Th1 cytokines that are currently used to evaluate the protective efficacy of the TB vaccine, do not align with the protection and failure of TB vaccine candidates in clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29151578"}, {"offsetInBeginSection": 610, "offsetInEndSection": 754, "text": "RESULTS: Of the stemless shoulder arthroplasty systems available on the market, 3 are currently undergoing clinical trials in the United States.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25027481"}, {"offsetInBeginSection": 834, "offsetInEndSection": 927, "text": "The study with 2-year minimum follow-up results is scheduled for completion in November 2014.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25027481"}, {"offsetInBeginSection": 1064, "offsetInEndSection": 1192, "text": "The Biomet Nano (Biomet, Warsaw, IN, USA) clinical trial began in October 2013 and also has a tentative completion date of 2017.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25027481"}]}, {"id": "5aa3fa73d6d6b54f79000008", "body": "Is subacute sclerosing panencephalitis caused by the Measles vaccine?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15384893", "http://www.ncbi.nlm.nih.gov/pubmed/850592", "http://www.ncbi.nlm.nih.gov/pubmed/3531224", "http://www.ncbi.nlm.nih.gov/pubmed/2019970", "http://www.ncbi.nlm.nih.gov/pubmed/2087249", "http://www.ncbi.nlm.nih.gov/pubmed/21311432", "http://www.ncbi.nlm.nih.gov/pubmed/1706253", "http://www.ncbi.nlm.nih.gov/pubmed/6685828", "http://www.ncbi.nlm.nih.gov/pubmed/2807674", "http://www.ncbi.nlm.nih.gov/pubmed/25802788"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Subacute sclerosing panencephalitis after intrauterine infection.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "UNLABELLED: Subacute sclerosing panencephalitis (SSPE), in the majority of cases, is caused by the wild measles virus, although there are some reports relating SSPE to vaccination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893"}, {"offsetInBeginSection": 407, "offsetInEndSection": 664, "text": "Subacute sclerosing panencephalitis is a fatal degenerative disease and, although it had largely disappeared because of nearly universal measles vaccination, it still remains a serious infection among children affected by human immunodeficiency virus (HIV).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893"}, {"offsetInBeginSection": 665, "offsetInEndSection": 923, "text": "The lack of newer cases of SSPE occurring among normal children nowadays should not wane alertness by obstetricians and paediatricians, to recognize the risk with measles during pregnancy and the need for prevention and recognition of SSPE at an early stage.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893"}, {"offsetInBeginSection": 924, "offsetInEndSection": 1075, "text": "Although some references exist which report on SSPE cases related to vaccination, new work weakens the possible links between measles vaccine and SSPE.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893"}, {"offsetInBeginSection": 1075, "offsetInEndSection": 1239, "text": "CONCLUSION: This report would like to stress the importance and success of reducing the SSPE problem with the aid of general measles vaccination with high coverage.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/850592"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Histories obtained in 350 of 375 clinically cofirmed cases of subacute sclerosing panencephalitis (SSPE) reported to a national registry showed that 292 patients had measles and 58 had no history of measles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/850592"}, {"offsetInBeginSection": 208, "offsetInEndSection": 285, "text": "Forty of the latter patients received live, attenuated measles virus vaccine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/850592"}, {"offsetInBeginSection": 286, "offsetInEndSection": 422, "text": "In patients with a history of measles, measles illness occurred before age 2 years in 46%, and a mean of 7.0 years before onset of SSPE.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/850592"}]}, {"id": "5a9d8ffe1d1251d03b000022", "body": "What are pQTLs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27532455", "http://www.ncbi.nlm.nih.gov/pubmed/27329291", "http://www.ncbi.nlm.nih.gov/pubmed/25087611", "http://www.ncbi.nlm.nih.gov/pubmed/23172855", "http://www.ncbi.nlm.nih.gov/pubmed/28129359", "http://www.ncbi.nlm.nih.gov/pubmed/25124843", "http://www.ncbi.nlm.nih.gov/pubmed/24823668", "http://www.ncbi.nlm.nih.gov/pubmed/28240269", "http://www.ncbi.nlm.nih.gov/pubmed/22595970", "http://www.ncbi.nlm.nih.gov/pubmed/21846806"], "snippets": [{"offsetInBeginSection": 573, "offsetInEndSection": 627, "text": "PQTLs consistently replicated between the two cohorts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532455"}, {"offsetInBeginSection": 628, "offsetInEndSection": 707, "text": "Features of pQTLs were compared to previously reported expression QTLs (eQTLs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532455"}, {"offsetInBeginSection": 1164, "offsetInEndSection": 1333, "text": "Some of these pQTLs [e.g., pQTLs for VDBP, sRAGE (gene = AGER), surfactant protein D (gene = SFTPD), and TNFRSF10C] have been previously associated with COPD phenotypes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532455"}, {"offsetInBeginSection": 105, "offsetInEndSection": 256, "text": "Here, we identify new common and rare genetic variants associated with cardiovascular-related protein levels (protein quantitative trait loci [pQTLs]).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329291"}, {"offsetInBeginSection": 257, "offsetInEndSection": 456, "text": "We functionally annotate these pQTLs, predict and experimentally confirm a novel molecular interaction, and determine which pQTLs are associated with diseases and physiological phenotypes.METHODS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329291"}, {"offsetInBeginSection": 1166, "offsetInEndSection": 1311, "text": "cis-pQTLs for kallikrein and F12 also show trans associations for proteins (uPAR, kininogen) known to be cleaved by kallikrein and with NTproBNP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329291"}, {"offsetInBeginSection": 1510, "offsetInEndSection": 1725, "text": "CONCLUSIONS: We have identified cis and trans genetic variation associated with the serum levels of 20 proteins and utilized these pQTLs to study molecular mechanisms underlying disease and physiological phenotypes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329291"}, {"offsetInBeginSection": 498, "offsetInEndSection": 788, "text": "We collected more than 250,000 protein level measurements comprising 441 transcription factor and signaling protein isoforms across 68 Yoruba (YRI) HapMap lymphoblastoid cell lines (LCLs) and identified 12 cis and 160 trans protein level QTLs (pQTLs) at a false discovery rate (FDR) of 20%.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25087611"}, {"offsetInBeginSection": 789, "offsetInEndSection": 919, "text": "Whereas up to two thirds of cis mRNA expression QTLs (eQTLs) were also pQTLs, many pQTLs were not associated with mRNA expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25087611"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Quantitative trait loci mapping of the mouse plasma proteome (pQTL).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23172855"}]}, {"id": "5a7428090384be9551000001", "body": "What can be predicted with the Wells criteria?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28260193", "http://www.ncbi.nlm.nih.gov/pubmed/23293869", "http://www.ncbi.nlm.nih.gov/pubmed/21610436", "http://www.ncbi.nlm.nih.gov/pubmed/17964711", "http://www.ncbi.nlm.nih.gov/pubmed/9447391", "http://www.ncbi.nlm.nih.gov/pubmed/28119448", "http://www.ncbi.nlm.nih.gov/pubmed/10599768", "http://www.ncbi.nlm.nih.gov/pubmed/12908858", "http://www.ncbi.nlm.nih.gov/pubmed/22653873", "http://www.ncbi.nlm.nih.gov/pubmed/20179688"], "snippets": [{"offsetInBeginSection": 72, "offsetInEndSection": 185, "text": "There are no recognized criteria to exactly distinguish between benign and malignant forms, or predict prognosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28260193"}, {"offsetInBeginSection": 702, "offsetInEndSection": 761, "text": "Tumors were categorized according to the Wienecke criteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28260193"}, {"offsetInBeginSection": 938, "offsetInEndSection": 1001, "text": "According to Wienecke scoring system, 13 cases were 3 criteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28260193"}, {"offsetInBeginSection": 1221, "offsetInEndSection": 1355, "text": "CONCLUSIONS: Wienecke criteria can be an appropriate points-scoring system to predict prognosis for adrenocortical tumors in children.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28260193"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Predicting recovery criteria for threatened and endangered plant species on the basis of past abundances and biological traits.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293869"}, {"offsetInBeginSection": 49, "offsetInEndSection": 179, "text": "Endangered Species Act are required to specify measurable criteria that can be used to determine when the species can be delisted.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293869"}, {"offsetInBeginSection": 180, "offsetInEndSection": 552, "text": "For the 642 listed endangered and threatened plant species that have recovery plans, we applied recursive partitioning methods to test whether the number of individuals or populations required for delisting can be predicted on the basis of distributional and biological traits, previous abundance at multiple time steps, or a combination of traits and previous abundances.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293869"}, {"offsetInBeginSection": 689, "offsetInEndSection": 864, "text": "We analyzed separately recovery criteria that were stated as number of populations and as number of individuals (population-based and individual-based criteria, respectively).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293869"}, {"offsetInBeginSection": 865, "offsetInEndSection": 961, "text": "Previous abundances alone were relatively good predictors of population-based recovery criteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293869"}, {"offsetInBeginSection": 1169, "offsetInEndSection": 1302, "text": "Previous abundances were also good predictors of individual-based delisting criteria when models included both abundances and traits.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293869"}]}, {"id": "5a8b292afcd1d6a10c00001f", "body": "Is there any role of interleukin-11 in cardiovascular fibrosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29160304", "http://www.ncbi.nlm.nih.gov/pubmed/20100971", "http://www.ncbi.nlm.nih.gov/pubmed/21646597", "http://www.ncbi.nlm.nih.gov/pubmed/23229370", "http://www.ncbi.nlm.nih.gov/pubmed/25304471"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "IL11 is a crucial determinant of cardiovascular fibrosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29160304"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Fibrosis is a final common pathology in cardiovascular disease", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29160304"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100971"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "BACKGROUND: Glycoprotein 130 is the common receptor subunit for the interleukin (IL)-6 cytokine family.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100971"}, {"offsetInBeginSection": 646, "offsetInEndSection": 900, "text": "Intravenous injection of IL-11 activated signal transducer and activator of transcription 3 (STAT3), a downstream signaling molecule of glycoprotein 130, in cardiomyocytes in vivo, suggesting that cardiac myocytes are target cells of IL-11 in the hearts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100971"}, {"offsetInBeginSection": 1048, "offsetInEndSection": 1136, "text": "IL-11 treatment reduced fibrosis area 14 days after MI, attenuating cardiac dysfunction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100971"}, {"offsetInBeginSection": 1399, "offsetInEndSection": 1549, "text": "Importantly, cardiac-specific ablation of STAT3 abrogated IL-11-mediated attenuation of fibrosis and was associated with left ventricular enlargement.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100971"}, {"offsetInBeginSection": 1739, "offsetInEndSection": 1809, "text": "CONCLUSIONS: IL-11 attenuated cardiac fibrosis after MI through STAT3.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100971"}, {"offsetInBeginSection": 1810, "offsetInEndSection": 1930, "text": "Activation of the IL-11/glycoprotein 130/STAT3 axis may be a novel therapeutic strategy against cardiovascular diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100971"}, {"offsetInBeginSection": 104, "offsetInEndSection": 419, "text": "Previously, we reported that pretreatment of IL-11, an IL-6 family cytokine, activates the glycoprotein 130 signaling pathway in cardiomyocytes and prevents ischemia/reperfusion injury in vivo; however, its long-term effects on cardiac remodeling after myocardial infarction (MI) remain to be elucidated.METHODS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100971"}]}, {"id": "5a9acc7b1d1251d03b000015", "body": "What is crenezumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27996029", "http://www.ncbi.nlm.nih.gov/pubmed/26467270", "http://www.ncbi.nlm.nih.gov/pubmed/24803227", "http://www.ncbi.nlm.nih.gov/pubmed/28924036", "http://www.ncbi.nlm.nih.gov/pubmed/25880481", "http://www.ncbi.nlm.nih.gov/pubmed/24490853", "http://www.ncbi.nlm.nih.gov/pubmed/24981190", "http://www.ncbi.nlm.nih.gov/pubmed/24445401"], "snippets": [{"offsetInBeginSection": 281, "offsetInEndSection": 467, "text": "Crenezumab is a humanized anti-A\u03b2 monoclonal IgG4 that binds multiple forms of A\u03b2, with higher affinity for aggregated forms, and that blocks A\u03b2 aggregation, and promotes disaggregation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27996029"}, {"offsetInBeginSection": 468, "offsetInEndSection": 611, "text": "To understand the structural basis for this binding profile and activity, we determined the crystal structure of crenezumab in complex with A\u03b2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27996029"}, {"offsetInBeginSection": 1247, "offsetInEndSection": 1440, "text": "These insights highlight crenezumab's unique mechanism of action, particularly regarding A\u03b2 oligomers, and provide a strong rationale for the evaluation of crenezumab as a potential AD therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27996029"}, {"offsetInBeginSection": 278, "offsetInEndSection": 485, "text": "Here, we report the immunohistochemical staining profiles of biosimilar antibodies of Solanezumab, Crenezumab and Bapineuzumab in human formalin-fixed, paraffin-embedded tissue and human fresh frozen tissue.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26467270"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Do current therapeutic anti-A\u03b2 antibodies for Alzheimer's disease engage the target?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24803227"}, {"offsetInBeginSection": 1176, "offsetInEndSection": 1275, "text": "Bapineuzumab demonstrated target engagement with brain A\u03b2, consistent with published clinical data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24803227"}, {"offsetInBeginSection": 1433, "offsetInEndSection": 1595, "text": "This lack of target engagement raises questions as to whether solanezumab and crenezumab are suitable drug candidates for the preventative clinical trials for AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24803227"}, {"offsetInBeginSection": 169, "offsetInEndSection": 299, "text": "The most developed method for targeting A\u03b2 is the use of monoclonal antibodies including bapineuzumab, solanezumab and crenezumab.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24803227"}, {"offsetInBeginSection": 202, "offsetInEndSection": 373, "text": "Here we simulate the recognition of monomeric, oligomeric, and fibril amyloid-\u03b2 (A\u03b2) by three homologous antibodies (solanezumab, crenezumab, and their chimera, CreneFab).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28924036"}, {"offsetInBeginSection": 679, "offsetInEndSection": 868, "text": "It is noteworthy that solanezumab targets A\u03b2 residues 16-26 preferentially in the monomeric state; conversely, crenezumab consistently targets residues 13-16 in different oligomeric states.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28924036"}]}, {"id": "5aa3fb7ad6d6b54f79000009", "body": "What drug cures hepatitis C?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22504355", "http://www.ncbi.nlm.nih.gov/pubmed/26043288", "http://www.ncbi.nlm.nih.gov/pubmed/21652618", "http://www.ncbi.nlm.nih.gov/pubmed/28644739", "http://www.ncbi.nlm.nih.gov/pubmed/22242928", "http://www.ncbi.nlm.nih.gov/pubmed/24782255", "http://www.ncbi.nlm.nih.gov/pubmed/21866039", "http://www.ncbi.nlm.nih.gov/pubmed/26666278", "http://www.ncbi.nlm.nih.gov/pubmed/26546955", "http://www.ncbi.nlm.nih.gov/pubmed/20039157"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Viral hepatitis is currently a major global cause of morbidity and mortality.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22504355"}, {"offsetInBeginSection": 254, "offsetInEndSection": 423, "text": "Furthermore, statistics indicate that patients with liver cirrhosis resulting from hepatitis B and C have an increased risk of developing hepatocellular carcinoma (HCC).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22504355"}, {"offsetInBeginSection": 424, "offsetInEndSection": 615, "text": "Scientists have worked tirelessly to find curative therapeutic strategies to control chronic hepatitis and liver cirrhosis, accompanied by improvements in public health and living conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22504355"}, {"offsetInBeginSection": 2525, "offsetInEndSection": 2731, "text": "The CJMWDDT 2007 was a highly successful scientific event that strengthened and promoted extensive cooperation between China and Japan for the development of new pharmaceutical products and hepatitis cures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22504355"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26043288"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Anno 2015, the race for developing the ideal therapy, or what is now called \"cure,\" for hepatitis C virus infection has continued unabatedly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26043288"}, {"offsetInBeginSection": 1178, "offsetInEndSection": 1363, "text": "Unlike hepatitis B virus and human immunodeficiency virus, HCV infection can be definitely and permanently cured by antiviral therapy because HCV has no long-term reservoir in the body.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26043288"}, {"offsetInBeginSection": 1364, "offsetInEndSection": 1587, "text": "Peginterferon combined with ribavirin and even the first-wave protease inhibitors telaprevir and boceprevir now belong to the milestones that had an important, although historical, role in the final conquest of hepatitis C.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26043288"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Directly acting antivirals against hepatitis C virus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21652618"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "The approval of directly acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection will represent a major breakthrough for the 180 million persons infected worldwide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21652618"}]}, {"id": "5a9d96564e03427e73000001", "body": "List major risk factors for Alzheimer's disease. ", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16945215", "http://www.ncbi.nlm.nih.gov/pubmed/11884656", "http://www.ncbi.nlm.nih.gov/pubmed/10396132", "http://www.ncbi.nlm.nih.gov/pubmed/23375669", "http://www.ncbi.nlm.nih.gov/pubmed/27688858", "http://www.ncbi.nlm.nih.gov/pubmed/14710446", "http://www.ncbi.nlm.nih.gov/pubmed/16314757", "http://www.ncbi.nlm.nih.gov/pubmed/21655757", "http://www.ncbi.nlm.nih.gov/pubmed/20182020", "http://www.ncbi.nlm.nih.gov/pubmed/26993513"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Interventions for heart disease and their effects on Alzheimer's disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "OBJECTIVES: To review the contributions of cardiovascular disease to Alzheimer's disease and vascular dementia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215"}, {"offsetInBeginSection": 145, "offsetInEndSection": 268, "text": "RESULTS: Alzheimer's disease and vascular dementia both share significant risk attributable to cardiovascular risk factors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215"}, {"offsetInBeginSection": 377, "offsetInEndSection": 433, "text": "Diabetes and obesity are also risk factors for dementia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215"}, {"offsetInBeginSection": 434, "offsetInEndSection": 577, "text": "Stressful medical procedures, such as coronary artery bypass and graft operations also appear to contribute to the risk of Alzheimer's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215"}, {"offsetInBeginSection": 578, "offsetInEndSection": 644, "text": "Apolipoprotein E is the major risk factor for Alzheimer's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215"}, {"offsetInBeginSection": 645, "offsetInEndSection": 880, "text": "Apolipoprotein E does not appear to contribute to Alzheimer's disease by increasing serum cholesterol, but it might contribute to the disease through a mechanism involving both Abeta and an increase in neuronal vulnerability to stress.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215"}, {"offsetInBeginSection": 880, "offsetInEndSection": 1060, "text": "DISCUSSION: The strong association of cardiovascular risk factors with Alzheimer's disease and vascular dementia suggest that these diseases share some biologic pathways in common.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215"}, {"offsetInBeginSection": 1061, "offsetInEndSection": 1241, "text": "The contribution of cardiovascular disease to Alzheimer's disease and vascular dementia suggest that cardiovascular therapies might prove useful in treating or preventing dementia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215"}, {"offsetInBeginSection": 1328, "offsetInEndSection": 1435, "text": "Statins might be beneficial in preventing the progression of dementia in subjects with Alzheimer's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215"}]}, {"id": "5a7486a90384be9551000003", "body": "Which molecules are inhibited by anticancer drug Dovitinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23041231", "http://www.ncbi.nlm.nih.gov/pubmed/22674553"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Dovitinib (TKI258/CHIR258) is a multi-kinase inhibitor in phase III development for the treatment of several cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231"}, {"offsetInBeginSection": 118, "offsetInEndSection": 256, "text": "Dovitinib is a benzimidazole-quinolinone compound that structurally resembles the bisbenzimidazole minor groove binding dye Hoechst 33258.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231"}, {"offsetInBeginSection": 257, "offsetInEndSection": 429, "text": "Dovitinib bound to DNA as shown by its ability to increase the DNA melting temperature and by increases in its fluorescence spectrum that occurred upon the addition of DNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231"}, {"offsetInBeginSection": 430, "offsetInEndSection": 619, "text": "Molecular modeling studies of the docking of dovitinib into an X-ray structure of a Hoechst 33258-DNA complex showed that dovitinib could reasonably be accommodated in the DNA minor groove.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231"}, {"offsetInBeginSection": 620, "offsetInEndSection": 814, "text": "Because DNA binders are often topoisomerase I (EC 5.99.1.2) and topoisomerase II (EC 5.99.1.3) inhibitors, the ability of dovitinib to inhibit these DNA processing enzymes was also investigated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231"}, {"offsetInBeginSection": 815, "offsetInEndSection": 892, "text": "Dovitinib inhibited the catalytic decatenation activity of topoisomerase II\u03b1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231"}, {"offsetInBeginSection": 1035, "offsetInEndSection": 1164, "text": "Using isolated human topoisomerase II\u03b1, dovitinib stabilized the enzyme-cleavage complex and acted as a topoisomerase II\u03b1 poison.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231"}, {"offsetInBeginSection": 1165, "offsetInEndSection": 1361, "text": "Dovitinib was also found to be a cellular topoisomerase II poison in human leukemia K562 cells and induced double-strand DNA breaks in K562 cells as evidenced by increased phosphorylation of H2AX.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231"}, {"offsetInBeginSection": 1495, "offsetInEndSection": 1736, "text": "In conclusion, the cell growth inhibitory activity and the anticancer activity of dovitinib may result not only from its ability to inhibit multiple kinases, but also, in part, from its ability to target topoisomerase I and topoisomerase II.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231"}]}, {"id": "5a67c497b750ff4455000012", "body": "Which method is available for whole genome identification of pathogenic regulatory variants in mendelian disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27569544"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "A Whole-Genome Analysis Framework for Effective Identification of Pathogenic Regulatory Variants in Mendelian Disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "The interpretation of non-coding variants still constitutes a major challenge in the application of whole-genome sequencing in Mendelian disease, especially for single-nucleotide and other small non-coding variants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544"}, {"offsetInBeginSection": 423, "offsetInEndSection": 717, "text": "Genomiser scores variants through either existing methods such as CADD or a bespoke machine learning method and combines these with allele frequency, regulatory sequences, chromosomal topological domains, and phenotypic relevance to\u00a0discover variants associated to specific Mendelian disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544"}, {"offsetInBeginSection": 718, "offsetInEndSection": 927, "text": "Overall, Genomiser is able to identify causal regulatory variants as the\u00a0top candidate in 77% of simulated whole genomes, allowing effective detection and discovery of regulatory variants in Mendelian disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544"}]}, {"id": "5a9acd921d1251d03b000016", "body": "In what phase of clinical trials is crenezumab? (November 2017)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25880481", "http://www.ncbi.nlm.nih.gov/pubmed/24445401", "http://www.ncbi.nlm.nih.gov/pubmed/28760727", "http://www.ncbi.nlm.nih.gov/pubmed/24803227", "http://www.ncbi.nlm.nih.gov/pubmed/24490853", "http://www.ncbi.nlm.nih.gov/pubmed/28591872", "http://www.ncbi.nlm.nih.gov/pubmed/29099493", "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "http://www.ncbi.nlm.nih.gov/pubmed/25027481", "http://www.ncbi.nlm.nih.gov/pubmed/29155424"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Molecular basis for mid-region amyloid-\u03b2 capture by leading Alzheimer's disease immunotherapies.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25880481"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-\u03b2 (A\u03b2) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25880481"}, {"offsetInBeginSection": 229, "offsetInEndSection": 359, "text": "A\u03b2 capture by these clinical antibodies is explained here with the first reported mid-region A\u03b2-anti-A\u03b2 complex crystal structure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25880481"}, {"offsetInBeginSection": 360, "offsetInEndSection": 600, "text": "Solanezumab accommodates a large A\u03b2 epitope (960 \u00c5(2) buried interface over residues 16 to 26) that forms extensive contacts and hydrogen bonds to the antibody, largely via main-chain A\u03b2 atoms and a deeply buried Phe19-Phe20 dipeptide core.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25880481"}, {"offsetInBeginSection": 782, "offsetInEndSection": 859, "text": "Remarkably, A\u03b2-binding residues are almost perfectly conserved in crenezumab.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25880481"}, {"offsetInBeginSection": 860, "offsetInEndSection": 1019, "text": "The structure explains the observed shared cross reactivity of solanezumab and crenezumab with proteins abundant in plasma that exhibit this Phe-Phe dipeptide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25880481"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401"}, {"offsetInBeginSection": 11, "offsetInEndSection": 210, "text": "REVIEW: We reviewed clinical trials on active and passive anti-\u03b2-amyloid (A\u03b2) immunotherapy for the treatment of Alzheimer's disease with a particular focus on monoclonal antibodies against A\u03b2.RECENT", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401"}, {"offsetInBeginSection": 211, "offsetInEndSection": 343, "text": "FINDINGS: Studies on anti-Alzheimer's disease immunotherapy published in the period from January 2012 to October 2013 were reviewed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401"}, {"offsetInBeginSection": 439, "offsetInEndSection": 589, "text": "However, an active anti-A\u03b2 vaccine (AN1792) has been discontinued because it caused meningoencephalitis in 6% of Alzheimer's disease patients treated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401"}]}, {"id": "5aa55b45d6d6b54f7900000d", "body": "What organism causes scarlet fever also known as scarletina?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2772682", "http://www.ncbi.nlm.nih.gov/pubmed/19868695", "http://www.ncbi.nlm.nih.gov/pubmed/2045646", "http://www.ncbi.nlm.nih.gov/pubmed/8415304", "http://www.ncbi.nlm.nih.gov/pubmed/1432423", "http://www.ncbi.nlm.nih.gov/pubmed/19869456", "http://www.ncbi.nlm.nih.gov/pubmed/7405299", "http://www.ncbi.nlm.nih.gov/pubmed/125514", "http://www.ncbi.nlm.nih.gov/pubmed/12843042", "http://www.ncbi.nlm.nih.gov/pubmed/19869457"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Group C beta-hemolytic streptococci causing pharyngitis and scarlet fever.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2772682"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "After a young woman had scarlet fever associated with group C beta-hemolytic streptococcal pharyngitis, we reviewed all cases of pharyngitis treated at a student health clinic during that semester.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2772682"}, {"offsetInBeginSection": 444, "offsetInEndSection": 634, "text": "The severity of symptoms and the demonstration of scarlet fever developing from infection with this organism supports antibiotic treatment of patients with group C streptococcal pharyngitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2772682"}, {"offsetInBeginSection": 46, "offsetInEndSection": 144, "text": "ANTIGENIC RELATIONSHIPS BETWEEN STRAINS OF STREPTOCOCCUS HAEMOLYTICUS ISOLATED FROM SCARLET FEVER.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695"}, {"offsetInBeginSection": 3, "offsetInEndSection": 139, "text": "Hemolytic streptococcus has been found in 100 per cent of the throats of patients with scarlet fever during the 1st week of the disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695"}, {"offsetInBeginSection": 247, "offsetInEndSection": 371, "text": "No morphological or cultural characteristics peculiar to the hemolytic streptococcus from scarlet fever can be demonstrated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695"}, {"offsetInBeginSection": 375, "offsetInEndSection": 568, "text": "Ten immune sera have been prepared from different strains of scarlet fever streptococci and each of the sera agglutinated more than 80 per cent of the strains isolated from scarlatinal throats.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695"}, {"offsetInBeginSection": 731, "offsetInEndSection": 866, "text": "Serum from patients convalescent from scarlet fever agglutinates weakly or not at all the homologous strain of hemolytic streptococcus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695"}, {"offsetInBeginSection": 987, "offsetInEndSection": 1180, "text": "Scarlatinal antistreptococcic serum affords some degree of protection against virulent scarlet fever streptococci but has no protective power against hemolytic streptococci from other diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695"}, {"offsetInBeginSection": 1184, "offsetInEndSection": 1427, "text": "In a small epidemic of scarlet fever a healthy carrier of hemolytic streptococcus was detected; the organism carried was identical in its serological reactions with strains of hemolytic streptococci isolated from active cases of scarlet fever.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695"}]}, {"id": "5a9da8df4e03427e73000006", "body": "What is emicizumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29042366", "http://www.ncbi.nlm.nih.gov/pubmed/28451690", "http://www.ncbi.nlm.nih.gov/pubmed/28691557", "http://www.ncbi.nlm.nih.gov/pubmed/27384849", "http://www.ncbi.nlm.nih.gov/pubmed/27223146", "http://www.ncbi.nlm.nih.gov/pubmed/27795538", "http://www.ncbi.nlm.nih.gov/pubmed/27960628"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29042366"}, {"offsetInBeginSection": 393, "offsetInEndSection": 507, "text": "Emicizumab is a bispecific antibody recognizing both the enzyme factor IXa (FIXa) and the substrate factor X (FX).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29042366"}, {"offsetInBeginSection": 993, "offsetInEndSection": 1284, "text": "Such insight might be useful in the clinical decision making for those who apply Emicizumab in their practice already or within the future, particularly in view of the thrombotic complications that have been reported when Emicizumab was used in combination with factor VIII-bypassing agents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29042366"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Emicizumab, a humanised bispecific antibody recognising factors (F) IX/IXa and X/Xa, can accelerate FIXa-catalysed FX activation by bridging FIXa and FX in a manner similar to FVIIIa.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28451690"}, {"offsetInBeginSection": 271, "offsetInEndSection": 412, "text": "In this study, we first showed by surface plasmon resonance analysis that emicizumab bound FIX, FIXa, FX, and FXa with moderate affinities (K", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28451690"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Emicizumab Prophylaxis in Hemophilia A with Inhibitors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557"}, {"offsetInBeginSection": 172, "offsetInEndSection": 318, "text": "This phase 3, multicenter trial assessed once-weekly subcutaneous emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557"}, {"offsetInBeginSection": 387, "offsetInEndSection": 564, "text": "Those who had previously received episodic treatment with bypassing agents were randomly assigned in a 2:1 ratio to emicizumab prophylaxis (group A) or no prophylaxis (group B).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557"}, {"offsetInBeginSection": 565, "offsetInEndSection": 652, "text": "The primary end point was the difference in bleeding rates between group A and group B.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557"}, {"offsetInBeginSection": 653, "offsetInEndSection": 782, "text": "Participants who had previously received prophylactic treatment with bypassing agents received emicizumab prophylaxis in group C.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557"}]}, {"id": "5a75df9883b0d9ea66000002", "body": "Which cancers compose Carney's triad?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19561114", "http://www.ncbi.nlm.nih.gov/pubmed/3827356", "http://www.ncbi.nlm.nih.gov/pubmed/22664948", "http://www.ncbi.nlm.nih.gov/pubmed/11878780", "http://www.ncbi.nlm.nih.gov/pubmed/12893072", "http://www.ncbi.nlm.nih.gov/pubmed/9591034", "http://www.ncbi.nlm.nih.gov/pubmed/8091266", "http://www.ncbi.nlm.nih.gov/pubmed/10468897", "http://www.ncbi.nlm.nih.gov/pubmed/24840526", "http://www.ncbi.nlm.nih.gov/pubmed/8272014"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "Incomplete Carney triad--a review of two cases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19561114"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "A curious association of three rare tumours was described by Carney in 1977.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19561114"}, {"offsetInBeginSection": 77, "offsetInEndSection": 210, "text": "'Carney's triad' characteristically includes multifocal pulmonary chondroma, gastric stromal sarcoma and extra-adrenal paraganglioma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19561114"}, {"offsetInBeginSection": 280, "offsetInEndSection": 358, "text": "Carney acknowledged that, of 79 patients, only 17 possessed all three tumours.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19561114"}, {"offsetInBeginSection": 359, "offsetInEndSection": 432, "text": "We report here two patients with incomplete expression of Carney's triad.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19561114"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Gastric autonomic nerve (GAN) tumor and extra-adrenal paraganglioma in Carney's triad.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3827356"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Carney's Triad comprises a triad of neoplasms: gastric stromal tumor, extra-adrenal paraganglioma (usually functional), and pulmonary chondroma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3827356"}, {"offsetInBeginSection": 488, "offsetInEndSection": 637, "text": "Based on this evidence it appears that both the gastric lesions and the paragangliomata of Carney's Triad are tumors of the autonomic nervous system.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3827356"}, {"offsetInBeginSection": 638, "offsetInEndSection": 787, "text": "Thus, the Triad may be a disorder of the autonomic nervous system rather than a multiple endocrine neoplasia syndrome or multiple hamartoma syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3827356"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "A case of bilateral multiple pulmonary chondroma: necessity of follow-up for Carney's triad.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22664948"}]}, {"id": "5a9d28981d1251d03b000017", "body": "Does verubecestat activate BACE?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27807285", "http://www.ncbi.nlm.nih.gov/pubmed/27023706", "http://www.ncbi.nlm.nih.gov/pubmed/28800329", "http://www.ncbi.nlm.nih.gov/pubmed/28720101", "http://www.ncbi.nlm.nih.gov/pubmed/27678025", "http://www.ncbi.nlm.nih.gov/pubmed/28749667"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27023706"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Alzheimer's disease (AD) is the primary cause of dementia in the elderly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27023706"}, {"offsetInBeginSection": 945, "offsetInEndSection": 1208, "text": "The most progressed mechanism-based therapies to date consist of immunological interventions to clear A\u03b2 oligomers, and pharmacological drugs to inhibit the secretase enzymes that produce A\u03b2, namely \u03b2-site amyloid precursor-cleaving enzyme (BACE) and \u03b3-secretase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27023706"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Alzheimer's disease (AD) is a major form of senile dementia, characterized by progressive memory and neuronal loss combined with cognitive impairment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101"}, {"offsetInBeginSection": 259, "offsetInEndSection": 546, "text": "Recent therapeutic approaches have been strongly influenced by five neuropathological hallmarks of AD: acetylcholine deficiency, glutamate excitotoxicity, extracellular deposition of amyloid-\u03b2 (A\u03b2 plague), formation of intraneuronal neurofibrillary tangles (NTFs), and neuroinflammation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101"}, {"offsetInBeginSection": 1158, "offsetInEndSection": 1423, "text": "These investigations include acetylcholinesterase inhibitors, agonists and antagonists of neurotransmitter receptors, \u03b2-secretase (BACE) or \u03b3-secretase inhibitors, vaccines or antibodies targeting A\u03b2 clearance or tau protein, as well as anti-inflammation compounds.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101"}, {"offsetInBeginSection": 531, "offsetInEndSection": 900, "text": "Expert opinion: Drugs in Phase III clinical development for AD include one inhibitor of the \u03b2-secretase cleaving enzyme (BACE) (verubecestat), three anti-A\u03b2 monoclonal antibodies (solanezumab, gantenerumab, and aducanumab), an inhibitor of receptor for advanced glycation end products (RAGE) (azeliragon) and the combination of cromolyn sodium and ibuprofen (ALZT-OP1).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27678025"}, {"offsetInBeginSection": 179, "offsetInEndSection": 339, "text": "Putative disease-modifying drugs are in development and target \u03b2-amyloid (A\u03b2) peptide and tau protein, the principal neurophatological hallmarks of the disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27678025"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28749667"}, {"offsetInBeginSection": 166, "offsetInEndSection": 350, "text": "One major target has been the \u03b2-site amyloid-precursor-protein-cleaving enzyme 1 (BACE-1), with many big pharma companies expending great resources in the search for BACE-1 inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28749667"}]}, {"id": "5a9dad764e03427e73000007", "body": "What is the preDIVA clinical trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28596452"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions: Magnetic Resonance Imaging Substudy of the PreDIVA Trial (Prevention of Dementia by Intensive Vascular Care).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452"}, {"offsetInBeginSection": 15, "offsetInEndSection": 246, "text": "PURPOSE: This study aimed to evaluate the effect of a nurse-led multidomain cardiovascular intervention on white matter hyperintensity (WMH) progression and incident lacunar infarcts in community-dwelling elderly with hypertension.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452"}, {"offsetInBeginSection": 246, "offsetInEndSection": 434, "text": "METHODS: The preDIVA trial (Prevention of Dementia by Intensive Vascular Care) was an open-label, cluster-randomized controlled trial in community-dwelling individuals aged 70 to 78 years.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452"}, {"offsetInBeginSection": 1481, "offsetInEndSection": 1566, "text": "There was no effect on lacunar infarcts incidence but numbers were low.CLINICAL TRIAL", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452"}]}, {"id": "5a76072283b0d9ea66000013", "body": "Does armodafinil improve fatigue of glioma patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26902850"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "BACKGROUND: Fatigue is common among glioma patients undergoing radiotherapy (RT) and impacts quality of life (QOL).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850"}, {"offsetInBeginSection": 116, "offsetInEndSection": 236, "text": "We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850"}, {"offsetInBeginSection": 388, "offsetInEndSection": 495, "text": "Patients were randomized 1:1 to armodafinil or placebo for 8 weeks beginning within 10 days of starting RT.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850"}, {"offsetInBeginSection": 496, "offsetInEndSection": 779, "text": "Fatigue and QOL were assessed at baseline, day 22, day 43, and day 56 with the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F), the Functional Assessment of Cancer Therapy - General (FACT-G), the Brief Fatigue Inventory (BFI), and the Cancer Fatigue Scale (CFS).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850"}, {"offsetInBeginSection": 780, "offsetInEndSection": 929, "text": "The primary aim was to detect a difference in the 42-day change in FACIT-F fatigue subscale between the 2 groups using a 2-sample Wilcoxon statistic.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850"}, {"offsetInBeginSection": 929, "offsetInEndSection": 1000, "text": "RESULTS: We enrolled 81 patients total (42 armodafinil and 39 placebo).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850"}, {"offsetInBeginSection": 1001, "offsetInEndSection": 1134, "text": "Armodafinil did not significantly improve fatigue or QOL based on the 42-day change in FACIT-F fatigue subscale, FACT-G, CFS, or BFI.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850"}, {"offsetInBeginSection": 1316, "offsetInEndSection": 1481, "text": "CONCLUSIONS: While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850"}]}, {"id": "5a9d29571d1251d03b000018", "body": "What effect does azeliragon have on RAGE?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27612394"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Advanced glycation end products (AGE) resulted from a reaction between free amino group of proteins and carbohydrates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394"}, {"offsetInBeginSection": 251, "offsetInEndSection": 289, "text": "AGEs bind to a cellular receptor RAGE.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394"}, {"offsetInBeginSection": 290, "offsetInEndSection": 481, "text": "RAGE engagement by ligands AGE, \u03b2-amyloid peptide, and S100 calgranulin induces a stimulation of NADPH oxidase, reactive oxygen intermediate formation, NF\u03baB activation and gene transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394"}, {"offsetInBeginSection": 614, "offsetInEndSection": 736, "text": "Blockade of RAGE by antibodies anti-RAGE, TTP488 (azeliragon), or rRAGE prevents or limits the deleterious effect of AGEs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394"}]}, {"id": "5a9e2386de7cb99d40000004", "body": "What is the drug forxiga used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25402624", "http://www.ncbi.nlm.nih.gov/pubmed/24030968"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Numerous clinical and epidemiological studies have provided direct evidence to strengthen the link between type 2 diabetes (T2D) and Alzheimer's disease (AD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624"}, {"offsetInBeginSection": 460, "offsetInEndSection": 693, "text": "This study explores the molecular interactions between AChE and SGLT2 with a new US Food and Drug Administration approved antidiabetic drug Forxiga (dapagliflozin) to explore a possible link between the treatments of AD and diabetes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1085, "text": "Free energy of binding (\u0394G) of \"dapagliflozin-SGLT2\" and \"dapagliflozin-CAS domain of AChE\" interactions was found to be -6.25 and -6.28 kcal/mol, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624"}, {"offsetInBeginSection": 1086, "offsetInEndSection": 1162, "text": "Hence, dapagliflozin might act as a potent dual inhibitor of SGLT2 and AChE.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624"}, {"offsetInBeginSection": 272, "offsetInEndSection": 459, "text": "Sodium glucose co-transporter 2 (SGLT2) is one of the best targets in the treatment of diabetes, whereas acetylcholinesterase (AChE) has long been regarded as a therapeutic target for AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624"}, {"offsetInBeginSection": 0, "offsetInEndSection": 44, "text": "Dapagliflozin (Forxiga) for type 2 diabetes?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030968"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "In the UK, diabetes mellitus affects around 3 million people, of whom over 90% have type 2 diabetes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030968"}, {"offsetInBeginSection": 333, "offsetInEndSection": 600, "text": "Management of diabetes includes patient support and education; addressing symptoms; lifestyle modification; targeting associated risk factors for cardiovascular disease; and surveillance for, and management of, complications including treatment-related hypoglycaemia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030968"}, {"offsetInBeginSection": 601, "offsetInEndSection": 742, "text": "Dapagliflozin (Forxiga) belongs to a new class of oral glucose-lowering drugs that inhibit renal glucose reabsorption and promote glycosuria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030968"}]}, {"id": "5a761ac3aacfb9cd4c000002", "body": "What is the most common feature of the Doege\u2013Potter syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17130256", "http://www.ncbi.nlm.nih.gov/pubmed/24793812", "http://www.ncbi.nlm.nih.gov/pubmed/7712654", "http://www.ncbi.nlm.nih.gov/pubmed/21510007", "http://www.ncbi.nlm.nih.gov/pubmed/23806618", "http://www.ncbi.nlm.nih.gov/pubmed/27197926", "http://www.ncbi.nlm.nih.gov/pubmed/17896212", "http://www.ncbi.nlm.nih.gov/pubmed/8745978", "http://www.ncbi.nlm.nih.gov/pubmed/24745007", "http://www.ncbi.nlm.nih.gov/pubmed/17159512"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Uric acid, the metabolic syndrome, and renal disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17130256"}, {"offsetInBeginSection": 0, "offsetInEndSection": 243, "text": "Metabolic syndrome, characterized by truncal obesity, hypertriglyceridemia, elevated BP, and insulin resistance, is recognized increasingly as a major risk factor for kidney disease and also is a common feature of patients who are on dialysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17130256"}, {"offsetInBeginSection": 244, "offsetInEndSection": 332, "text": "One feature that is common to patients with metabolic syndrome is an elevated uric acid.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17130256"}, {"offsetInBeginSection": 333, "offsetInEndSection": 477, "text": "Although often considered to be secondary to hyperinsulinemia, recent evidence supports a primary role for uric acid in mediating this syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17130256"}, {"offsetInBeginSection": 478, "offsetInEndSection": 665, "text": "Specifically, fructose, which rapidly can cause metabolic syndrome in rats, also raises uric acid, and lowering uric acid in fructose-fed rats prevents features of the metabolic syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17130256"}, {"offsetInBeginSection": 812, "offsetInEndSection": 1020, "text": "It is proposed that fructose- and purine-rich foods that have in common the raising of uric acid may have a role in the epidemic of metabolic syndrome and renal disease that is occurring throughout the world.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17130256"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Congenital diaphragmatic hernia (CDH) is a common birth defect with a high mortality and morbidity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24793812"}, {"offsetInBeginSection": 0, "offsetInEndSection": 34, "text": "Malignancy in Maffucci's syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7712654"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Maffucci's syndrome is characterized by multiple enchondromas and subcutaneous hemangiomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7712654"}, {"offsetInBeginSection": 192, "offsetInEndSection": 362, "text": "Malignant transformations are a common feature of this syndrome and have been reported in approximately 30% of reported cases, with chondrosarcomas being the most common.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7712654"}]}, {"id": "5a9d2a8f1d1251d03b000019", "body": "What is INCB3619?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16843264", "http://www.ncbi.nlm.nih.gov/pubmed/17363546", "http://www.ncbi.nlm.nih.gov/pubmed/18757423", "http://www.ncbi.nlm.nih.gov/pubmed/27489286"], "snippets": []}, {"id": "5aa4faaed6d6b54f7900000b", "body": "Is Citrobacter rodentium pathogenic?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19897651", "http://www.ncbi.nlm.nih.gov/pubmed/25088150", "http://www.ncbi.nlm.nih.gov/pubmed/16309456", "http://www.ncbi.nlm.nih.gov/pubmed/23462619", "http://www.ncbi.nlm.nih.gov/pubmed/24358033", "http://www.ncbi.nlm.nih.gov/pubmed/24831469", "http://www.ncbi.nlm.nih.gov/pubmed/11101562", "http://www.ncbi.nlm.nih.gov/pubmed/17557113", "http://www.ncbi.nlm.nih.gov/pubmed/22144475", "http://www.ncbi.nlm.nih.gov/pubmed/25624355"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "The Citrobacter rodentium genome sequence reveals convergent evolution with human pathogenic Escherichia coli.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Citrobacter rodentium (formally Citrobacter freundii biotype 4280) is a highly infectious pathogen that causes colitis and transmissible colonic hyperplasia in mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651"}, {"offsetInBeginSection": 166, "offsetInEndSection": 405, "text": "In common with enteropathogenic and enterohemorrhagic Escherichia coli (EPEC and EHEC, respectively), C. rodentium exploits a type III secretion system (T3SS) to induce attaching and effacing (A/E) lesions that are essential for virulence.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651"}, {"offsetInBeginSection": 541, "offsetInEndSection": 874, "text": "The genome sequence revealed key information about the phylogeny of C. rodentium and identified 1,585 C. rodentium-specific (without orthologues in EPEC or EHEC) coding sequences, 10 prophage-like regions, and 17 genomic islands, including the locus for enterocyte effacement (LEE) region, which encodes a T3SS and effector proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651"}, {"offsetInBeginSection": 983, "offsetInEndSection": 1052, "text": "In addition, we identified a novel C. rodentium effector, named EspS.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651"}, {"offsetInBeginSection": 1169, "offsetInEndSection": 1410, "text": "Our analysis suggests that C. rodentium and EPEC/EHEC have converged on a common host infection strategy through access to a common pool of mobile DNA and that C. rodentium has lost gene functions associated with a previous pathogenic niche.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651"}, {"offsetInBeginSection": 406, "offsetInEndSection": 540, "text": "Here, we report the fully annotated genome sequence of the 5.3-Mb chromosome and four plasmids harbored by C. rodentium strain ICC168.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Citrobacter rodentium: infection, inflammation and the microbiota.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25088150"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "Citrobacter rodentium is a mucosal pathogen of mice that shares several pathogenic mechanisms with enteropathogenic Escherichia coli (EPEC) and enterohaemorrhagic E. coli (EHEC), which are two clinically important human gastrointestinal pathogens.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25088150"}, {"offsetInBeginSection": 367, "offsetInEndSection": 673, "text": "In this Review, we discuss recent studies in which C. rodentium has been used to study mucosal immunology, including the deregulation of intestinal inflammatory responses during bacteria-induced colitis and the role of the intestinal microbiota in mediating resistance to colonization by enteric pathogens.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25088150"}]}, {"id": "5a679e8cb750ff4455000006", "body": "Milwaukee protocol was tested for treatment of which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18465396", "http://www.ncbi.nlm.nih.gov/pubmed/26639059", "http://www.ncbi.nlm.nih.gov/pubmed/21208030", "http://www.ncbi.nlm.nih.gov/pubmed/25956434", "http://www.ncbi.nlm.nih.gov/pubmed/18305449", "http://www.ncbi.nlm.nih.gov/pubmed/23369672", "http://www.ncbi.nlm.nih.gov/pubmed/19545499", "http://www.ncbi.nlm.nih.gov/pubmed/11890620", "http://www.ncbi.nlm.nih.gov/pubmed/20881935", "http://www.ncbi.nlm.nih.gov/pubmed/24708671"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 22, "text": "Milwaukee brace today.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18465396"}, {"offsetInBeginSection": 314, "offsetInEndSection": 437, "text": "RESULTS: Milwaukee brace 23-hours wearing protocol was most effective for the treatment of adolescent idiopathic scoliosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18465396"}, {"offsetInBeginSection": 438, "offsetInEndSection": 637, "text": "However, 23-hours wearing protocol has some drawbacks, and even the patients using thoraco-lumbo-sacral orthosis wore their brace only for around 60% of the time prescribed as their wearing protocol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18465396"}, {"offsetInBeginSection": 638, "offsetInEndSection": 802, "text": "Our Milwaukee brace part-time wearing treatment was effective, and by its use combined with physical therapy, better results than the natural history were obtained.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18465396"}, {"offsetInBeginSection": 802, "offsetInEndSection": 968, "text": "CONCLUSION: With part-time wearing protocol, the Milwaukee brace can survive today as a treatment option for idiopathic scoliosis with thoracic curve or double curve.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18465396"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Critical Appraisal of the Milwaukee Protocol for Rabies: This Failed Approach Should Be Abandoned.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26639059"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "The Milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26639059"}, {"offsetInBeginSection": 153, "offsetInEndSection": 263, "text": "We have reviewed the literature with reference to specific treatment recommendations made within the protocol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26639059"}, {"offsetInBeginSection": 384, "offsetInEndSection": 550, "text": "Therapies suggested in the Milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26639059"}, {"offsetInBeginSection": 724, "offsetInEndSection": 853, "text": "The recommendations made by the Milwaukee protocol warrant serious reconsideration before any future use of this failed protocol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26639059"}]}, {"id": "5a9d2dd21d1251d03b00001a", "body": "What do the trispecific HIV antibodies target?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28931639", "http://www.ncbi.nlm.nih.gov/pubmed/26176328"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28931639"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "The development of an effective AIDS vaccine has been challenging because of viral genetic diversity and the difficulty of generating broadly neutralizing antibodies (bnAbs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28931639"}, {"offsetInBeginSection": 175, "offsetInEndSection": 404, "text": "We engineered trispecific antibodies (Abs) that allow a single molecule to interact with three independent HIV-1 envelope determinants: the CD4 binding site, the membrane-proximal external region (MPER), and the V1V2 glycan site.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28931639"}, {"offsetInBeginSection": 405, "offsetInEndSection": 707, "text": "Trispecific Abs exhibited higher potency and breadth than any previously described single bnAb, showed pharmacokinetics similar to those of human bnAbs, and conferred complete immunity against a mixture of simian-human immunodeficiency\u00a0viruses (SHIVs) in nonhuman primates, in contrast to single bnAbs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28931639"}, {"offsetInBeginSection": 708, "offsetInEndSection": 925, "text": "Trispecific Abs thus constitute a platform to engage multiple therapeutic targets through a single protein, and they may be applicable for treatment of diverse diseases, including infections, cancer, and autoimmunity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28931639"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Development of a Trispecific Antibody Designed to Simultaneously and Efficiently Target Three Different Antigens on Tumor Cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Targeting Eph (erythropoietin producing hepatoma) receptors with monoclonal antibodies is being explored as therapy for several types of cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328"}, {"offsetInBeginSection": 145, "offsetInEndSection": 405, "text": "To test whether simultaneous targeting of EphA2, EphA4, and EphB4 would be an effective approach to cancer therapy, we generated a recombinant trispecific antibody using the variable domain genes of anti-EphA2, anti-EphA4, and anti-EphB4 monoclonal antibodies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328"}, {"offsetInBeginSection": 569, "offsetInEndSection": 897, "text": "Here we demonstrate that the trispecific antibody is expressed at high levels by mammalian cells, monodispersed in solution, thermostable, capable of simultaneously binding the three receptors, and able to activate the three targets effectively as evidenced by receptor internalization and degradation both in vitro and in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328"}, {"offsetInBeginSection": 898, "offsetInEndSection": 1078, "text": "Furthermore, pharmacokinetic analysis using tumor-bearing nude mice showed that the trispecific antibody remains in the circulation similarly to its respective parental antibodies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328"}]}, {"id": "5aa6c800d6d6b54f79000012", "body": "What is liquid liquid phase transition?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16774199", "http://www.ncbi.nlm.nih.gov/pubmed/10646596", "http://www.ncbi.nlm.nih.gov/pubmed/26165855", "http://www.ncbi.nlm.nih.gov/pubmed/22069236", "http://www.ncbi.nlm.nih.gov/pubmed/16095377", "http://www.ncbi.nlm.nih.gov/pubmed/16942294", "http://www.ncbi.nlm.nih.gov/pubmed/21054046", "http://www.ncbi.nlm.nih.gov/pubmed/11497749", "http://www.ncbi.nlm.nih.gov/pubmed/11102052", "http://www.ncbi.nlm.nih.gov/pubmed/19566187"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Direct Raman evidence for a weak continuous phase transition in liquid water.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16774199"}, {"offsetInBeginSection": 520, "offsetInEndSection": 611, "text": "The minimum in C(p)() is shallow, and the transition is a weak-continuous phase transition.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16774199"}, {"offsetInBeginSection": 762, "offsetInEndSection": 932, "text": "The viscosity minimum tracks the liquid phase transition in the P, T plane where it connects with the minimum in the freezing point of pure water in the same plane (Proc.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16774199"}, {"offsetInBeginSection": 1166, "offsetInEndSection": 1406, "text": "These observations coupled with recent measurements of the coordination shell of water near 300 K (Science 2004, 304, 995(5)) suggest that the structural component that changes during the phase transition is tetrahedrally coordinated water.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16774199"}, {"offsetInBeginSection": 1407, "offsetInEndSection": 1569, "text": "At temperatures above the transition, there is no tetrahedrally coordinated water in the liquid and locally planar water structures dominate the liquid structure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16774199"}, {"offsetInBeginSection": 1570, "offsetInEndSection": 1657, "text": "Water is a structured liquid with distinct local structures that vary with temperature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16774199"}, {"offsetInBeginSection": 1658, "offsetInEndSection": 1764, "text": "Furthermore, liquid water has a liquid-liquid phase transition near the middle of the normal liquid range.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16774199"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "A first-order liquid-liquid phase transition in phosphorus", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10646596"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "First-order structural phase transitions are common in crystalline solids, whereas first-order liquid-liquid phase transitions (that is, transitions between two distinct liquid forms with different density and entropy) are exceedingly rare in pure substances.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10646596"}, {"offsetInBeginSection": 419, "offsetInEndSection": 610, "text": "Here we report an in situ X-ray diffraction observation of a liquid-liquid transition in phosphorus, involving an abrupt, pressure-induced structural change between two distinct liquid forms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10646596"}]}, {"id": "5a70ec6899e2c3af2600000c", "body": "Is pregabalin effective for sciatica?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23845078", "http://www.ncbi.nlm.nih.gov/pubmed/28328324", "http://www.ncbi.nlm.nih.gov/pubmed/26633090", "http://www.ncbi.nlm.nih.gov/pubmed/26818733", "http://www.ncbi.nlm.nih.gov/pubmed/15067505"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078"}, {"offsetInBeginSection": 367, "offsetInEndSection": 518, "text": "Our objectives are to determine the efficacy of pregabalin on reducing leg pain intensity and its cost-effectiveness in patients with sciatica.METHODS/", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078"}, {"offsetInBeginSection": 518, "offsetInEndSection": 676, "text": "DESIGN: PRECISE is a prospectively registered, double-blind, randomised placebo-controlled trial of pregabalin compared to placebo, in addition to usual care.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078"}, {"offsetInBeginSection": 801, "offsetInEndSection": 937, "text": "Participants will be randomised to receive either pregabalin with usual care (n = 102) or placebo with usual care (n = 102) for 8 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078"}, {"offsetInBeginSection": 1473, "offsetInEndSection": 1566, "text": "The primary outcome will determine the efficacy of pregabalin in reducing leg pain intensity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078"}, {"offsetInBeginSection": 1567, "offsetInEndSection": 1651, "text": "Secondary outcomes will include back pain intensity, disability and quality of life.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078"}, {"offsetInBeginSection": 1803, "offsetInEndSection": 2038, "text": "DISCUSSION: This study will establish the efficacy of pregabalin in reducing leg pain intensity in patients with sciatica and provide important information regarding the effect of pregabalin treatment on disability and quality of life.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078"}, {"offsetInBeginSection": 2039, "offsetInEndSection": 2184, "text": "The impact of this research may allow the future development of a cost-effective conservative treatment strategy for patients with sciatica.TRIAL", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "Trial of Pregabalin for Acute and Chronic Sciatica.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28328324"}, {"offsetInBeginSection": 93, "offsetInEndSection": 168, "text": "Pregabalin is effective in the treatment of some types of neuropathic pain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28328324"}]}, {"id": "5a9d30241d1251d03b00001b", "body": "Can gas vesicles be detected by ultrasound?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24633522", "http://www.ncbi.nlm.nih.gov/pubmed/27351374", "http://www.ncbi.nlm.nih.gov/pubmed/28880278", "http://www.ncbi.nlm.nih.gov/pubmed/28258771", "http://www.ncbi.nlm.nih.gov/pubmed/28889941"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Biogenic gas nanostructures as ultrasonic molecular reporters.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24633522"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "Ultrasound is among the most widely used non-invasive imaging modalities in biomedicine, but plays a surprisingly small role in molecular imaging due to a lack of suitable molecular reporters on the nanoscale.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24633522"}, {"offsetInBeginSection": 210, "offsetInEndSection": 369, "text": "Here, we introduce a new class of reporters for ultrasound based on genetically encoded gas nanostructures from microorganisms, including bacteria and archaea.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24633522"}, {"offsetInBeginSection": 370, "offsetInEndSection": 530, "text": "Gas vesicles are gas-filled protein-shelled compartments with typical widths of 45-250 nm and lengths of 100-600 nm that exclude water and are permeable to gas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24633522"}, {"offsetInBeginSection": 531, "offsetInEndSection": 816, "text": "We show that gas vesicles produce stable ultrasound contrast that is readily detected in vitro and in vivo, that their genetically encoded physical properties enable multiple modes of imaging, and that contrast enhancement through aggregation permits their use as molecular biosensors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24633522"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Ultrasound is among the most widely used biomedical imaging modalities, but has limited ability to image specific molecular targets due to the lack of suitable nanoscale contrast agents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374"}, {"offsetInBeginSection": 187, "offsetInEndSection": 357, "text": "Gas vesicles-genetically encoded protein nanostructures isolated from buoyant photosynthetic microbes-have recently been identified as nanoscale reporters for ultrasound.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374"}, {"offsetInBeginSection": 358, "offsetInEndSection": 542, "text": "Their unique physical properties give gas vesicles significant advantages over conventional microbubble contrast agents, including nanoscale dimensions and inherent physical stability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374"}, {"offsetInBeginSection": 543, "offsetInEndSection": 773, "text": "Furthermore, as a genetically encoded material, gas vesicles present the possibility that the nanoscale mechanical, acoustic, and targeting properties of an imaging agent can be engineered at the level of its constituent proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374"}, {"offsetInBeginSection": 774, "offsetInEndSection": 1040, "text": "Here, we demonstrate that genetic engineering of gas vesicles results in nanostructures with new mechanical, acoustic, surface, and functional properties to enable harmonic, multiplexed, and multimodal ultrasound imaging as well as cell-specific molecular targeting.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374"}]}, {"id": "5aa82388fcf4565872000001", "body": "Which proteins are regulated by Nrf2?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20399915", "http://www.ncbi.nlm.nih.gov/pubmed/15601839", "http://www.ncbi.nlm.nih.gov/pubmed/25827424", "http://www.ncbi.nlm.nih.gov/pubmed/20427290", "http://www.ncbi.nlm.nih.gov/pubmed/21812759", "http://www.ncbi.nlm.nih.gov/pubmed/22641035", "http://www.ncbi.nlm.nih.gov/pubmed/20410673", "http://www.ncbi.nlm.nih.gov/pubmed/27816475", "http://www.ncbi.nlm.nih.gov/pubmed/24859727", "http://www.ncbi.nlm.nih.gov/pubmed/22814021"], "snippets": [{"offsetInBeginSection": 453, "offsetInEndSection": 690, "text": "To define the range of Nrf2-regulated proteins at the constitutive level, protein expression profiling of livers from Nrf2(-/-) and wild type mice was conducted using both stable isotope labelling (iTRAQ) and gel electrophoresis methods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20399915"}, {"offsetInBeginSection": 807, "offsetInEndSection": 908, "text": "Correlative network analysis (MetaCore) identified two predominant groups of Nrf2-regulated proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20399915"}, {"offsetInBeginSection": 909, "offsetInEndSection": 1038, "text": "As expected, one group comprised proteins involved in phase II drug metabolism, which were down-regulated in the absence of Nrf2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20399915"}, {"offsetInBeginSection": 1039, "offsetInEndSection": 1183, "text": "Surprisingly, the most profound changes were observed amongst proteins involved in the synthesis and metabolism of fatty acids and other lipids.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20399915"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "The concentrations and functions of many eukaryotic proteins are regulated by the ubiquitin pathway, which consists of ubiquitin activation (E1), conjugation (E2), and ligation (E3).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15601839"}, {"offsetInBeginSection": 429, "offsetInEndSection": 566, "text": "Via a distinct N-terminal domain, individual cullins bind to a protein motif present in multiple proteins to recruit specific substrates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15601839"}, {"offsetInBeginSection": 942, "offsetInEndSection": 1103, "text": "Here, we provided evidence that the expression of xCT, the light chain subunit of system xc(-), is regulated by NRF2 in representative human breast cancer cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827424"}, {"offsetInBeginSection": 1264, "offsetInEndSection": 1364, "text": "Overexpression of NRF2 up-regulated the activity of the xCT promoter, which contains a proximal ARE.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827424"}, {"offsetInBeginSection": 1365, "offsetInEndSection": 1552, "text": "In contrast, overexpression of KEAP1 repressed promoter activity and decreased xCT protein levels, while siRNA knockdown of KEAP1 up-regulated xCT protein levels and transporter activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827424"}, {"offsetInBeginSection": 107, "offsetInEndSection": 235, "text": "Mammalian cells respond to this damage by increased transcription of cytoprotective phase II genes, which are regulated by NRF2.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20427290"}]}, {"id": "5a9d31711d1251d03b00001c", "body": "What is the approximate size of gas vesicles?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19007418", "http://www.ncbi.nlm.nih.gov/pubmed/807555", "http://www.ncbi.nlm.nih.gov/pubmed/3098234", "http://www.ncbi.nlm.nih.gov/pubmed/1956294", "http://www.ncbi.nlm.nih.gov/pubmed/9573198", "http://www.ncbi.nlm.nih.gov/pubmed/3091230", "http://www.ncbi.nlm.nih.gov/pubmed/19230840", "http://www.ncbi.nlm.nih.gov/pubmed/7683649", "http://www.ncbi.nlm.nih.gov/pubmed/26988462", "http://www.ncbi.nlm.nih.gov/pubmed/22846397"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Anaerobiosis inhibits gas vesicle formation in halophilic Archaea.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "The effect of anaerobiosis on the gas vesicle formation was investigated in three Halobacterium salinarum strains, Haloferax mediterranei and in Haloferax volcanii transformants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418"}, {"offsetInBeginSection": 179, "offsetInEndSection": 292, "text": "All these strains significantly reduced gas vesicle formation or lacked these structures under anoxic conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418"}, {"offsetInBeginSection": 335, "offsetInEndSection": 383, "text": "salinarum PHH4 lacked gas vesicles, whereas Hbt.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418"}, {"offsetInBeginSection": 384, "offsetInEndSection": 552, "text": "salinarum PHH1 and NRC-1 contained 5-20 small gas vesicles arranged in two to three aggregates per cell instead of the 30-80 gas vesicles present under oxic conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418"}, {"offsetInBeginSection": 656, "offsetInEndSection": 767, "text": "volcanii transformants lacked gas vesicles under anoxic growth and yielded a 10-fold reduced gvp transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418"}, {"offsetInBeginSection": 768, "offsetInEndSection": 939, "text": "Even the gas vesicle-overproducing DeltaD transformants did not form gas vesicles under anoxic conditions, demonstrating that the repressing protein GvpD was not involved.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418"}, {"offsetInBeginSection": 940, "offsetInEndSection": 1038, "text": "The presence of large amounts of GvpA implied that the assembly of the gas vesicles was inhibited.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418"}, {"offsetInBeginSection": 1049, "offsetInEndSection": 1215, "text": "salinarum PHH1 and NRC-1 were grown with dimethyl sulphoxide or trimethylamine N-oxid under anoxic conditions the number but not the size of gas vesicles was reduced.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418"}, {"offsetInBeginSection": 1216, "offsetInEndSection": 1379, "text": "This was in contrast to the previously reported overproduction of gas vesicles in NRC-1 that turned out to depend on the citrate-containing medium used for growth.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418"}]}, {"id": "5aacdcf1fcf4565872000009", "body": "List BET proteins.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26137204"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Post-translational modifications of the nucleosomal histone proteins orchestrate chromatin organization and gene expression in normal and cancer cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204"}, {"offsetInBeginSection": 310, "offsetInEndSection": 495, "text": "The bromodomain and extra-terminal (BET) proteins are epigenetic readers which utilize tandem bromodomains (BRD) modules to recognize and dock themselves on the acetylated lysine tails.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204"}, {"offsetInBeginSection": 496, "offsetInEndSection": 652, "text": "The BET proteins act as scaffolds for the recruitment of transcription factors and chromatin organizers required in transcription initiation and elongation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204"}, {"offsetInBeginSection": 1180, "offsetInEndSection": 1305, "text": "I-BET762 is currently being tested in early phase clinical trials, along with a rapidly growing list of other BET inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204"}, {"offsetInBeginSection": 1306, "offsetInEndSection": 1525, "text": "Unlike older epigenetic therapies, the study of BET inhibitors has offered substantial, context-specific, mechanistic insights of their antitumour activity, which will facilitate optimal therapeutic targeting in future.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204"}, {"offsetInBeginSection": 1526, "offsetInEndSection": 1799, "text": "Here, we review the development of this novel class of epigenetic drugs, the biology of BET protein inhibition, the emerging evidence from preclinical work and early phase clinical studies and we discuss their potential role in the treatment of haematological malignancies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204"}]}, {"id": "5aa38f75d6d6b54f79000005", "body": "What is host induced gene silencing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28856645", "http://www.ncbi.nlm.nih.gov/pubmed/21818318", "http://www.ncbi.nlm.nih.gov/pubmed/21112837", "http://www.ncbi.nlm.nih.gov/pubmed/19573239", "http://www.ncbi.nlm.nih.gov/pubmed/28954400", "http://www.ncbi.nlm.nih.gov/pubmed/22678572", "http://www.ncbi.nlm.nih.gov/pubmed/21533687", "http://www.ncbi.nlm.nih.gov/pubmed/19547658", "http://www.ncbi.nlm.nih.gov/pubmed/25057444", "http://www.ncbi.nlm.nih.gov/pubmed/22678574"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Investigating Gene Function in Cereal Rust Fungi by Plant-Mediated Virus-Induced Gene Silencing.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28856645"}, {"offsetInBeginSection": 823, "offsetInEndSection": 986, "text": "Since genetic manipulations such as gene deletion and genetic transformation are not yet feasible in rust fungi, performing functional gene studies is challenging.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28856645"}, {"offsetInBeginSection": 987, "offsetInEndSection": 1148, "text": "Recently, Host-induced gene silencing (HIGS) has emerged as a useful tool to characterize gene function in rust fungi while infecting and growing in host plants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28856645"}, {"offsetInBeginSection": 1149, "offsetInEndSection": 1355, "text": "We utilized Barley stripe mosaic virus-mediated virus induced gene silencing (BSMV-VIGS) to induce HIGS of candidate rust fungal genes in the wheat host to determine their role in plant-fungal interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28856645"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Geminiviruses, like all viruses, rely on the host cell machinery to establish a successful infection, but the identity and function of these required host proteins remain largely unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818318"}, {"offsetInBeginSection": 352, "offsetInEndSection": 581, "text": "The transgenic 2IRGFP N. benthamiana plants, used in combination with Virus Induced Gene Silencing (VIGS), entail an important potential as a tool in reverse genetics studies to identify host factors involved in TYLCSV infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818318"}, {"offsetInBeginSection": 725, "offsetInEndSection": 987, "text": "Moreover, we have determined that TYLCSV and Tobacco rattle virus (TRV) do not dramatically influence each other when co-infected in N. benthamiana, what makes the use of TRV-induced gene silencing in combination with TYLCSV for reverse genetic studies feasible.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818318"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Development of a virus induced gene silencing vector from a legumes infecting tobamovirus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21112837"}, {"offsetInBeginSection": 135, "offsetInEndSection": 305, "text": "Viral vectors can be used for expressing foreign genes or for virus-induced gene silencing (VIGS), what is a fast and powerful tool to determine gene functions in plants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21112837"}, {"offsetInBeginSection": 675, "offsetInEndSection": 774, "text": "We constructed two VIGS vectors differing in the promoter element to drive foreign gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21112837"}]}, {"id": "5aad4b37fcf456587200000a", "body": "What is the proteoform?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28968100", "http://www.ncbi.nlm.nih.gov/pubmed/27451424", "http://www.ncbi.nlm.nih.gov/pubmed/26941048", "http://www.ncbi.nlm.nih.gov/pubmed/27291504", "http://www.ncbi.nlm.nih.gov/pubmed/28003265", "http://www.ncbi.nlm.nih.gov/pubmed/24922115", "http://www.ncbi.nlm.nih.gov/pubmed/28453668", "http://www.ncbi.nlm.nih.gov/pubmed/26133526", "http://www.ncbi.nlm.nih.gov/pubmed/28491292", "http://www.ncbi.nlm.nih.gov/pubmed/29165996"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Elucidating Escherichia coli Proteoform Families Using Intact-Mass Proteomics and a Global PTM Discovery Database.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968100"}, {"offsetInBeginSection": 113, "offsetInEndSection": 250, "text": "We have previously described a strategy to identify proteoforms and elucidate proteoform families in complex mixtures of intact proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968100"}, {"offsetInBeginSection": 251, "offsetInEndSection": 538, "text": "The strategy is based upon measurements of two properties for each proteoform: (i) the accurate proteoform intact-mass, measured by liquid chromatography/mass spectrometry (LC-MS), and (ii) the number of lysine residues in each proteoform, determined using an isotopic labeling approach.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968100"}, {"offsetInBeginSection": 759, "offsetInEndSection": 872, "text": "A match between the measured properties and those in the catalog constitutes an identification of the proteoform.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968100"}, {"offsetInBeginSection": 873, "offsetInEndSection": 1136, "text": "In the present study, this strategy is extended by utilizing a global PTM discovery database and is applied to the widely studied model organism Escherichia coli, providing the most comprehensive elucidation of E. coli proteoforms and proteoform families to date.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968100"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Proteoform-Specific Insights into Cellular Proteome Regulation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27451424"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Knowledge regarding compositions of proteomes at the proteoform level enhances insights into cellular phenotypes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27451424"}, {"offsetInBeginSection": 220, "offsetInEndSection": 368, "text": "This strategy involved analysis of data obtained by bottom-up mass spectrometry of multiple protein OGE separations on a fraction by fraction basis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27451424"}, {"offsetInBeginSection": 1481, "offsetInEndSection": 1556, "text": "Western blotting and Protomap analyses validated the proteoform regulation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27451424"}, {"offsetInBeginSection": 1557, "offsetInEndSection": 1706, "text": "Discovery of STAT1, WARS, MX1, and HSPB1 proteoform regulation by human respiratory syncytial virus highlighted the impact of the profiling strategy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27451424"}]}, {"id": "5aa393b3d6d6b54f79000006", "body": "What does the Ribosome-bound Quality Control complex do?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28298488", "http://www.ncbi.nlm.nih.gov/pubmed/28528489", "http://www.ncbi.nlm.nih.gov/pubmed/23178123", "http://www.ncbi.nlm.nih.gov/pubmed/25578875", "http://www.ncbi.nlm.nih.gov/pubmed/23007158", "http://www.ncbi.nlm.nih.gov/pubmed/27129255"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "The ribosome-bound quality control complex remains associated to aberrant peptides during their proteasomal targeting and interacts with Tom1 to limit protein aggregation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28298488"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Protein quality control mechanisms eliminate defective polypeptides to ensure proteostasis and to avoid the toxicity of protein aggregates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28298488"}, {"offsetInBeginSection": 140, "offsetInEndSection": 333, "text": "In eukaryotes, the ribosome-bound quality control (RQC) complex detects aberrant nascent peptides that remain stalled in 60S ribosomal particles due to a dysfunction in translation termination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28298488"}, {"offsetInBeginSection": 513, "offsetInEndSection": 744, "text": "Whereas the steps from stalled 60S recognition to aberrant peptide polyubiquitylation by the RQC complex have been described, the mechanism leading to proteasomal degradation of these defective translation products remains unknown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28298488"}, {"offsetInBeginSection": 745, "offsetInEndSection": 878, "text": "We show here that the RQC complex also exists as a ribosome-unbound complex during the escort of aberrant peptides to the proteasome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28298488"}, {"offsetInBeginSection": 1180, "offsetInEndSection": 1327, "text": "Taken together, these results reveal new roles for Tom1 in protein quality control, aggregate prevention, and, therefore, proteostasis maintenance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28298488"}, {"offsetInBeginSection": 879, "offsetInEndSection": 989, "text": "In addition, we identify a new partner of this light version of the RQC complex, the E3 ubiquitin ligase Tom1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28298488"}, {"offsetInBeginSection": 334, "offsetInEndSection": 512, "text": "The RQC complex polyubiquitylates aberrant polypeptides and recruits a Cdc48 hexamer to extract them from 60S particles in order to escort them to the proteasome for degradation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28298488"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "The ribosome-bound quality control complex: from aberrant peptide clearance to proteostasis maintenance.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28528489"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "Proteostasis in eukaryotes is maintained by compartment-specific quality control pathways, which enable the refolding or the degradation of defective polypeptides to prevent the toxicity that may arise from their aggregation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28528489"}]}]}